Document:

EX-10.5

 Exhibit 10.5 

VIR BIOTECHNOLOGY, INC. 
  

 
 2016 EQUITY
INCENTIVE PLAN 
  
  

Amended and Restated as of August 9, 2018 

 VIR BIOTECHNOLOGY, INC. 

 
  

2016 EQUITY INCENTIVE PLAN 
  

 
 ARTICLE I

 PURPOSE 
 The
purpose of this 2016 Equity Incentive Plan is to enhance the profitability and value of the Company for the benefit of its stockholders by enabling the Company to offer Eligible Employees, Consultants and
Non-Employee Directors stock-based incentives in the Company to attract, retain and reward such individuals and strengthen the mutuality of interests between such individuals and the Company’s
stockholders. 
 ARTICLE II 

DEFINITIONS 
 For purposes
of the Plan, the following terms shall have the following meanings: 
 2.1 “Acquisition Event” means a merger
or consolidation in which the Company is not the surviving entity, any transaction that results in the acquisition of all or substantially all of the Company’s outstanding Common Stock by a Person, or the sale or other disposition of all or
substantially all of the assets of the Company and its Subsidiaries, taken as a whole. The occurrence of an Acquisition Event shall be determined by the Committee. 

2.2 “Affiliate” of any specified Person means any other Person directly or indirectly controlling,
controlled by or under direct or indirect common control with such specified Person. No Person shall be deemed to be an Affiliate of another Person solely by virtue of the fact that both Persons own shares of the capital stock of the Company. 

2.3 “Appreciation Award” means any Stock Option or any Other Stock-Based Award that is based on
the appreciation in value of a share of Common Stock in excess of an amount at least equal to the Fair Market Value on the date such Other Stock-Based Award is granted. 

2.4 “Award” means any award granted or made under the Plan of any Stock Option, any Restricted Stock or any
Other Stock-Based Award. All Awards shall be subject to the terms of a written agreement executed by the Company and the Participant. 

2.5 “Board” means the Board of Directors of the Company. 

2.6 “Bylaws” means the Bylaws of the Company, as amended or amended and restated from time to time. 

2.7 “Certificate of Incorporation” means the Company’s Certificate of Incorporation, as amended or amended
and restated from time to time. 

  
 1. 

 2.8 “Cause” means with respect to a Participant’s
Termination of Employment or Termination of Consultancy, the following: (a) in the case where there is no employment agreement, consulting agreement, change in control agreement or similar agreement in effect between the Company or any of its
Affiliates and the Participant at the time of the grant of the Award (or where there is such an agreement but it does not define “cause” (or words of like import) or where it only applies upon the occurrence of a change in control and one
has not yet taken place), termination due to: (i) the Participant’s (x) being indicted for or charged with a felony under United States or applicable state or local law or (y) conviction of, or plea of guilty or nolo
contendere to a misdemeanor where imprisonment is imposed (other than for a traffic-related offense); (ii) perpetration by the Participant of an illegal act, dishonesty, or fraud (whether or not with regard to the Company or any Parent or
Subsidiary) that could cause economic or reputational injury to the Company or any of its Affiliates or any act of moral turpitude by the Participant, as determined in the sole discretion of the Committee; (iii) the Participant’s
insubordination, refusal to perform his or her duties or responsibilities for any reason other than illness or incapacity, or unsatisfactory performance of his or her duties for the Company or any of its Affiliates; (iv) willful and deliberate
failure by the Participant to perform the Participant’s duties after the Participant has been given notice and an opportunity to effectuate a cure as determined by the Committee in its sole discretion; (v) the Participant’s misconduct
or gross negligence with regard to the Company or any of its Affiliates; (vi) the Participant’s unlawful appropriation of a material corporate opportunity; or (vii) the Participant’s breach of any agreement with the Company or
any of its Affiliates, including any confidentiality or other restrictive covenant agreement entered into between the Participant and the Company or any of its Affiliates or (b) in the case where there is an employment agreement, consulting
agreement, change in control agreement or similar agreement in effect between the Company or any of its Affiliates and the Participant at the time of the grant of the Award that defines “cause” (or words of like import), “cause”
as defined under such agreement; provided, that with regard to any agreement under which the definition of “cause” only applies upon an occurrence of a change in control, such definition of “cause” shall not apply until a change
in control actually takes place and then only with regard to a termination thereafter. With respect to a Participant’s Termination of Directorship, “cause” means an act or failure to act that constitutes cause for removal of a
director under applicable Delaware law. 
 2.9 “Change in Control” means, unless otherwise determined by the
Committee in the applicable Award agreement, the occurrence of any of the following: 
 (a) the acquisition (including any acquisition
through purchase, reorganization, merger, consolidation or similar transaction), directly or indirectly, in one or more transactions by a Person (other than any holder of Voting Securities on the Effective Date) of beneficial ownership (within the
meaning of Rule 13d-3 of under the Exchange Act) of shares or securities representing 50% or more of the total voting power of the Voting Securities, in each case calculated on a fully diluted basis after
giving effect to such acquisition; provided that none of the following shall constitute a Change in Control under this clause (a): (i) any acquisition by any Permitted Holder, (ii) any acquisition that does not result in any Person (other than
a Permitted Holder), beneficially owning shares or securities representing 50% or more of the total voting power of the Voting Securities, and (iii) any acquisition, after which the Company or its Affiliates have the right or ability by voting
power, contract or otherwise to elect or designate for election a majority of the Board; 
 (b) after an Initial Public Offering, any
election has occurred of Persons to the Board that causes two-thirds of the Board to consist of Persons other than (i) members of the Board on the Effective Date, (ii) Persons who were nominated for
election as members of the Board at a time when two-thirds of the Board consisted of Persons who were members of the Board on the Effective Date and (iii) Persons who were designated for election as
members of the Board pursuant to the Voting Agreement; provided that any Person nominated for election by a Board at least two-thirds of whom constituted Persons described in clauses (i), (ii) or (iii) or
by Persons who were themselves nominated by such Board shall, for this purpose, be deemed to have been nominated by a Board composed of Persons described in clause (i); or 

  
 2. 

 (c) the sale or other disposition (including by means of a merger or consolidation),
directly or indirectly, of all or substantially all of the assets of the Company and its Subsidiaries, taken as a whole, to any Person, other than a Person at least 50% of whose voting securities (measured by voting power rather than number of
securities) are owned and controlled by one or more Permitted Holders. 
 For clarity, for purposes of the Plan, the completion of an Initial
Public Offering shall not be considered a Change in Control. 
 2.10 “Change in Control Price” has the meaning
set forth in Section 9.1(b). 
 2.11 “Chief Executive Officer” means the chief
executive officer of the Company. 
 2.12 “CIC Notice” has the meaning set forth in
Section 10.3(b). 
 2.13 “Code” means the Internal Revenue Code of 1986, as amended.
Any reference to any section of the Code shall also be a reference to any successor provision and any Treasury Regulation promulgated thereunder. 

2.14 “Committee” means (a) prior to a Registration Date, a committee or subcommittee of the Board appointed
from time to time by the Board, or, if none, the full Board and (b) upon and following a Registration Date, a committee or subcommittee of the Board appointed from time to time by the Board that may consist solely of two or more “non-employee directors” each of whom is intended to be (i) to the extent required by Rule 16b-3, a “nonemployee director” as defined in Rule 16b-3; (ii) to the extent required by Section 162(m), an “outside director” as defined under Section 162(m); and (iii) as applicable, an “independent director” as defined under the
Nasdaq Listing Rules, the NYSE Listed Company Manual or other applicable stock exchange rules; provided that if for any reason the appointed Committee does not meet the requirements of Rule 16b-3 or
Section 162(m), such noncompliance shall not affect the validity of grants, interpretations or other actions of the Committee. With respect to the application of the Plan to Non-Employee Directors, the
Committee shall mean the Board. Notwithstanding the foregoing, if and to the extent that no Committee exists that has the authority to administer the Plan, the functions of the Committee shall be exercised by the Board and all references herein to
the Committee shall be deemed references to the Board. 
 2.15 “Common Stock” means the common stock of the
Company, par value $0.0001 per share. 
 2.16 “Company” means Vir Biotechnology, Inc., a Delaware corporation,
or its successors by operation of law. 
 2.17 “Consultant” means any natural person who (a) provides,
either directly or through a limited liability company or a similar entity, bona fide consulting or advisory services to the Company or any of its Affiliates pursuant to a written agreement, which services are not in connection with the offer or
sale of securities in a capital-raising transaction, and (b) who does not, directly or indirectly, promote or maintain a market for the Company’s or any of its Affiliates’ securities. 

2.18 “control” means, with respect to any Person, the power to direct or cause the direction of the management
and policies of such Person, directly or indirectly, whether through the ownership of voting securities, by contract or otherwise; and words such as “controlled” and “controlling” have meanings correlative to the
foregoing. 

  
 3. 

 2.19 “Customers” means any Person who is a customer or client
of the Company or any of its Affiliates and with whom the Participant had business-related contact (whether in person, by telephone, or by paper or electronic correspondence) on behalf of the Company or any of its Affiliates. 

2.20 “Detrimental Activity” means: 

(a) disclosing, divulging, furnishing or making available to any Person, except as necessary in the furtherance of Participant’s
responsibilities to the Company or any of its Affiliates, either during or subsequent to Participant’s service relationship with the Company or any of its Affiliates, any knowledge or information with respect to trade secrets or confidential or
proprietary information, methods, processes, plans or materials of the Company or any of its Affiliates, or with respect to any other confidential or proprietary aspects of the business of the Company or any of its Affiliates, acquired by the
Participant at any time prior to the Participant’s Termination; 
 (b) any activity while employed by, or performing services for, the
Company or any of its Affiliates that results, or if known could reasonably be expected to result, in the Participant’s Termination for Cause; 

(c) directly or indirectly soliciting, enticing or inducing any employee of the Company or any of its Affiliates to be employed by any Person
that is, (i) directly or indirectly, engaged in the Business; (ii) directly or indirectly approaching any such employee for such purposes; or (iii) authorizing or knowingly approving the taking of any such actions by any other Person
on behalf of any such Person, or assisting any such Person in taking such actions; 
 (d) direct or indirect Disparagement, or inducing
others to engage in Disparagement; or 
 (e) a material breach of any agreement between the Participant and the Company or an Affiliate of
the Company. 
 Unless otherwise determined by the Committee at grant or unless a longer post-Termination recoupment period is provided in
the applicable award agreement, Detrimental Activity shall not be deemed to occur after the end of the one-year period following the Participant’s Termination. 

For purposes of subsections (a), (c) and (e) above, the Committee has the authority to provide the Participant with written authorization
to engage in the activities contemplated thereby and no other Person shall have authority to provide the Participant with such authorization. 

2.21 “Disability” means with respect to a Participant’s Termination, a permanent and total disability as
defined in Section 22(e)(3) of the Code. A Disability shall only be deemed to occur at the time of the determination by the Committee of the Disability. Notwithstanding the foregoing, for an Award that provides for payment or settlement
triggered upon a Disability and that constitutes “non-qualified deferred compensation” pursuant to Section 409A of the Code, the foregoing definition shall apply for purposes of vesting of such
Award, provided that for purposes of payment or settlement of such Award, such Award shall not be paid (or otherwise settled) until the earliest of: (A) the Participant’s “disability” within the meaning of
Section 409A(a)(2)(C)(i) or (ii) of the Code, (B) the Participant’s “separation from service” within the meaning of Section 409A of the Code and (C) the date such Award would otherwise be settled pursuant to
the terms of the Award agreement. 

  
 4. 

 2.22 “Disparagement” means making comments or statements to
the press, the Company’s or its Affiliates’ employees, consultants or any individual or entity with whom the Company or its Affiliates has a business relationship which could reasonably be expected to adversely affect in any manner:
(a) the conduct of the business of the Company or its Affiliates (including, without limitation, any products or business plans or prospects); or (b) the business reputation of the Company or its Affiliates, or any of their products, or
their past or present officers, directors or employees. 
 2.23 “Effective Date” means the effective date of
the Plan as defined in Article XIII. 
 2.24 “Eligible Employee” means each employee of the Company or
one of its Affiliates. 
 2.25 “Exchange Act” means the Securities Exchange Act of 1934, as amended, and all
rules and regulations promulgated thereunder. Any references to any section of the Exchange Act shall also be a reference to any successor provision. 

2.26 “Exercisable Awards” has the meaning set forth in Section 4.2(d).

 2.27 “Fair Market Value” means, unless otherwise required by any applicable provision of the Code, with
respect to a share of Common Stock or other security, as of any date, (i) if the Common Stock or other security is not then traded on an established securities market, the fair market value of a share of the Common Stock or other security as
determined by the Committee in whatever manner it considers appropriate, taking into account the requirements of Section 422 or 409A of the Code, as applicable, or (ii) if the Common Stock or other security is then traded on an established
securities market, the closing price reported on the principal market on which the Common Stock or other security is traded on such date or, if there is no sale of Common Stock or other security on such date, then on the last previous date on which
there was a sale. 
 2.28 “Family Member” means “family member” as defined in Rule 701 under the
Securities Act and, following the filing of a Form S-8 pursuant to the Securities Act with respect to the Plan, as defined in Section A.1.(5) of the general instructions of Form
S-8, as may be amended from time to time. 
 2.29 “Good
Reason” with respect to a Participant’s voluntary Termination of Employment shall have the meaning ascribed to such term under an employment or similar agreement in effect between the Company and the Participant; a
Participant shall not have “Good Reason” in the absence of such an agreement providing for and defining such term. With regard to any agreement under which “Good Reason” only applies upon an occurrence of a change in control, a
Participant shall not have “Good Reason” until a change in control actually takes place and then only with regard to a termination thereafter that satisfies such “Good Reason” requirements. 

2.30 “Incentive Stock Option” means any Stock Option awarded to an Eligible Employee of the Company, its
Subsidiaries or its Parent (if any) under the Plan intended to be and designated as an “Incentive Stock Option” within the meaning of Section 422 of the Code. 

2.31 “Initial Public Offering” means an initial public offering of common stock of the Company pursuant to an
effective registration statement filed under the Securities Act (excluding registration statements filed on Form S-8, any similar successor form or another form used for a purpose similar to the intended use
for such forms). 
 2.32 “Investors’ Rights Agreement” means the Investors’ Rights Agreement, dated
September 12, 2016 by and among the Company and the other stockholders party thereto, as the same may be amended, modified, supplemented or replaced from time to time. 

  
 5. 

 2.33 “Issued Shares” means shares of Common
Stock acquired by a Participant (or his or her estate or legal representative) upon vesting or exercise of an outstanding Award granted under the Plan. For purposes of Section 10.3, “Issued Shares” shall include
all of a Participant’s or his or her Permitted Transferee’s Issued Shares that presently or as a result of any such transaction may be acquired upon the exercise or vesting of an Award (following the payment of any applicable exercise or
purchase price therefor). 
 2.34 “Joinder Agreement” means an adoption agreement to any of the Stockholders
Agreements or any similar joinder agreement to a stockholders agreement (or similar agreement) entered into by the Company after the Effective Date. 

2.35 “Lead Underwriter” has the meaning set forth in Section 13.22. 

2.36 “Lock-Up Period” has the meaning set forth in
Section 13.22. 
 2.37 “Non-Employee
Director” means a non-employee director of the Company as defined in Rule 16b-3. 

2.38 “Non-Qualified Stock Option” means any Stock Option awarded under
the Plan that is not an Incentive Stock Option. 
 2.39 “Other Extraordinary Event” has the meaning set forth
in Section 4.2(b). 
 2.40 “Other Stock-Based Award” means an Award under Article
VIII of this Plan that is valued in whole or in part by reference to, or is payable in or otherwise based on, Common Stock, including an Award valued by reference to an Affiliate. 

2.41 “Parent” means any parent corporation of the Company within the meaning of Section 424(e) of the Code.

 2.42 “Participant” means an Eligible Employee, Consultant or
Non-Employee Director to whom an Award has been granted pursuant to the Plan. 
 2.43
“Permitted Holder” means any holder of Voting Securities on the Effective Date and their respective Affiliates and Permitted Transferees, and any group consisting solely of such Persons. 

2.44 “Permitted Transferee” means: 

(a) with respect to a Participant or any stockholder of the Company who is a natural person, (i) such person’s
spouse, parents, parents-in-law, descendants, nephews, nieces, brothers, sisters,
brothers-in-law, sisters-in-law and children-in-law, (ii) such person’s heirs, legatees, beneficiaries or devisees and (iii) any trust, corporation, partnership or other entity, the beneficiaries, stockholders, partners or other
owners of which consist entirely of such person or such other persons referred to in clauses (i) and (ii) above; 
 (b)
with respect to a trust that is a Permitted Transferee pursuant to section (a)(iii) above, any other trust, corporation, partnership or other entity, the beneficiaries, stockholders, partners or other owners of which consist entirely of such trust
or such trust’s beneficiaries; 
 (c) with respect to any stockholder of the Company that is an investment fund, an
investment partnership or an investment account, any Related Person of such stockholder; and 

  
 6. 

 (d) with respect to any stockholder of the Company that is an entity and to
which clause (c) above is not applicable, any controlled Affiliate of such stockholder so long as such transferee remains a controlled Affiliate of such stockholder of the Company following the applicable Transfer; 

provided that, in any of such cases, such Permitted Transferee is an accredited investor within the meaning of Regulation D under the Securities Act, and
provided, further, that the Committee may at any time restrict or prevent any Transfer if the Committee determines, in its sole discretion, that such restriction or prevention is necessary or advisable to avoid a violation of, or to prevent the
Company from becoming subject to, any applicable Federal or state securities law, rule or regulation. 
 2.45
“Person” means any individual, entity (including any employee benefit plan or any trust for an employee benefit plan) or group (within the meaning of Section 13(d)(3) or Section 14(d)(2) of the Exchange Act, or any
successor provision). 
 2.46 “Plan” means this Vir Biotechnology, Inc. 2016 Equity Incentive Plan, as amended
from time to time. 
 2.47 “Proposed Transferee” has the meaning set forth in
Section 10.2(b). 
 2.48 “Registration Date” means the first date after the
Effective Date (a) on which the Company consummates an Initial Public Offering or (b) any class of common equity securities of the Company is required to be registered under Section 12 of the Exchange Act. 

2.49 “Related Person” means, with respect to any Person, (a) an Affiliate of such Person, (b) any
investment manager, investment advisor, managing member or general partner of such Person, (c) any investment fund, investment partnership, investment account or other investment Person whose investment manager, investment advisor, managing
member or general partner is such Person or a Related Person of such Person, or (d) any equity investor, member, partner or officer of such Person. 

2.50 “Restatement Effective Date” means August 9, 2018. 

2.51 “Restricted Stock” means an Award of shares of Common Stock that is subject to restrictions under
Article VII. 
 2.52 “Restriction Period” has the meaning set forth in
Section 7.1(b). 
 2.53 “ROFR and Co-Sale
Agreement” means the Right of First Refusal and Co-Sale Agreement, dated September 12, 2016 by and among the Company and the other stockholders party thereto, as the same may be amended,
modified, supplemented or replaced from time to time. 
 2.54 “Rule
16b-3” means Rule 16b-3 under Section 16(b) of the Exchange Act as then in effect or any successor provision. 

2.55 “Sale Proposal” has the meaning set forth in Section 10.3(a). 

2.56 “Section 162(m)” means the exception for performance-based compensation
under Section 162(m) of the Code. 
 2.57 “Section 4.2 Event” has the
meaning set forth in Section 4.2(b). 

  
 7. 

 2.58 “Section 409A Covered
Award” has the meaning set forth in Section 13.15. 
 2.59
“Section 409A of the Code” means the nonqualified deferred compensation rules under Section 409A of the Code and any applicable Treasury Regulation or other official guidance promulgated
thereunder. 
 2.60 “Securities Act” means the Securities Act of 1933, as amended and all rules and
regulations promulgated thereunder. Any reference to any section of the Securities Act shall also be a reference to any successor provision. 

2.61 “Stock Option” or “Option” means any option to purchase shares of Common Stock
granted to Eligible Employees, Non-Employee Directors or Consultants pursuant to Article VI. 

2.62 “Stockholders Agreements” means the Investors’ Rights Agreement, the ROFR and Co-Sale Agreement and the Voting Agreement. 
 2.63 “Subsidiary” means any
subsidiary corporation of the Company within the meaning of Section 424(f) of the Code. 
 2.64
“Supplier” means any Person who supplies products or services to the Company or any Subsidiary and with whom a Participant had business-related contact (whether in person, by telephone or by paper or electronic
correspondence) on behalf of the Company or any of its Affiliates. 
 2.65 “Ten Percent Stockholder” means an
individual who owns stock possessing more than ten percent of the total combined voting power of all classes of stock of the Company, its Subsidiaries or its Parent. 

2.66 “Termination” means a Termination of Consultancy, Termination of Directorship or Termination of Employment,
as applicable. 
 2.67 “Termination of Consultancy” means: (a) that the Participant is no longer acting
as a consultant to the Company or one of its Affiliates; or (b) that an entity that is retaining a Participant as a Consultant ceases to be an Affiliate of the Company unless the Participant otherwise is, or thereupon becomes, a Consultant to
the Company or another of its Affiliates at the time the entity ceases to be an Affiliate of the Company. In the event that a Consultant becomes an Eligible Employee or a Non-Employee Director upon the
termination of his or her consultancy, unless otherwise determined by the Committee, no Termination of Consultancy shall be deemed to occur until such time as such Consultant is no longer a Consultant, an Eligible Employee or a Non-Employee Director. Notwithstanding the foregoing, the Committee may otherwise define Termination of Consultancy in the Award agreement or, if no rights of a Participant are reduced, may otherwise define
Termination of Consultancy thereafter. 
 2.68 “Termination of Directorship” means that a Participant has
ceased to be a Non-Employee Director; except that if such Participant becomes an Eligible Employee or a Consultant upon the termination of his or her directorship, his or her ceasing to be a director of the
Company shall not be treated as a Termination of Directorship unless and until such Participant has a subsequent Termination of Employment or Termination of Consultancy, as the case may be. 

2.69 “Termination of Employment” means: (a) a termination of employment (for reasons other than a military
or approved personal leave of absence granted by the Company) of a Participant from the Company and its Affiliates; or (b) that an entity that is employing a Participant ceases to be an Affiliate of the Company, unless the Participant otherwise
is, or thereupon becomes, employed by the Company or 

  
 8. 

 
another Affiliate of the Company at the time the entity ceases to be an Affiliate of the Company. In the event that an Eligible Employee becomes a Consultant or a
Non-Employee Director upon the termination of his or her employment, unless otherwise determined by the Committee, no Termination of Employment shall be deemed to occur until such time as such Eligible
Employee is no longer an Eligible Employee, a Consultant or a Non-Employee Director. Notwithstanding the foregoing, the Committee may otherwise define Termination of Employment in the Award agreement or, if no
rights of a Participant are reduced, may otherwise define Termination of Employment thereafter. 
 2.70
“Transfer” means: (a) when used as a noun, any direct or indirect transfer, offer, sale, assignment, pledge, lease, donation, grant, gift, bequest, hypothecation, encumbrance or other disposition (including the issuance
of equity in a Person), whether for value or no value and whether voluntary or involuntary (including by operation of law), and (b) when used as a verb, to directly or indirectly transfer, offer, sell, assign, pledge, lease, donate, grant,
gift, bequest, encumber, charge, hypothecate or otherwise dispose of (including the issuance of equity in a Person) whether for value or for no value and whether voluntarily or involuntarily (including by operation of law). “Transferable”
and “Transferred” shall have a correlative meaning. 
 2.71 “Transfer Notice” has the meaning set
forth in Section 10.2(b). 
 2.72 “Voting Agreement” means the Voting Agreement,
dated September 12, 2016 by and among the Company and the other stockholders party thereto, as the same may be amended, modified, supplemented or replaced from time to time. 

2.73 “Voting Securities” means the securities of the Company entitled to vote in the election of directors of
the Board. 
 ARTICLE III 

ADMINISTRATION 
 3.1
The Committee. The Plan shall be administered and interpreted by the Committee. 
 3.2 Grants of Awards. The Committee
shall have full authority to grant Awards pursuant to the terms of the Plan, to Eligible Employees, Consultants and Non-Employee Directors. In particular, the Committee shall have the authority: 

(a) to select the Eligible Employees, Consultants and Non-Employee Directors to whom Awards may from
time to time be granted hereunder; 
 (b) to determine whether and to what extent Awards are to be granted hereunder to one or more Eligible
Employees, Consultants or Non-Employee Directors; 
 (c) to determine, in accordance with the terms
of the Plan, the number of shares of Common Stock to be covered by each Award granted hereunder; 
 (d) to determine the terms and
conditions, not inconsistent with the terms of the Plan, of any Award granted hereunder (including the exercise or purchase price (if any), any restriction or limitation, any vesting schedule or acceleration thereof, or any forfeiture restrictions
or waiver thereof), based on such factors, if any, as the Committee shall determine); 

  
 9. 

 (e) to determine whether and under what circumstances the exercise price of any Exercisable
Award may be paid in cash or Common Stock; 
 (f) to determine whether, to what extent and under what circumstances to provide loans (which
may be on a recourse basis and shall bear interest at the rate the Committee shall provide) to Participants in order to exercise Awards or to purchase or pay for shares of Common Stock issuable pursuant to Awards under the Plan; provided that
(i) on and after the Registration Date executive officers and directors are not eligible to receive such loans, and (ii) all outstanding loans with respect to such executive officers and directors shall be repaid before the Registration
Date; 
 (g) to determine whether a Stock Option is an Incentive Stock Option or Non-Qualified Stock
Option; 
 (h) to determine at the time of grant whether to require an Eligible Employee,
Non-Employee Director or Consultant, as a condition of the granting of any Stock 
 Option, not to
Transfer shares of Common Stock acquired pursuant to the exercise of a Stock Option for a period of time as determined by the Committee, following the date of acquisition of such shares of Common Stock; 

(i) to modify, extend or renew an Award, subject to Article X and Section 6.4(l); and 

(j) generally, to exercise such powers and to perform such acts as the Committee deems necessary or expedient to promote the best interests of
the Company that are not in conflict with the provisions of the Plan. 
 3.3 Guidelines. Subject to Article X, the
Committee shall have the authority to adopt, alter and repeal such administrative rules, guidelines and practices governing the Plan and perform all acts, including the delegation of its responsibilities (to the extent permitted by applicable law
and applicable stock exchange rules), as it shall, from time to time, deem necessary or advisable; to construe and interpret the terms and provisions of the Plan and any Award granted under the Plan (and any agreements relating thereto); and to
otherwise supervise the administration of the Plan. The Committee may correct any defect, supply any omission or reconcile any inconsistency in the Plan or in any agreement relating thereto in the manner and to the extent it shall deem necessary to
effectuate the purpose and intent of the Plan. The Committee may adopt special guidelines and provisions for Persons who are residing in or employed in, or subject to the taxes of, any domestic or foreign jurisdictions to comply with applicable tax
and securities laws of such domestic or foreign jurisdictions, and may impose such limitations and restrictions that it deems necessary or advisable to comply with such laws. To the extent applicable, the Plan is intended to comply with the
applicable requirements of Rule 16b-3 and shall be limited, construed and interpreted in a manner so as to comply therewith. 

3.4 Delegation; Advisors. The Committee may, as it from time to time as it deems advisable, to the extent permitted by applicable
law and stock exchange rules: 
 (a) delegate its responsibilities to officers or employees of the Company and its Affiliates, including
delegating authority to officers to grant Awards or execute agreements or other documents on behalf of the Committee; and 
 (b) engage legal
counsel, consultants, professional advisors and agents to assist in the administration of the Plan and rely upon any opinion or computation received from any such Person. Expenses incurred by the Committee or the Board in the engagement of any such
person shall be paid by the Company. 

  
 10. 

 3.5 Decisions Final. Any decision, interpretation, determination, evaluation,
election, approval, authorization, appointment, consent or other action made or taken by or at the direction of the Company, the Board or the Committee (or any of its members) arising out of or in connection with the Plan or any agreement relating
to an Award or the Plan shall be within the sole and absolute discretion of all and each of them, as the case may be, and shall be final, binding and conclusive on the Company and all employees and Participants, Permitted Transferees and their
respective beneficiaries, heirs, executors, administrators, successors and assigns. Nothing in the Plan shall obligate the Company, the Board or the Committee (or any of its members) to treat any Participants alike, and the exercise of any power or
discretion by any such Person with respect to any Participant shall not create any obligation on the part of such Person to take any similar action in the case of any other Participant; it being understood that any power or discretion of the
Company, the Board or the Committee (or any of its members) shall be treated as having been so conferred as to each Participant separately. 

3.6 Procedures. If the Committee is appointed, the Board shall designate one of the members of the Committee as chairman and the
Committee shall hold meetings, subject to the Bylaws of the Company, at such times and places as it shall deem advisable, including by telephone conference or by written consent to the extent permitted by applicable law. A majority of the Committee
members shall constitute a quorum. All determinations of the Committee shall be made by a majority of its members. Any decision or determination reduced to writing and signed by all of the Committee members in accordance with the Bylaws of the
Company, shall be as fully effective as if it had been made by a vote at a meeting duly called and held. The Committee shall keep minutes of its meetings and shall make such rules and regulations for the conduct of its business as it shall deem
advisable. 
 3.7 Limitation of Liability; Indemnification. 

(a) The Committee, its members and any Person designated pursuant to Section 3.4 shall not be liable for any action
or determination made in good faith with respect to the Plan. To the maximum extent permitted by applicable law, no current or former officer or employee of the Company or any of its Subsidiaries or member or former member of the Committee or of the
Board shall be liable for any action or determination made in good faith with respect to the Plan or any Award granted under it. 
 (b) To
the maximum extent permitted by applicable law and the Certificate of Incorporation and Bylaws of the Company and to the extent not covered by insurance directly insuring such person, each current and former officer or employee of the Company or any
of its Affiliates and member or former member of the Committee or the Board shall be indemnified and held harmless by the Company against any cost or expense (including reasonable fees of counsel reasonably acceptable to the Committee) or liability
(including any sum paid in settlement of a claim with the approval of the Committee), and advanced amounts necessary to pay the foregoing at the earliest time and to the fullest extent permitted, arising out of any act or omission to act in
connection with the administration of the Plan, except to the extent arising out of such officer’s, employee’s, member’s or former officer’s, employee’s or member’s own fraud or bad faith. Such indemnification shall be
in addition to any rights of indemnification the employees, officers, directors or members or former employees, officers, directors or members may have under applicable law or under the Certificate of Incorporation or Bylaws of the Company or any of
its Affiliates. Notwithstanding anything else herein, this indemnification will not apply to the actions or determinations made by an individual with regard to Awards granted to him or her under the Plan. 

3.8 Stockholders Agreements. Notwithstanding anything herein to the contrary, the Plan and the operation and administration of
the Plan (including any action taken by the Committee) shall be subject to the terms and conditions set forth in the Stockholders Agreements to the greatest extent permissible under applicable law. 

  
 11. 

 ARTICLE IV 

SHARE LIMITATIONS 

4.1 General Limitations. The aggregate number of shares of Common Stock that may be issued or used for reference purposes under
the Plan or with respect to which Awards may be granted under the Plan, including with respect to Incentive Stock Options, shall not exceed 83,000,000 shares of Common Stock (subject, in each case, to any increase or decrease pursuant to
Section 4.2), which may be either authorized and unissued Common Stock or Common Stock held in or acquired for the treasury of the Company or both. If any Award granted under the Plan expires, terminates or is canceled or
forfeited for any reason (in the case of any Stock Option, without having been exercised in full), the number of shares of Common Stock underlying such Award (in the case of any Stock Option, to the extent unexercised) shall again be available for
issuance under the Plan. To the extent that a distribution pursuant to a Stock Option is made in cash, the share reserve shall be reduced by the number of shares of Common Stock bearing a value equal to the amount of the cash distribution as of the
time that such amount was determined. Shares of Common Stock tendered to the Company by a Participant to (a) purchase shares of Common Stock upon the exercise of an Award or (b) satisfy tax withholding obligations (including shares
retained from the Award that was exercised or that created the tax obligation) shall be added back to the number of shares available for the future grant of Awards. No fractional shares of Common Stock shall be issued under the Plan. 

4.2 Changes. 
 (a)
The existence of the Plan and the Awards granted hereunder shall not affect in any way the right or power of the Board or the stockholders of the Company to make or authorize (i) any adjustment, recapitalization, reorganization or other change
in the Company’s capital structure, (ii) any merger or consolidation of the Company or any of its Affiliates, (iii) any issuance of bonds, debentures, preferred or prior preference stock ahead of or affecting the Common Stock,
(iv) the dissolution or liquidation of the Company or any of its Affiliates, (v) any sale or Transfer of all or part of the assets or business of the Company or any of its Affiliates, (vi) any Section 4.2
Event or (vii) any other corporate act or proceeding. 
 (b) Subject to the provisions of this Section 4.2(b),
in the event of any change in the capital structure of the Company by reason of any stock split, reverse stock split, stock dividend, special dividend, combination or reclassification of shares, recapitalization, merger, consolidation, spin off,
reorganization or partial or complete liquidation, issuance of rights or warrants to purchase Common Stock or securities convertible into Common Stock, sale or transfer of all or part of the Company’s assets or business, or other corporate
transaction or event that would be considered an “equity restructuring” within the meaning of FASB ASC Topic 718 (each, a “Section 4.2 Event”) then then (i) the aggregate number
or kind of shares that thereafter may be issued under the Plan, (ii) the number or kind of shares or other property (including cash) subject to an Award, or (iii) the purchase or exercise price of Awards, shall be adjusted by the Committee
as the Committee determines, in good faith, to be necessary or advisable to prevent substantial dilution or enlargement of the rights of Participants under the Plan. In connection with any Section 4.2 Event, the Committee
may provide for the cancellation of outstanding Awards and payment in cash or other property in exchange therefor. In addition, subject to Section 4.2(d), in the event of any change in the capital structure of the Company
that is not a Section 4.2 Event (an “Other Extraordinary Event”), then the Committee may make the adjustments described in clauses (i) through (iv) above as it determines, in good faith, to be
necessary or advisable to prevent substantial dilution or enlargement of the 

  
 12. 

 
rights of Participants under the Plan. Notice of any such adjustment shall be given by the Committee to each Participant whose Award has been adjusted and such adjustment (whether or not such
notice is given) shall be binding for all purposes of the Plan. Except as expressly provided in this Section 4.2(b) or in the applicable Award agreement, a Participant shall have no rights by reason of any
Section 4.2 Event or any Other Extraordinary Event. Notwithstanding the foregoing, (x) any adjustments made pursuant to this Section 4.2(b) to Awards that are considered “non-qualified deferred compensation” within the meaning of Section 409A of the Code shall be made in a manner intended to comply with the requirements of Section 409A of the Code; and
(y) any adjustments made pursuant to this Section 4.2(b) to Awards that are not considered “non-qualified deferred compensation” subject to Section 409A of the
Code shall be made in a manner intended to ensure that after such adjustment, the Awards either (A) continue not to be subject to Section 409A of the Code or (B) comply with the requirements of Section 409A of the Code. 

(c) Fractional shares of Common Stock resulting from any adjustment in Awards pursuant to Section 4.2(a) or
(b) shall be aggregated until, and eliminated at, the time of exercise by rounding-down for fractions less than one-half and rounding-up for fractions equal
to or greater than one-half. No cash settlements shall be made with respect to fractional shares eliminated by rounding. 

(d) Upon the occurrence of an Acquisition Event, the Committee may terminate all outstanding and unexercised Stock Options or any Other
Stock-Based Award that provides for a Participant-elected exercise (collectively, “Exercisable Awards”), effective as of the date of the Acquisition Event, by delivering notice of termination to each Participant at least 20
days prior to the date of consummation of the Acquisition Event, in which case during the period from the date on which such notice of termination is delivered to the consummation of the Acquisition Event, each such Participant shall have the right
to exercise in full all of such Exercisable Awards that are then outstanding to the extent vested on the date such notice of termination is given (or, at the discretion of the Committee, without regard to any limitations on exercisability otherwise
contained in the Award agreements), but any such exercise shall be contingent on the occurrence of the Acquisition Event, and, provided that, if the Acquisition Event does not take place within a specified period after giving such notice for any
reason whatsoever, the notice and exercise pursuant thereto shall be null and void and the applicable provisions of Section 4.2(b) and Article IX shall apply. For the avoidance of doubt, in the event of an
Acquisition Event, the Committee may terminate any Exercisable Award for which the exercise price is equal to or exceeds the Fair Market Value on the date of the Acquisition Event without payment of consideration therefor. 

If an Acquisition Event occurs but the Committee does not terminate the outstanding Exercisable Awards pursuant to this
Section 4.2(d), then the applicable provisions of Section 4.2(b) and Article IX shall apply. 

4.3 Minimum Purchase Price. Notwithstanding any provision of the Plan to the contrary, if authorized but previously unissued
shares of Common Stock are issued under the Plan, such shares shall not be issued for a consideration that is less than as permitted under applicable law. 

ARTICLE V 
 ELIGIBILITY
AND GENERAL REQUIREMENTS FOR AWARDS 
 5.1 General Eligibility. All current Eligible Employees, Consultants and Non-Employee Directors and prospective Eligible Employees, Consultants and Non-Employee Directors are eligible to be granted
Non-Qualified Stock Options, Restricted Stock and Other Stock-Based Awards. Eligibility for the grant of Awards and actual participation in the Plan shall be determined by the Committee. Notwithstanding
anything herein to the contrary, no Award under which a Participant may receive shares of Common Stock may be granted to an Eligible Employee, Consultant or Non-Employee Director if such shares of Common

  
 13. 

 
Stock do not constitute “service recipient stock” for purposes of Section 409A of the Code with respect to such Eligible Employee, Consultant or
Non-Employee Director if such shares are required to constitute “service recipient stock” for such Award to comply with, or be exempt from, Section 409A of the Code. 

5.2 Incentive Stock Options. Notwithstanding anything herein to the contrary, only Eligible Employees of the Company, its
Subsidiaries and its Parent (if any) are eligible to be granted Incentive Stock Options under the Plan. Eligibility for the grant of an Incentive Stock Option and actual participation in the Plan shall be determined by the Committee. 

5.3 General Requirement. The grant of Awards to a prospective Eligible Employee or Consultant and the vesting and exercise of
such Awards shall be conditioned upon such Person actually becoming an Eligible Employee or Consultant; provided, however, that no Award may be granted to a prospective Eligible Employee or Consultant unless the Company determines that the Award
will comply with applicable laws, including the securities laws of all relevant jurisdictions (and, in the case of an Award to an Eligible Employee or Consultant pursuant to which Common Stock would be issued prior to such Person performing services
for the Company, the Company may require payment of not less than the par value of the Common Stock by cash or check in order to ensure proper issuance of the shares in compliance with applicable law). Awards may be awarded in consideration for past
services actually rendered to the Company or any of its Affiliates. 
 ARTICLE VI 

STOCK OPTIONS 
 6.1
Stock Options. Each Stock Option granted under the Plan shall be one of two types: (a) an Incentive Stock Option; or (b) a Non-Qualified Stock Option. 

6.2 Grants. The Committee shall have the authority to grant to any Eligible Employee (subject to
Section 5.2) Incentive Stock Options, Non-Qualified Stock Options or both types of Stock Options. To the extent that any Stock Option does not qualify as an Incentive Stock Option
(whether because of its provisions or the time or manner of its exercise or otherwise), such Stock Option or the portion thereof that does not qualify, shall constitute a separate Non-Qualified Stock Option.
The Committee shall have the authority to grant any Consultant or Non-Employee Director one or more Non-Qualified Stock Options. 

6.3 Incentive Stock Options. Notwithstanding anything in the Plan to the contrary, no term of the Plan relating to Incentive
Stock Options shall be interpreted, amended or altered, nor shall any discretion or authority granted under the Plan be so exercised, so as to disqualify the Plan under Section 422 of the Code, or, without the consent of the Participants
affected, to disqualify any Incentive Stock Option under Section 422 of the Code. 
 6.4 Terms of Stock Options. Stock
Options granted under the Plan shall be subject to the following terms and conditions, and shall be in such form and contain such additional terms and conditions, not inconsistent with the terms of the Plan, as the Committee shall determine: 

(a) Exercise Price. The exercise price per share of Common Stock subject to a Stock Option shall be determined by the Committee on or
before the date of the grant, provided that the per share exercise price of a Stock Option shall not be less than 100% (or, in the case of an Incentive Stock Option granted to a Ten Percent Stockholder, 110%) of the Fair Market Value of the Common
Stock on the date of the grant. 

  
 14. 

 (b) Stock Option Term. The term of each Stock Option shall be fixed by the Committee;
provided, that (i) no Stock Option shall be exercisable more than ten years after the date such Stock Option is granted; and (ii) the term of an Incentive Stock Option granted to a Ten Percent Stockholder shall not exceed five years. 

(c) Exercisability. Stock Options shall be exercisable at such time or times and subject to such terms and conditions as shall be
determined by the Committee at the time of grant. 
 (d) Method of Exercise. To the extent vested, a Stock Option may be exercised in
whole or in part at any time and from time to time during the Stock Option term by giving written notice of exercise to the Company specifying the number of shares of Common Stock to be acquired. Such notice shall be in a form acceptable to the
Committee and shall be accompanied by (x) at the Company’s request, Joinder Agreements executed by the holder thereof and (y) payment in full of the exercise price as follows: (i) in cash or by check, bank draft or money order
payable to the order of the Company; (ii) solely to the extent permitted by applicable law and authorized by the Committee, if the Common Stock is traded on a national securities exchange or quoted on a national quotation system sponsored by
the Financial Industry Regulatory Authority, through a procedure whereby the Participant delivers irrevocable instructions to a broker reasonably acceptable to the Committee to deliver promptly to the Company an amount equal to the purchase price;
or (iii) on such other terms and conditions as may be acceptable to the Committee (including the relinquishment of Stock Options or by payment in full or in part in the form of Common Stock owned by the Participant (for which the Participant
has good title free and clear of any liens and encumbrances)). No shares of Common Stock shall be issued until payment therefor, as provided herein, has been made or provided for. 

(e) Non-Transferability of Options. No Stock Option shall be Transferable by the Participant
other than by will or by the laws of descent and distribution, and all Stock Options shall be exercisable, during the Participant’s lifetime, only by the Participant. Notwithstanding the foregoing, the Committee may determine that a Non-Qualified Stock Option that otherwise is not Transferable pursuant to this section is Transferable to a Family Member in whole or in part, and in such circumstances, and under such conditions as specified by the
Committee. A Non-Qualified Stock Option that is Transferred to a Family Member pursuant to the preceding sentence (i) may not be Transferred subsequently other than by will or by the laws of descent and
distribution and (ii) remains subject to the terms of the Plan and the applicable Award agreement. 
 (f) Termination by Death or
Disability. Unless otherwise determined by the Committee at grant (or, if no rights of the Participant (or, in the case of his death, his estate) are reduced, thereafter), if a Participant’s Termination is by reason of death or Disability,
all Stock Options that are held by such Participant that are vested and exercisable on the date of the Participant’s Termination may be exercised by the Participant (or, in the case of death, by the legal representative of the
Participant’s estate) at any time within a period of one year after the date of such Termination, but in no event beyond the expiration of the stated term of such Stock Options. 

(g) Involuntary Termination Without Cause. Unless otherwise determined by the Committee at grant (or, if no rights of the Participant
(or, in the case of his death, his estate) are reduced, thereafter), if a Participant’s Termination is by involuntary termination without Cause, all Stock Options that are held by such Participant that are vested and exercisable on the date of
the Participant’s Termination may be exercised by the Participant at any time within a period of 90 days after the date of such Termination, but in no event beyond the expiration of the stated term of such Stock Options. 

  
 15. 

 (h) Voluntary Termination. Unless otherwise determined by the Committee at grant (or,
if no rights of the Participant (or, in the case of his death, his estate) are reduced, thereafter), if a Participant’s Termination is voluntary (other than a voluntary Termination described in subsection (i)(ii) below), all Stock Options that
are held by such Participant that are vested and exercisable on the date of the Participant’s Termination may be exercised by the Participant at any time within a period of 30 days after the date of such Termination, but in no event beyond the
expiration of the stated term of such Stock Options. 
 (i) Termination for Cause. Unless otherwise determined by the Committee at
grant (or, if no rights of the Participant (or, in the case of his death, his estate) are reduced, thereafter), if a Participant’s Termination (i) is for Cause or (ii) is a voluntary Termination after the occurrence of an event that
would be grounds for a Termination for Cause, all Stock Options, whether vested or not vested, that are held by such Participant shall terminate and expire on the date of such Termination. 

(j) Unvested Stock Options. Unless otherwise determined by the Committee, Stock Options that are not vested as of the date of a
Participant’s Termination for any reason shall terminate and expire on the date of such Termination. 
 (k) Incentive Stock Option
Limitations. To the extent that the aggregate Fair Market Value (determined as of the date of grant) of the Common Stock with respect to which Incentive Stock Options are exercisable for the first time by an Eligible Employee during any calendar
year under the Plan or any other stock option plan of the Company, any Subsidiary or any Parent exceeds $100,000, such Options shall be treated as Non-Qualified Stock Options. In addition, if an Eligible
Employee does not remain employed by the Company, any Subsidiary or any Parent at all times from the date an Incentive Stock Option is granted until three months prior to the date of exercise thereof (or such other period as required by applicable
law), such Stock Option shall be treated as a Non-Qualified Stock Option. Should any provision of the Plan not be necessary in order for the Stock Options to qualify as Incentive Stock Options, or should any
additional provisions be required, the Committee may amend the Plan accordingly, without the necessity of obtaining the approval of the stockholders of the Company. 

(l) Form, Modification, Extension and Renewal of Stock Options. Stock Options may be evidenced by such form of agreement as is approved
by the Committee. The Committee may (i) modify, extend or renew outstanding Stock Options (provided that (A) the rights of a Participant are not reduced or adversely affected without his or her consent and (B) such action does not
subject the Stock Options to Section 409A of the Code or otherwise extend the Stock Options beyond their stated term), and (ii) accept the surrender of outstanding Stock Options and authorize the granting of new Stock Options in
substitution therefor. Notwithstanding anything herein to the contrary, an outstanding Stock Option may not be modified to reduce the exercise price thereof nor may a new Stock Option at a lower price be substituted for a surrendered Stock Option
(other than adjustments or substitutions in accordance with Section 4.2), unless such action is approved by the stockholders of the Company. 

(m) Early Exercise. The Committee may provide that a Stock Option include a provision whereby the Participant may elect at any time
before the Participant’s Termination to exercise the Stock Option as to any part or all of the shares of Common Stock subject to the Stock Option prior to the full vesting of the Stock Option and such shares shall be subject to certain
restrictions as determined by the Committee and be treated as Restricted Stock. Any unvested shares of Common Stock so purchased may be subject to a repurchase option in favor of the Company or to any other restriction the Committee determines to be
appropriate. 
 (n) Detrimental Activity. Unless otherwise determined by the Committee at grant, with respect to Stock Options granted
on and after the Restatement Effective Date, (i) in the event the Participant engages in Detrimental Activity prior to any exercise of the Stock Option, all Stock Options (whether vested or unvested) held by the Participant shall thereupon
terminate and expire, (ii) as a condition of the exercise of a Stock Option, the Participant shall be required to certify (or shall be deemed to have certified) at the 

  
 16. 

 
time of exercise in a manner acceptable to the Company that the Participant is in compliance with the terms and conditions of the Plan and that the Participant has not engaged in, and does not
intend to engage in, any Detrimental Activity, and (iii) in the event the Participant engages in Detrimental Activity during the one year period following the later of (x) Participant’s Termination of Employment or (y) the date
the Stock Option is exercised, that any Stock Options shall be immediately forfeited (whether or not then vested) and the Company shall be entitled to recover from the Participant at any time within one year after the later of (x) or (y), and
the Participant shall pay over to the Company, an amount equal to any gain realized as a result of the exercise of any Stock Options (whether at the time of exercise or thereafter). 

(o) Other Terms and Conditions. Stock Options may contain such other provisions, which shall not be inconsistent with any of the terms
of the Plan, as the Committee shall deem appropriate. 
 ARTICLE VII 

RESTRICTED STOCK 

7.1 Awards of Restricted Stock. 

(a) Restricted Stock may be issued either alone or in addition to other Awards granted under the Plan. The Committee shall determine the
Eligible Employees, Consultants and Non-Employee Directors to whom, and the time or times within which, grants of Restricted Stock will be made, the number of shares to be awarded, the purchase price (if any)
to be paid by the Participant (subject to Section 7.2), the time or times at which such Awards may be subject to forfeiture (if any), the vesting schedule (if any) and rights to acceleration thereof (if any), and all other
terms and conditions of the Awards. The Committee may condition the grant or vesting of Restricted Stock upon the attainment of specified performance targets or such other factors as the Committee may determine. 

(b) Restriction Period. The Participant shall not be permitted to Transfer shares of Restricted Stock awarded under the Plan during a
period set by the Committee (if any) (the “Restriction Period”) commencing with the date of such Award, as set forth in the applicable Award agreement and such agreement shall set forth a vesting schedule and any events that
would accelerate vesting of the shares of Restricted Stock. Within these limits, based on service or such other factors or criteria as the Committee may determine, the Committee may condition the grant or provide for the lapse of such restrictions
in installments in whole or in part, or may accelerate the vesting of all or any part of any Restricted Stock Award. 
 (c) Detrimental
Activity. Unless otherwise determined by the Committee at grant, each Award of Restricted Stock granted on and after the Restatement Effective Date shall provide that (A) in the event the Participant engages in Detrimental Activity prior to
any vesting of Restricted Stock, all unvested Restricted Stock shall be immediately forfeited, and (B) in the event the Participant engages in Detrimental Activity during the one year period after any vesting of such Restricted Stock, the
Committee shall be entitled to recover from the Participant (at any time within one year after such engagement in Detrimental Activity) an amount equal to the Fair Market Value as of the vesting date(s) of any Restricted Stock that had vested in the
period referred to above. Unless otherwise determined by the Committee at grant, this paragraph shall cease to apply upon a Change in Control. 

7.2 Awards and Certificates. The Committee may require, as a condition to the effectiveness of an Award of Restricted Stock, that
the Participant execute and deliver to the Company an Award agreement or other documentation and comply with the terms of such Award agreement or other documentation. Further, Restricted Stock shall be subject to the following conditions: 

  
 17. 

 (a) Purchase Price. The purchase price of Restricted Stock, if any, shall be fixed by
the Committee. In accordance with Section 4.3, the purchase price for shares of Restricted Stock may be zero to the extent permitted by applicable law, and, to the extent not so permitted, such purchase price may not be
less than par value. 
 (b) Legend. Each Participant receiving Restricted Stock shall be issued a stock certificate in respect of such
shares of Restricted Stock, unless the Committee elects to use another system, such as book entries by the transfer agent, as evidencing ownership of shares of Restricted Stock. Such certificate shall be registered in the name of such Participant,
and shall, in addition to such legends required by applicable securities laws, bear an appropriate legend referring to the terms, conditions, and restrictions applicable to such Award, substantially in the following form: 

“The securities represented hereby have been acquired for investment and have not been registered under the Securities Act of 1933. Such
shares may not be sold, pledged, or transferred in the absence of such registration or a valid exemption from the registration and prospectus delivery requirements of said Act. 

The anticipation, alienation, attachment, sale, transfer, assignment, pledge, encumbrance or charge of the shares of stock represented hereby
are subject to the terms and conditions (including forfeiture) of the Vir Biotechnology, Inc. (the “Company”) 2016 Equity Incentive Plan (as amended from time to time) (the “Plan”), and an Award
agreement entered into between the registered owner and the Company dated                         . Copies of such Plan and Award
agreement are on file at the principal office of the Company.” 
 (c) Custody. If stock certificates are issued in respect of
shares of Restricted Stock, the Committee may require that such stock certificates be held in custody by the Company until the restrictions on the shares shall have lapsed, and that, as a condition of any grant of Restricted Stock, the Participant
shall have delivered a duly signed stock power, endorsed in blank, relating to the Common Stock covered by such Award. 
 (d) Rights as
Stockholder. Except as otherwise determined by the Committee, the Participant shall have all the rights of a holder of shares of Common Stock of the Company with respect to Restricted Stock, subject to the following provisions of this
Section 7.2(d). Except as otherwise determined by the Committee, (i) the Participant shall have no right to tender shares of Restricted Stock, (ii) dividends or other distributions (collectively,
“dividends”) on shares of Restricted Stock shall be withheld, in each case, while the Restricted Stock is subject to restrictions, and (iii) in no event shall dividends or other distributions payable thereunder be paid unless and
until the shares of Restricted Stock to which they relate no longer are subject to a risk of forfeiture. Dividends that are not paid currently shall be credited to bookkeeping accounts on the Company’s records for purposes of the Plan and,
except as otherwise determined by the Committee, shall not accrue interest. Such dividends shall be paid to the Participant in the same form as paid on the Common Stock upon the lapse of the restrictions. 

(e) Termination. Upon a Participant’s Termination for any reason during the Restriction Period, all Restricted Stock still subject
to restriction will vest or be forfeited in accordance with the terms and conditions established by the Committee at grant, or, if no rights of a Participant are reduced, thereafter. 

(f) Lapse of Restrictions. If and when the Restriction Period expires without a prior forfeiture of the Restricted Stock subject to such
Restriction Period, the certificates for such shares shall be delivered to the Participant, and any and all unpaid distributions or dividends payable thereunder shall be paid. The second paragraph of the legend referred to in subsection
(b) above shall be removed from said certificates at the time of delivery to the Participant except as otherwise required by applicable law or other limitations imposed by the Committee. Notwithstanding the foregoing, actual certificates shall
not be issued to the extent that book entry recordkeeping is used. 

  
 18. 

 ARTICLE VIII 

OTHER STOCK-BASED AWARDS 

8.1 Other Awards. The Committee is authorized to grant Other Stock-Based Awards that are payable in, valued in whole or in part
by reference to, or otherwise based on or related to shares of Common Stock, including but not limited to, shares of Common Stock awarded purely as a bonus and not subject to any restrictions or conditions, shares of Common Stock in payment of the
amounts due under an incentive or performance plan sponsored or maintained by the Company or any of its Affiliates, stock appreciation rights, stock equivalent units, restricted stock units, and Awards valued by reference to book value of shares of
Common Stock. 
 The Committee shall have authority to determine the Participants, to whom, and the time or times at which, Other
Stock-Based Awards shall be made, the number of shares of Common Stock to be awarded pursuant to such Awards, and all other terms and conditions of the Awards. 

The Committee may condition the grant or vesting of Other Stock-Based Awards upon the attainment of performance goals or such other factors as
the Committee may determine. 
 To the extent permitted by law, the Committee may permit Eligible Employees or Non-Employee Directors to defer all or a portion of their cash compensation in the form of Other Stock-Based Awards granted under this Plan, subject to the terms and conditions of any deferred compensation
arrangement established by the Company, which shall be carried out in a manner intended to comply with Section 409A of the Code. 

8.2 Terms and Conditions. Other Stock-Based Awards made pursuant to this Article VIII shall be subject to the following
terms and conditions: 
 (a) Non-Transferability. The Participant may not Transfer Other
Stock-Based Awards or the Common Stock underlying such Awards prior to the date on which the underlying Common Stock is issued, or, if later, the date on which any restriction, performance or deferral period applicable to such Common Stock lapses.

 (b) Dividends. The Committee shall determine to what extent, and under what conditions, the Participant shall have the right to
receive dividends, dividend equivalents or other distributions (collectively, “dividends”) with respect to shares of Common Stock covered by Other Stock-Based Awards. Except as otherwise determined by the Committee, dividends with respect
to unvested Other Stock-Based Awards shall be withheld until such Other Stock-Based Awards vest. Dividends that are not paid currently shall be credited to bookkeeping accounts on the Company’s records for purposes of the Plan and, except as
otherwise determined by the Committee, shall not accrue interest. Such dividends shall be paid to the Participant in the same form as paid on the Common Stock or such other form as is determined by the Committee upon the lapse of the restrictions.

 (c) Vesting. Other Stock Based Awards and any underlying Common Stock shall vest or be forfeited to the extent set forth in the
applicable Award agreement or as otherwise determined by the Committee. The Committee may, at or after grant, accelerate the vesting of all or any part of any Other Stock-Based Award. 

  
 19. 

 (d) Price. Common Stock issued on a bonus basis under this Article VIII may be
issued for no cash consideration; Common Stock purchased pursuant to a purchase right awarded under this Article VIII shall be priced as determined by the Committee. 

(e) Payment. Form of payment for the Other Stock-Based Award shall be specified in the Award agreement. 

(f) Detrimental Activity. Unless otherwise determined by the Committee at grant, each Other Stock-Based Award granted on and after the
Restatement Effective Date shall provide that (A) in the event the Participant engages in Detrimental Activity prior to any vesting of such Other Stock-Based Award, all unvested Other Stock-Based Award shall be immediately forfeited, and
(B) in the event the Participant engages in Detrimental Activity during the one year period after any vesting of such Other Stock-Based Award, the Committee shall be entitled to recover from the Participant (at any time within the one-year period after such engagement in Detrimental Activity) an amount equal to any gain the Participant realized from any Other Stock-Based Award that had vested in the period referred to above. Unless otherwise
determined by the Committee at grant, this Section 8.2(f) shall cease to apply upon a Change in Control. 

ARTICLE IX 
 CHANGE IN
CONTROL PROVISIONS 
 9.1 In the event of a Change in Control of the Company, except as otherwise provided by the Committee in an
Award agreement or otherwise in writing, a Participant’s unvested Award shall not vest and a Participant’s Award shall be treated in accordance with one of the following methods as determined by the Committee: 

(a) Awards, whether or not then vested, may be continued, assumed, have new rights substituted therefor or be treated in accordance with
Section 4.2(d), and Restricted Stock or other Awards may, where appropriate in the discretion of the Committee, receive the same distribution as other Common Stock on such terms as determined by the Committee; provided
that, the Committee may decide to award additional Restricted Stock or any other Award in lieu of any cash distribution. Notwithstanding anything to the contrary herein, any assumption or substitution of Incentive Stock Options shall be structured
in a manner intended to comply with the requirements of Treasury Regulation §1.424-1 (and any amendments thereto). 

(b) Awards may be purchased by the Company or an Affiliate for an amount of cash equal to the Change in Control Price (as defined below) per
share of Common Stock covered by such Awards), less, in the case of an Appreciation Award, the exercise price per share of Common Stock covered by such Award. The “Change in Control Price” means the price per share of Common
Stock paid in the Change in Control transaction. 
 (c) Appreciation Awards may be cancelled without payment, if the Change in Control Price
is less than the exercise price per share of such Appreciation Awards. 
 Notwithstanding anything else herein, the Committee may provide
for accelerated vesting or lapse of restrictions, of an Award at any time. 

  
 20. 

 ARTICLE X 

COMPANY CALL RIGHTS; RIGHT OF FIRST REFUSAL; DRAG ALONG RIGHT 

10.1 Company Call Rights. 

(a) With respect to Awards granted on and after the Restatement Effective Date, unless otherwise determined by the Committee in the applicable
Award agreement, in the event of a Termination for Cause or the discovery that the Participant engaged in Detrimental Activity, then the Company shall have the right but not the obligation exercisable at any time during the period commencing on the
date of such Termination for Cause (or the discovery that the Participant engaged in Detrimental Activity) or Termination without Good Reason and ending on the ninety (90) day anniversary thereof, to repurchase from the Participant any shares
of Common Stock previously acquired by the Participant under the Plan at a repurchase price equal to the lesser of (i) the original purchase price or exercise price (as applicable), if any, and (ii) Fair Market Value as of the date of
repurchase or the date of Termination (or discovery that the Participant engaged in Detrimental Activity). 
 (b) Unless otherwise determined
by the Committee in the applicable award agreement, if the Company elects to exercise the call rights under this Section 10.1, it shall do so by delivering to the Participant a notice of such election, specifying the number
of shares to be purchased and the closing date and time of such purchase. Such closing shall take place at the Company’s principal executive offices or as otherwise determined by the Company within sixty (60) days after the exercise of the
right contained in this Section 10.1. At such closing, the Company will pay the Participant the repurchase price as specified in this Section 10.1 in cash, or by cancellation of indebtedness of the
Participant to the Company; provided, however, the Company may elect to pay the repurchase price in three (3) equal installments with the first installment paid at the closing and subsequent installments paid on the first two
(2) anniversaries of the closing. The installment payments shall bear interest at the applicable federal rate. 
 (c) Notwithstanding
anything herein to the contrary, the Company shall not be obligated to repurchase any shares of Common Stock previously acquired pursuant an Award under the Plan from the Participant, or from the estate of the Participant, and may defer such
repurchase, if (i) there exists and is continuing a default or an event of default on the part of the Company or under any guarantee or other agreement under which the Company or any of its Subsidiaries has borrowed money, (ii) such
repurchase would constitute a breach of, or result in a default or an event of default on the part of the Company or any of its Subsidiaries under, any such guarantee or agreement, (iii) such repurchase would not be permitted under any
applicable laws or stock exchange rules or regulations, or (iv) such repurchase would result in adverse accounting consequences for the Company. If the Company is unable to make a re-purchase generally in
accordance with the preceding sentence, the Company shall pay the Participant for such Common Stock as soon as possible, with interest at the federal short-term interest rate in effect on the first day of the month of exercise of the repurchase
right, to be recalculated on the first day of each month thereafter until all payments due are made. 
 10.2 Transfer Restrictions;
Right of First Refusal. 
 (a) No Participant may Transfer all or any fraction of any shares of Common Stock previously acquired by the
Participant under the Plan to any Person other than a Permitted Transferee unless in each such instance the Participant (or his or her estate or legal representative) shall have first offered to the Company the shares of Common Stock proposed to be
Transferred pursuant to a bona fide offer to a third party. 

  
 21. 

 (b) Notice of Proposed Transfer. Prior to any proposed Transfer of shares of Common
Stock, the Participant shall give a written notice (the “Transfer Notice”) to the Company describing fully the proposed Transfer, including the number of shares of Common Stock, the name and address of the proposed Transferee
(the “Proposed Transferee”) and if the Transfer is voluntary, the proposed Transfer price, and containing such information necessary to show that the Participant has obtained a bona fide binding offer to Transfer the shares
of Common Stock for case from a third party. The Participant shall provide a separate Transfer Notice with regard to each Proposed Transferee. The Transfer Notice shall be signed by both the Participant and the Proposed Transferee and must
constitute a binding and unconditional commitment of the Participant and the Proposed Transferee for the Transfer of the shares of Common Stock to the Proposed Transferee for cash subject only to the right of first refusal specified herein. 

(c) Bona Fide Transfer. If the Company determines that the information provided by the Participant in the Transfer Notice is
insufficient to establish the bona fide nature of a proposed voluntary Transfer, the Company shall give the Participant written notice of the Participant’s failure to comply with the procedure described herein, and that the Participant shall
have no right to Transfer the Issued Shares without first complying with this procedure. The Participant shall not be permitted to Transfer any shares of Common Stock if the Proposed Transfer is not bona fide. 

(d) Exercise of Right of First Refusal. If the Company determines the proposed Transfer to be a bona fide Transfer, the Company shall
have the right to repurchase all or any part of the shares of Common Stock at the proposed Transfer price per share, by delivering to the Participant (or his or her estate or legal representative) written notice of such exercise within twenty
(20) days after the date the Company has determined that the proposed Transfer is bona fide. The Company’s exercise or failure to exercise the right of first refusal with respect to any proposed Transfer described in a Transfer Notice
shall not affect the Company’s right to exercise the right of first refusal with respect to any proposed Transfer described in any other Transfer Notice, whether or not such other Transfer Notice is issued by the Participant or issued by a
person other than the Participant with respect to a proposed Transfer to the same Proposed Transferee. If the Company exercises the right of first refusal, the Company and the Participant shall thereupon consummate the sale of shares of Common Stock
to the Company within twenty (20) days after the date the Company has determined that the proposed Transfer is bona fide (unless a longer period is offered by the Proposed Transferee); provided, however, that in the event the Transfer Notice
provides for the payment for the shares of Common Stock other than in cash, the Company shall have the option of paying for the shares of Common Stock by the present value cash equivalent of the consideration described in the Transfer Notice as
reasonably determined by the Company. For purposes of the foregoing, cancellation of any indebtedness of the Participant to the Company shall be treated as payment to the Participant in cash to the extent of the unpaid principal and any accrued
interest canceled. 
 (e) Failure to Exercise Right of First Refusal. If the Company fails to exercise the right of first refusal with
respect to any shares of Common Stock within the period specified in Section 10.2(d) above, and the Company has not given notice to the Participant that the proposed Transfer is not a bona fide Transfer pursuant to
Section 10.2(d), the Participant may conclude a Transfer to the Proposed Transferee of the Issued Shares on the terms and conditions described in the Transfer Notice, provided such Transfer occurs not later than twenty
(20) days after the date the Company has determined that the proposed Transfer is bona fide. The Company shall have the right to demand further assurances from the Participant and the Proposed Transferee (in a form satisfactory to the Company)
that the Transfer of the Common Stock was actually carried out on the terms and conditions described in the Transfer Notice. No shares of Common Stock shall be transferred on the books of the Company until the Company has received such assurances,
if so demanded, and has approved the proposed Transfer as bona fide. Any proposed Transfer on terms and conditions different from those described in the Transfer Notice, as well as any subsequent proposed Transfer by the Participant (or his or her
estate or legal representative), shall again be subject to the right of first refusal and shall require compliance by the Participant with the procedure described in this Section 10.2. 

  
 22. 

 (f) Assignment of Right of First Refusal. The Company shall have the right to assign
the right of first refusal at any time, whether or not there has been an attempted Transfer, to one or more persons as may be selected by the Company, from time to time. 

(g) Application to Transferees. This Section 10.2 shall apply to any transferee (other than to a transferee
who acquires the shares of Common Stock pursuant to Section 10.2(d) above) in the same manner as it applies to a Participant. 

10.3 Drag Along Right. 

(a) In the event the Board receives or is otherwise presented with a bona fide offer from an independent third party to consummate a Change in
Control (a “Sale Proposal”) and approves such Change in Control, then the Participants shall be required to participate in the Change in Control in the manner set forth in this Section 10.3. 

(b) Upon the Board’s approval of a Change in Control, the Company shall deliver a notice (a “CIC Notice”) with
respect to such Change in Control to all Participants no more than five Business Days after the execution and delivery by all of the parties thereto of the definitive agreement or letter of intent or similar document entered into with respect to
such Change in Control and, in any event, no later than fifteen (15) Business Days prior to the closing date of such Change in Control. The CIC Notice shall include the terms of the Sale Proposal (including the name of the purchaser, the
proposed date of the closing of the Change in Control, the purchase price for the shares of Common Stock and any other material terms and conditions, and the copy of any form of agreement proposed to be executed in connection with the Change in
Control). 
 (c) Each Participant, upon receipt of a CIC Notice, shall be obligated (and such obligation shall be enforceable by the Company
and the other Participants), to (i) sell its Issued Shares and participate in the Change in Control contemplated by the CIC Notice, (ii) to vote, if applicable, its Issued Shares in favor of the change in Control at any meeting of
stockholders called to vote on or approve the Change in Control and/or to consent in writing to the Change in Control, (iii) waive all dissenters’ or appraisal rights in connection with the Change in Control, (iv) enter into
agreements of sale or merger agreements relating to the Change in Control and otherwise execute and deliver all agreements, releases and instruments requested by the Company in order to effectuate or that are otherwise incident to such Change in
Control, (v) otherwise to take all actions and execute all documents necessary or desirable to cause the Company and the Participants to consummate the Change in Control, and (vi) upon request of the Company, deliver an executed instrument
of transfer with respect to its Issued Shares to counsel designated by the Company, which instrument will be held in escrow by such counsel (pending receipt of the purchase price therefor). Any such Sale Proposal, and the terms of any Change in
Control, may be amended or modified from time to time, and any such CIC Notice may be rescinded, upon the approval of the. The Company shall give prompt written notice of any such amendment, modification or rescission to all of the Participants.

 (d) Each Board member shall have full and plenary power and authority, as the agent of the Company, to cause the Company to enter into a
transaction providing for a Change in Control and to take any and all such further action in connection therewith as such Board member may deem necessary or appropriate in order to consummate such Change in Control. Each Board member shall have
complete discretion over the terms and conditions of any Change in Control effected hereby, including, without limitation, price, type of consideration, payment terms, conditions to closing, representations, warranties, affirmative covenants,
negative covenants, indemnification, holdbacks and escrows. 

  
 23. 

 (e) The obligations of the Participants pursuant to this
Section 10.3 are subject to the satisfaction of the following conditions: 
 (i) each of the Participants
(including each shall receive the same form of consideration and the same proportion of the aggregate consideration from such Change in Control that such Participants would have received if such aggregate consideration had been distributed by the
Company to its stockholders in complete liquidation in accordance with applicable law and any organizational documents of the Company as in effect immediately prior to the Change in Control; 

(ii) each Participant shall make or provide the same representations, warranties, covenants, indemnities and agreements in connection with the
Change in Control (except that in the case of representations, warranties, covenants, indemnities and agreements pertaining specifically to any Participant, each other Participant shall make the comparable representations, warranties, covenants,
indemnities and agreements pertaining specifically to itself); and 
 (iii) any expenses incurred for the benefit of the Company or all
Participants, and any indemnities, holdbacks, escrows and similar items relating to the Change in Control, that are not paid or established by the Company (other than those that relate to representations or indemnities concerning a
Participant’s valid ownership of his Issued Shares free and clear of all liens, claims and encumbrances or a Participant’s authority, power and legal right to enter into and consummate a purchase or merger agreement or ancillary
documentation) shall be paid or established by the Participants in proportion to the reduced amount of consideration each Participant would have received if the aggregate consideration from such Change in Control had been reduced by the aggregate
amount of such expenses, indemnities, holdbacks, escrows or similar items. 
 (iv) EACH PARTICIPANT SHALL BE OBLIGATED IN ITS INDIVIDUAL
AWARD AGREEMENT TO APPOINT EACH MEMBER OF THE BOARD AND HIS OR HER SUCCESSORS AND ASSIGNS AS SUCH PARTICIPANT’S PROXY AND ATTORNEY-IN-FACT TO VOTE SUCH
PARTICIPANT’S ISSUED SHARES AND TAKE ANY AND ALL SUCH OTHER ACTION WITH RESPECT TO SUCH PARTICIPANT’S ISSUED SHARES AND OTHER SECURITIES OF THE COMPANY AS SUCH BOARD MEMBER MAY DIRECT IN CONNECTION WITH A CHANGE IN CONTROL EFFECTED BY THE
COMPANY IN ACCORDANCE WITH THIS SECTION 10.3 SOLELY IN THE EVENT THAT SUCH PARTICIPANT FAILS TO VOTE SUCH PARTICIPANT’S ISSUED SHARES OR TAKE ANY AND ALL SUCH OTHER ACTION IN CONNECTION WITH A CHANGE IN CONTROL IN ACCORDANCE WITH THIS
SECTION 10.3. SUCH APPOINTMENT OF EACH BOARD MEMBER AS PROXY AND ATTORNEY-IN-FACT SHALL BE COUPLED WITH AN INTEREST AND SHALL BE VALID THROUGH THE DATE THERE SHALL BE
CONSUMMATED A CHANGE IN CONTROL. 
 10.4 Effect of Public Offering. Notwithstanding the foregoing, neither the Company nor any other
Person shall have any rights pursuant to this Article X following the completion of an initial public offering of the Common Stock. 

  
 24. 

 ARTICLE XI 

TERMINATION OR AMENDMENT 

11.1 Notwithstanding any other provision of the Plan, the Board or the Committee (to the extent permitted by law) may at any time, and
from time to time, amend, in whole or in part, any or all of the provisions of the Plan (including any amendment deemed necessary to ensure that the Company may comply with any regulatory requirement referred to in Section 409A of the Code as
described below), or suspend or terminate it entirely, retroactively or otherwise; provided that if the Committee determines that the rights of a Participant with respect to Awards granted prior to such amendment, suspension or termination, may be
adversely impaired, the consent of such Participant shall be required; and provided further, without the approval of the stockholders of the Company entitled to vote in accordance with applicable law, no amendment may be made that would
(a) require stockholder approval in order for the Plan to continue to comply with the applicable provisions of Section 422 of the Code (to the extent applicable to Incentive Stock Options), or (b) require stockholder approval under
the rules of any exchange or system on which the Company’s securities are listed or traded at the request of the Company. 
 The
Committee may amend the terms of any Award theretofore granted, prospectively or retroactively; provided that no such amendment reduces the rights of any Participant without the Participant’s consent. Actions taken by the Committee in
accordance with Article IV shall not be deemed to reduce the rights of any Participant. 
 Notwithstanding anything herein to the
contrary, the Board or the Committee may amend the Plan or any Award at any time without a Participant’s consent to comply with Section 409A of the Code or any other applicable law. 

ARTICLE XII 
 UNFUNDED
PLAN 
 12.1 The Plan is intended to constitute an “unfunded” plan. With respect to any payments as to which a
Participant has a fixed and vested interest but that are not yet made to a Participant by the Company, nothing contained herein shall give any such Participant any rights that are greater than those of a general unsecured creditor of the Company.

 ARTICLE XIII 

GENERAL PROVISIONS 

13.1 Legend. The Committee may require each Person receiving shares of Common Stock pursuant to an Award granted under the Plan to
represent to and agree with the Company in writing that such Person is acquiring the shares without a view to distribution thereof and such other securities law related representations as the Committee shall request. In addition to any legend
required by the Plan, the certificates or book entry accounts for such shares may include any legend that the Committee deems appropriate to reflect any restrictions on Transfer. 

All certificates and book entry accounts for shares of Common Stock delivered under the Plan shall be subject to such stop transfer orders and
other restrictions as the Committee may deem advisable under the rules, regulations and other requirements of the Securities and Exchange Commission, any stock exchange upon which the Common Stock is then listed or any national automated quotation
system on which the Common Stock is then quoted, any applicable Federal or state securities law, and any applicable 

  
 25. 

 
corporate law, and the Committee may cause a legend or legends to be put on any such certificates to make appropriate reference to such restrictions. If necessary or advisable in order to prevent
a violation of applicable securities laws or to avoid the imposition of public company reporting requirements, then, notwithstanding anything herein to the contrary, any stock-settled Awards shall be paid in cash in an amount equal to the Fair
Market Value on the date of settlement of such Awards. 
 13.2 Other Plans. Nothing contained in the Plan shall prevent the
Board from adopting other or additional compensation arrangements, subject to stockholder approval if such approval is required; and such arrangements may be either generally applicable or applicable only in specific cases. 

13.3 No Right to Employment/Consultancy/Directorship. Neither the Plan nor the grant of any Award hereunder shall give any
Participant or other Person any right to employment, consultancy or directorship by the Company or any of its Affiliates, or shall limit in any way the right of the Company or any of its Affiliates by which an employee is employed or a Consultant or
Non-Employee Director is retained to terminate his or her employment, consultancy or directorship at any time. 

13.4 Withholding of Taxes. The Company shall have the right to deduct from any payment to be made to a Participant, or to
otherwise require, prior to the issuance or delivery of any shares of Common Stock or the payment of any cash hereunder, payment by the Participant of, any Federal, state or local taxes required by law to be withheld. Upon the vesting of Restricted
Stock (or any other Award that is taxable upon vesting), or upon making an election under Section 83(b) of the Code, a Participant shall pay or otherwise provide for all required withholding taxes to the Company. Any statutorily required
withholding obligation with regard to any Participant may be satisfied, subject to the consent of the Committee, by reducing the number of shares of Common Stock otherwise deliverable or by delivering shares of Common Stock already owned. Any
fraction of a share of Common Stock required to satisfy such tax obligations shall be disregarded and the amount due shall be paid instead in cash by the Participant. 

13.5 No Assignment of Benefits. No Award or other benefit payable under the Plan shall, except as otherwise specifically provided
in the Plan or permitted by the Committee, be Transferable in any manner, and any attempt to Transfer any such benefit shall be void, and any such benefit shall not in any manner be liable for or subject to the debts, contracts, liabilities,
engagements or torts of any person who shall be entitled to such benefit, nor shall it be subject to attachment or legal process for or against such person. 

13.6 Listing and Other Conditions. 

(a) Unless otherwise determined by the Committee, if at any time the Common Stock is listed on a national securities exchange or national
automated quotation system, the issuance of any shares of Common Stock pursuant to an Award shall be conditioned upon such shares being listed on such exchange or system. The Company shall have no obligation to issue such shares unless and until
such shares are so listed, and the right to exercise any Award with respect to such shares shall be suspended until such listing has been effected. 

(b) If at any time counsel to the Company shall be of the opinion that any sale or delivery of shares of Common Stock pursuant to an Award is
or may in the circumstances be unlawful or result in the imposition of excise taxes on the Company under the statutes, rules or regulations of any applicable jurisdiction, the Company shall have no obligation to make such sale or delivery, or to
make any application or to effect or to maintain any qualification or registration under the Securities Act or otherwise with respect to shares of Common Stock or Awards, and the right to exercise any Award shall be suspended until, in the opinion
of said counsel, such sale or delivery shall be lawful and will not result in the imposition of excise taxes on the Company. 

  
 26. 

 (c) Upon termination of any period of suspension under this
Section 13.6, an Award affected by such suspension that shall not then have expired or terminated shall be reinstated as to all shares available before such suspension and as to shares that would otherwise have become
available during the period of such suspension, but no such suspension shall extend the term of any Award. 
 (d) A Participant shall be
required to supply the Company with any certificates, representations and information that the Company requests and otherwise cooperate with the Company in obtaining any listing, registration, qualification, exemption, consent or approval the
Company deems necessary or appropriate. 
 (e) The Company shall not be obligated to issue any shares of Common Stock to a Participant if, in
the opinion of counsel for the Company, the issuance of such Common Stock will constitute a violation by the Participant or the Company of any provisions of any rule or regulation of any governmental authority or any national securities exchange.

 13.7 Stockholders Agreements and Other Requirements. Notwithstanding anything herein to the contrary, as a condition to the
receipt of shares of Common Stock pursuant to an Award granted under the Plan, the Participant shall execute and deliver Joinder Agreements or such other documentation as required by the Committee which shall set forth certain restrictions on
transferability of the shares of Common Stock acquired upon exercise or purchase, a right of first refusal or a right of first offer of the Company and other Persons with respect to shares, and such other terms or restrictions as the Board or
Committee shall from time to time establish, including any drag along rights, tag along rights, transfer restrictions and registration rights. The Stockholders Agreements or other documentation shall apply to the Common Stock acquired under the Plan
and covered by the Stockholders Agreements or other documentation. The Company may require, as a condition of exercise, the Participant or any Permitted Transferee to become a party to the Stockholders Agreements or any other existing stockholders
agreement or other agreement. 
 13.8 Governing Law. All matters arising out of or relating to the Plan, the actions taken in
connection herewith and the transactions contemplated hereby, including its validity, interpretation, construction, performance and enforcement, shall be governed by and construed in accordance with the internal laws of the State of Delaware,
without giving effect to its principles of conflict of laws. 
 13.9 Construction. Wherever any words are used in the Plan in
the masculine gender they shall be construed as though they were also used in the feminine gender in all cases where they would so apply. As used herein, (i) “or” shall mean “and/or” and (ii) “including” or
“include” shall mean “including, without limitation.” Any reference herein to an agreement in writing shall be deemed to include an electronic writing to the extent permitted by applicable law. 

13.10 Other Benefits. No Award granted or paid out under the Plan shall be deemed compensation for purposes of computing benefits
under any retirement plan of the Company or its Affiliates nor affect any benefits under any other benefit plan now or subsequently in effect under which the availability or amount of benefits is related to the level of compensation, unless
expressly provided to the contrary in such benefit plan. 
 13.11 Costs. The Company shall bear all expenses associated with
administering the Plan, including expenses of issuing Common Stock pursuant to any Award granted hereunder. 
 13.12 No Right to
Same Benefits. The provisions of Awards need not be the same with respect to each Participant, and Awards granted to individual Participants need not be the same. 

  
 27. 

 13.13 Death/Disability. The Committee may require the transferee of a
Participant to supply it with written notice of the Participant’s death or Disability and to supply it with a copy of the will (in the case of the Participant’s death) or such other evidence as the Committee deems necessary or advisable to
establish the validity of the transfer of an Award. The Committee also may require that the transferee agree to be bound by all of the terms and conditions of the Plan. 

13.14 Section 16(b) of the Exchange Act. On and after the Registration Date, all elections and transactions under the Plan by
Persons subject to Section 16 of the Exchange Act involving shares of Common Stock are intended to comply with any applicable exemptive condition under Rule 16b-3. The Committee may establish and adopt
written administrative guidelines, designed to facilitate compliance with Section 16(b) of the Exchange Act, as it may deem necessary or proper for the administration and operation of the Plan and the transaction of business thereunder. 

13.15 Section 409A. Although the Company does not guarantee to a Participant the particular tax treatment of any Award, all
Awards are intended to comply with, or be exempt from, the requirements of Section 409A of the Code and the Plan and any Award agreement shall be limited, construed and interpreted in accordance with such intent. To the extent that any Award
constitutes “non-qualified deferred compensation” pursuant to Section 409A of the Code (a “Section 409A Covered Award”), it is intended
to be paid in a manner that will comply with Section 409A of the Code. In no event shall the Company be liable for any additional tax, interest or penalties that may be imposed on a Participant by Section 409A of the Code or for any
damages for failing to comply with Section 409A of the Code. Notwithstanding anything in the Plan or in an Award to the contrary, the following provisions shall apply to Section 409A Covered Awards: 

(a) A termination of employment shall not be deemed to have occurred for purposes of any provision of a Section 409A Covered Award
providing for payment upon or following a termination of the Participant’s employment unless such termination is also a “separation from service” within the meaning of Section 409A of the Code and, for purposes of any such
provision of a Section 409A Covered Award, references to a “termination,” “termination of employment” or like terms shall mean separation from service. Notwithstanding any provision to the contrary in the Plan or the Award,
if the Participant is deemed on the date of the Participant’s Termination to be a “specified employee” within the meaning of that term under Section 409A(a)(2)(B) of the Code and using the identification methodology selected by
the Company from time to time, or if none, the default methodology set forth in Section 409A of the Code, then with regard to any such payment under a Section 409A Covered Award, to the extent required to be delayed in compliance with
Section 409A(a)(2)(B) of the Code, such payment shall not be made prior to the earlier of (i) the expiration of the six-month period measured from the date of the Participant’s separation from
service, and (ii) the date of the Participant’s death. All payments delayed pursuant to this Section 13.15(a) shall be paid to the Participant on the first day of the seventh month following the date of the Participant’s
separation from service or, if earlier, on the date of the Participant’s death. 
 (b) With respect to any payment pursuant to a
Section 409A Covered Award that is triggered upon a Change in Control, the settlement of such Award shall not occur until the earliest of (i) the Change in Control if such Change in Control constitutes a “change in the ownership of
the corporation,” a “change in effective control of the corporation” or a “change in the ownership of a substantial portion of the assets of the corporation,” within the meaning of Section 409A(a)(2)(A)(v) of the Code,
(ii) the date such Award otherwise would be settled pursuant to the terms of the applicable Award agreement and (iii) the Participant’s “separation from service” within the meaning of Section 409A of the Code, subject
to Section 13.15(a). 

  
 28. 

 (c) For purposes of Section 409A of the Code, a Participant’s right to receive any
installment payments under the Plan or pursuant to an Award shall be treated as a right to receive a series of separate and distinct payments. 

(d) Whenever a payment under the Plan or pursuant to an Award specifies a payment period with reference to a number of days (e.g.,
“payment shall be made within 30 days following the date of termination”), the actual date of payment within the specified period shall be within the sole discretion of the Company. 

13.16 Headings and Captions. The headings and captions herein are provided for reference and convenience only, shall not be
considered part of the Plan, and shall not be employed in the construction of the Plan. 
 13.17 Securities Act Compliance.
Except as the Company or Committee shall otherwise determine, the Plan is intended to comply with Section 4(2) or Rule 701 of the Securities Act, and any provisions inconsistent with such Section or Rule of the Securities Act shall be
inoperative and shall not affect the validity of the Plan. 
 13.18 Successors and Assigns. The Plan shall be binding on all
successors and permitted assigns of a Participant, including the estate of such Participant and the executor, administrator or trustee of such estate. 

13.19 Payments to Minors, Etc. Any benefit payable to or for the benefit of a minor, an incompetent person or other Person
incapable of receipt thereof shall be deemed paid when paid to such Person’s guardian or to the party providing or reasonably appearing to provide for the care of such Person, and such payment shall fully discharge the Committee, the Board, the
Company, its Affiliates and their employees, agents and representatives with respect thereto. 
 13.20 Reformation. If any
provision regarding Detrimental Activity or any other provision set forth in the Plan or an Award Agreement is found by any court of competent jurisdiction or arbitrator to be invalid, void or unenforceable or to be excessively broad as to duration,
activity, geographic application or subject, such provision or provisions shall be construed, by limiting or reducing them to the extent legally permitted, so as to be enforceable to the maximum extent compatible with then applicable law. 

13.21 Electronic Communications. Notwithstanding anything else herein to the contrary, any Award agreement, notice of exercise of
an Exercisable Award, or other document or notice required or permitted by the Plan or an Award that is required to be delivered in writing may, to the extent determined by the Committee, be delivered and accepted electronically. Signatures also may
be electronic if permitted by the Committee. The term “written agreement” as used in the Plan shall include any document that is delivered and/or accepted electronically. 

13.22 Agreement. As a condition to the grant of a Award, if requested by the Company or the lead underwriter of any public
offering of the Common Stock (the “Lead Underwriter”), a Participant shall irrevocably agree not to sell, contract to sell, grant any option to purchase, transfer the economic risk of ownership in, make any short sale of,
pledge or otherwise Transfer or dispose of, any interest in any Common Stock or any securities convertible into, derivative of, or exchangeable or exercisable for Common Stock, or any other rights to purchase or acquire Common Stock (except Common
Stock included in such public offering or acquired on the public market after such offering) during such period of time following the effective date of a registration statement of the Company filed under the Securities Act that the Lead Underwriter
shall specify (the “Lock-up Period”). The Participant shall further agree to sign such documents as may be requested by the Lead Underwriter or the Company to effect the foregoing and
agree that the Company may impose stop-transfer instructions with respect to Common Stock acquired pursuant to an Award until the end of such Lock-up Period. 

  
 29. 

 13.23 No Rights as Stockholder. Subject to the provisions of the Award
agreement, no Participant or Permitted Transferee shall have any rights as a stockholder of the Company with respect to any Award until such individual becomes the holder of record of the shares of Common Stock underlying the Award. 

ARTICLE XIV 
 EFFECTIVE
DATE OF PLAN 
 The Plan was adopted by the Board on September 12, 2016, effective on such date (the “Effective
Date”). The Plan was approved by the stockholders of the Company on September 12, 2016. An amendment to the Plan was adopted by the Board on December 12, 2016 and approved by stockholders of the Company on December 12,
2016. An amendment and restatement of the Plan was adopted by the Board on January 29, 2017 and approved by stockholders of the Company on January 29, 2017. An amendment and restatement of the Plan was adopted by the Board on July 19,
2018 and approved by the stockholders of the Company on August 9, 2018. 
 ARTICLE XV 

TERM OF PLAN 
 No Award
shall be granted pursuant to the Plan on or after the tenth anniversary of the Effective Date, but Awards granted prior to such tenth anniversary may, and the Committee’s authority to administer the terms of such Awards shall, extend beyond
that date. 

  
 30.EX-10.6

 Exhibit 10.6 

VIR BIOTECHNOLOGY, INC. 

2016 EQUITY INCENTIVE PLAN 

INCENTIVE STOCK OPTION GRANT NOTICE AND AGREEMENT 

Vir Biotechnology, Inc. (the “Company”), pursuant to its 2016 Equity Incentive Plan (the
“Plan”), hereby grants to Participant an Option to purchase the number of shares of the Company’s Common Stock (referred to herein as “Shares”) set forth below. This Option is subject to all of
the terms and conditions as set forth herein and in the Incentive Stock Option Agreement attached hereto as Exhibit A (the “Agreement”) and the Plan, each of which is incorporated herein by reference. Unless otherwise
defined herein, the terms defined in the Plan shall have the same defined meanings in this Incentive Stock Option Grant Notice (“Grant Notice”) and the Agreement. 

 

			
	Participant:	  	«Participant_Name»
		
	Grant Date:	  	«Grant_Date»
		
	Vesting Commencement Date:	  	«Vesting_Commencement_Date»
		
	Exercise Price per Share:	  	$«Exercise_Price»
		
	Total Number of Shares Subject to Option:	  	«No_of_Shares»
		
	Expiration Date:	  	«Expiration_Date»
		
	Type of Option:	  	Incentive Stock Option
		
	Vesting Schedule:	  	[Subject to Section 3(b), the Option shall vest and become exercisable over a four-year period commencing on the Vesting Commencement Date, with 25% of the Option vesting on the one-year
anniversary of the Vesting Commencement Date, and the remainder of the Option vesting in 36 equal installments beginning on the date that is the one-month anniversary of such
one-year anniversary date, and each one-month anniversary date thereafter; provided, however, that the Participant has not experienced a Termination prior to each
applicable vesting date.]

 By his or her signature and the Company’s signature below, Participant agrees to be bound by the terms
and conditions of the Plan, the Agreement and this Grant Notice. Participant has reviewed the Agreement, the Plan and this Grant Notice in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Grant Notice
and fully understands all provisions of this Grant Notice, the Agreement and the Plan. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Committee upon any questions arising under the Plan
or the Agreement. 
  

									
	VIR BIOTECHNOLOGY, INC.	 	    	  	PARTICIPANT:
					
	By:	 	
                     
    
	 		  	By:	 	
                     
                

	Print Name:	 	  
	 		  	Print Name:	 	  

	Title:	 	  
	 		  	State of Residence:	 	  

 EXHIBIT A 

TO STOCK OPTION GRANT NOTICE 

INCENTIVE STOCK OPTION AGREEMENT 

PURSUANT TO THE 
 VIR
BIOTECHNOLOGY, INC. 
 2016 EQUITY INCENTIVE PLAN 

Pursuant to the Grant Notice to which this Agreement is attached, the Company has granted to Participant an Option under the Plan to purchase
the number of Shares indicated in the Grant Notice. 
 Preliminary Statement 

The Committee hereby grants this stock option (the “Option”) as of the Grant Date pursuant to the Vir Biotechnology,
Inc. 2016 Equity Incentive Plan, as it may be amended from time to time (the “Plan”), to purchase the number of shares of the common stock of the Company, $0.0001 par value per share (the “Common
Stock”), set forth in the Grant Notice, to the Participant, as an Eligible Employee of the Company or one of its Affiliates (collectively, the Company and all of its Affiliates shall be referred to as the
“Employer”). Except as otherwise indicated, any capitalized term used but not defined herein shall have the meaning ascribed to such term in the Grant Notice or the Plan, as applicable. A copy of the Plan has been delivered
to the Participant. By signing and returning this Agreement, the Participant acknowledges having received and read a copy of the Plan and agrees to comply with it, this Agreement and all applicable laws and regulations. 

Accordingly, the parties hereto agree as follows: 

1. Tax Matters. The Option is intended to qualify as an “incentive stock option” under Section 422 of the
Internal Revenue Code of 1986, as amended. Notwithstanding the foregoing, the Option will not qualify as an “incentive stock option,” among other events, (i) if the Participant disposes of any shares of Common Stock acquired pursuant
to the Option at any time during the two (2) year period following the date of this Agreement or the one (1) year period following the date on which the Option is exercised; (ii) except in the event of the Participant’s death or
disability, as defined in Section 22(e)(3) of the Code, if the Participant is not employed by the Company, any “parent corporation” of the Company within the meaning of Section 424(e) of the Code
(“Parent”), or any “subsidiary corporation” within the meaning of Section 424(f) of the Code (“Subsidiary”), at all times during the period beginning on the Grant Date (as defined
herein) and ending on the day three (3) months before the date of exercise of the Option; or (iii) to the extent the aggregate Fair Market Value (determined as of the time the Option is granted) of the shares of Common Stock subject to
“incentive stock options” which become exercisable for the first time by the Participant in any calendar year exceeds $100,000. To the extent that the Option does not qualify as an “incentive stock option,” it shall not affect
the validity of the Option and shall constitute a separate non-qualified stock option. 
 2.
Common Stock Subject to Option; Exercise Price. Subject in all respects to the Plan and the terms and conditions set forth herein and therein, the Option entitles the Participant to purchase from the Company, upon exercise, the
Total Number of Shares Subject to Option (as set forth in the Grant Notice ) at the Exercise Price per Share (as set forth in the Grant Notice). 

 3. Vesting; Exercise. 

(a) Subject to Section 3(b), the Option shall vest and become exercisable over a [four-year period commencing on the Vesting Commencement
Date, with 25% of the Option vesting on the one-year anniversary of the Vesting Commencement Date, and the remainder of the Option vesting in 36 equal installments beginning on the date that is the one-month anniversary of such one-year anniversary date, and each one-month anniversary date thereafter; provided, however, that the
Participant has not experienced a Termination prior to each applicable vesting date.] 
 (b) To the extent that the Option has become vested
and exercisable with respect to a number of shares of Common Stock, the Option may thereafter be exercised by the Participant, in whole or in part, at any time or from time to time prior to the expiration of the Option in accordance with the Plan.
Notwithstanding the foregoing, the Participant may not exercise the Option unless the offering of shares of Common Stock issuable upon such exercise (i) is then registered under the Securities Act, or, if such offering is not then so
registered, the Company has determined that such offering is exempt from the registration requirements of the Securities Act and (ii) complies with all other applicable laws and regulations governing the Option, and the Participant may not
exercise the Option if the Committee determines that such exercise would not be so registered or exempt and otherwise in compliance with such laws and regulations. 

(c) To exercise the Option, unless otherwise directed or permitted by the Committee, the Participant must: 

(i) execute and deliver to the Company a properly completed Notice of Exercise in the form attached hereto as Exhibit I.

 (ii) execute and deliver such other documentation as required by the Committee (including, without limitation, the
Stockholder Agreements) which may set forth certain restrictions on transferability of the shares of Common Stock acquired upon exercise, a right of first refusal or a right of first offer of the Company and other Persons with respect to shares, and
such other terms or restrictions as the Board or Committee may from time to time establish, including any drag along rights, tag along rights, transfer restrictions and registration rights, and 

(iii) remit the aggregate Exercise Price to the Company in full, payable (A) in cash or by check, bank draft or money
order payable to the order of the Company; or (B) on such other terms and conditions as may be acceptable to the Committee (including, without limitation, making arrangements with the Company to have such Exercise Price withheld from other
compensation). 
 (d) In addition, unless otherwise directed or permitted by the Committee, the Participant must pay or provide for all
applicable withholding taxes in respect of the exercise of the Option, by (i) remitting the aggregate amount of such taxes to the Company in full, in cash or by check, bank draft or money order payable to the order of the Company, or
(ii) making arrangements with the Company to have such taxes withheld from other compensation, to the extent permitted by the Committee. 

4. Termination. The term of the Option shall be until the tenth anniversary of the Grant Date, after which time it shall
expire (the “Expiration Date”), subject to earlier termination in the event of the Participant’s Termination as specified in the Plan and this Agreement. Notwithstanding anything herein to the contrary, upon the
Expiration Date, the Option (whether vested or not) shall be immediately forfeited, canceled and terminated for no consideration and no longer shall be exercisable. The provisions in the Plan regarding Termination shall apply to the Option,
provided that, to the extent applicable, if the Participant’s employment agreement expressly provides more favorable rights with respect to the Option in the event of Termination, such rights shall apply. 

  
 Page 2 of 5 

 5. Market Stand-Off. If
requested by the Company or the lead underwriter of any public offering of the Common Stock (the “Lead Underwriter”), the Participant shall irrevocably agree not to sell, contract to sell, grant any option to purchase,
transfer the economic risk of ownership in, make any short sale of, pledge or otherwise Transfer or dispose of, any interest in any Common Stock or any securities convertible into, derivative of, or exchangeable or exercisable for Common Stock, or
any other rights to purchase or acquire Common Stock (except Common Stock included in such public offering or acquired on the public market after such offering) during such period of time following the effective date of a registration statement of
the Company filed under the Securities Act that the Lead Underwriter shall specify (the “Lock-up Period”). The Participant shall further agree to sign such documents as may be requested
by the Lead Underwriter or the Company to effect the foregoing and agree that the Company may impose stop transfer instructions with respect to Common Stock acquired pursuant to an Award until the end of such
Lock-up Period. 
 6. Restriction on Transfer of Option. Unless otherwise
determined by the Committee in accordance with the Plan, (a) no part of the Option shall be Transferable other than by will or by the laws of descent and distribution and (b) during the lifetime of the Participant, the Option may be
exercised only by the Participant. Any attempt to Transfer the Option other than in accordance with the Plan shall be void. 
 7. No
Rights as Stockholder. The Participant shall have no rights as a stockholder with respect to any shares of Common Stock covered by the Option unless and until the Participant has become the holder of record of such shares, and no
adjustments shall be made for dividends (whether in cash, in kind or other property), distributions or other rights in respect of any such shares, except as otherwise specifically provided for in the Plan. 

8. Provisions of Plan Control. This Agreement is subject to all the terms, conditions and provisions of the Plan,
including the amendment provisions thereof, and to such rules, regulations and interpretations relating to the Plan as may be adopted by the Committee and as may be in effect from time to time. The Plan is incorporated herein by reference. If and to
the extent that this Agreement conflicts or is inconsistent with the Plan, the Plan shall control, and this Agreement shall be deemed to be modified accordingly. 

9. Withholding of Taxes. The Company shall have the right to deduct from any payment to be made to the Participant pursuant to
this Agreement, or to otherwise require, prior to the issuance or delivery of any shares of Common Stock or the payment of any cash hereunder, payment by the Participant of, any Federal, state or local taxes required by law to be withheld. 

10. No Right to Employment. This Agreement is not an agreement of employment. None of this Agreement, the Plan or the
grant of the Option hereunder shall (a) guarantee that the Employer will employ the Participant for any specific time period or (b) modify or limit in any respect the Employer’s right to terminate or modify the Participant’s
employment or compensation. Moreover, this Agreement is not intended to and does not amend any existing employment contract between the Participant and the Company or any of its Affiliates; to the extent there is a conflict between this Agreement
and such an employment contract, the employment contract shall govern and take priority. 

  
 Page 3 of 5 

 11. Notices. All notices, demands or requests made pursuant to, under
or by virtue of this Agreement must be in writing or by electronic means as set forth in Section 11 below and sent to the party to which the notice, demand or request is being made: 

(a) unless otherwise specified by the Company in a notice delivered by the Company in accordance with this Section 11, any notice required
to be delivered to the Company shall be properly delivered if delivered to: 
 Vir Biotechnology, Inc. 

499 Illinois Street, Floor 5 
 San
Francisco, CA 94158 
 (b) if to the Participant, to the address on file with the Company. 

Any notice, demand or request, if made in accordance with this Section 11 shall be deemed to have been duly given: (i) when delivered in person or by
electronic means; (ii) three days after being sent by United States mail; or (iii) on the first business day following the date of deposit if delivered by a nationally recognized overnight delivery service. 

12. Mode of Communications. The Participant agrees, to the fullest extent permitted by applicable law, in lieu of
receiving documents in paper format, to accept electronic delivery of any documents that the Company or any of its Affiliates may deliver in connection with this Option grant and any other grants offered by the Company, including, without
limitation, prospectuses, grant notifications, account statements, annual or quarterly reports, and other communications. The Participant further agrees that electronic delivery of a document may be made via the Company’s email system or by
reference to a location on the Company’s intranet or website or the online brokerage account system. 
 13. Governing
Law. All matters arising out of or relating to this Agreement and the transactions contemplated hereby, including its validity, interpretation, construction, performance and enforcement, shall be governed by and construed in
accordance with the internal laws of the State of Delaware, without giving effect to principles of conflict of laws which would result in the application of the laws of any other jurisdiction. 

14. Dispute Resolution. All controversies and claims arising out of or relating to this Agreement, or the breach hereof,
shall be settled by the Employer’s mandatory dispute resolution procedures as may be in effect from time to time with respect to matters arising out of or relating to Participant’s employment with the Employer. 

15. WAIVER OF JURY TRIAL. EACH PARTY TO THIS AGREEMENT, FOR ITSELF AND ITS AFFILIATES, HEREBY IRREVOCABLY AND UNCONDITIONALLY
WAIVES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW ANY RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THE ACTIONS OF THE PARTIES HERETO OR
THEIR RESPECTIVE AFFILIATES PURSUANT TO THIS AGREEMENT OR IN THE NEGOTIATION, ADMINISTRATION, PERFORMANCE OR ENFORCEMENT OF THIS AGREEMENT. 

16. Construction. All section titles and captions in this Agreement are for convenience only, shall not be deemed part of this
Agreement, and in no way shall define, limit, extend or describe the scope or intent of any provisions of this Agreement. Wherever any words are used in this Agreement in the masculine gender they shall be construed as though they were also used in
the feminine gender in all cases where they would so apply. As used herein, (i) “or” shall mean “and/or” and (ii) “including” or “include” shall mean “including, without limitation.” Any reference
herein to an agreement in writing shall be deemed to include an electronic writing to the extent permitted by applicable law. 

  
 Page 4 of 5 

 17. Severability of Provisions. If at any time any of the provisions of
this Agreement shall be held invalid or unenforceable, or are prohibited by the laws of the jurisdiction where they are to be performed or enforced, by reason of being vague or unreasonable as to duration or geographic scope or scope of the
activities restricted, or for any other reason, such provisions shall be considered divisible and shall become and be immediately amended to include only such restrictions and to such extent as shall be deemed to be reasonable and enforceable by the
court or other body having jurisdiction over this Agreement and the Company and the Participant agree that the provisions of this Agreement, as so amended, shall be valid and binding as though any invalid or unenforceable provisions had not been
included; provided that if the Company’s call rights and rights of first refusal or rights of first offer set forth in the Stockholder Agreements or any other agreement shall be held invalid or unenforceable, the Option shall be cancelled and
terminated. 
 18. No Waiver. No failure by any party to insist upon the strict performance of any covenant, duty,
agreement or condition of this Agreement or to exercise any right or remedy consequent upon a breach thereof shall constitute waiver of any such breach or any other covenant, duty, agreement or condition. 

19. Entire Agreement. This Agreement contains the entire understanding of the parties with respect to the subject matter
hereof and supersedes any prior agreements between the Company and the Participant with respect to the subject matter hereof. 
 20.
Counterparts. This Agreement may be executed in counterparts, all of which together shall constitute one agreement binding on all the parties hereto, notwithstanding that all such parties are not signatories to the original or
the same counterpart. 
 [Remainder of Page Left Intentionally Blank] 

  
 Page 5 of 5 

 Exhibit I 

VIR BIOTECHNOLOGY, INC. 

2016 EQUITY INCENTIVE PLAN 

NOTICE OF EXERCISE 
 Date: [●],
20     
 Vir Biotechnology, Inc. 

499 Illinois Street, Floor 5 
 San Francisco, CA 94158 

Attention: [●] 
 Ladies and Gentlemen: 

This document constitutes notice under my stock option agreement that I elect to purchase the number of shares for the aggregate payment set forth below. 

 

					
	 Type of option (check one):
	  	Incentive  ☒   Nonqualified  ☐	  	                        
			
	 Option number and grant date:
	  	 [●] options – [●], 20    

 
	  	
			
	 Number of shares as to which option is exercised:
	  		  	
			
	 Per share exercise price:
	  	  
 $[●]

 
	  	
			
	 Aggregate exercise price (number of shares as to which option is exercised multiplied by per share exercise
price):
	  	 $
	  	

 I (i) agree that the shares purchased pursuant to this Notice of Exercise will be bound by and subject to the terms of
(a) that certain Right of First Refusal and Co-Sale Agreement dated as of August 25, 2017 (the “ROFR Agreement”), by and among Vir Biotechnology, Inc. and certain of its
stockholders, as such ROFR Agreement may be amended or restated and (b) that certain Voting Agreement dated as of August 25, 2017 (the “Voting Agreement” and together with the ROFR Agreement, the
“Agreements”), by and among Vir Biotechnology, Inc. and certain of its stockholders, as such Voting Agreement may be amended or restated; (ii) hereby adopt the Agreements with the same force and effect as if I were
originally a party thereto; (iii) acknowledge that I will be considered a “Key Holder” for all purposes of the Agreements; and (iv) agree to sign any such documents as may be required in connection with my becoming a party
to the Agreements. 
 Any notice required or permitted by the Agreements will be given to me at the address listed below my signature hereto. 

☐ Attached is [cash, or] a check, bank draft or money order payable to Vir Biotechnology, Inc. in the amount of
$             (aggregate exercise price). 
  

							
	Estimated withholding taxes:	  	$	  		  	

 ☐ Attached is [cash, or] a check, bank draft or money order payable to Vir Biotechnology, Inc. in the
amount of $             (estimated withholding taxes). 
 ☐ I have
made arrangements with Vir Biotechnology, Inc. to have the aggregate exercise price and/or the applicable withholding taxes withheld from other compensation. 

 By signing below, I (i) acknowledge that I remain subject to the applicable provisions of my option
award agreement, (ii) acknowledge and make the representations and warranties set forth below, and (iii) acknowledge that the Company is relying in part upon such representations and warranties: 

(a) I am acquiring and will hold the shares of Common Stock for investment for my account only and not with a view to, or for resale in
connection with, any “distribution” thereof within the meaning of the Securities Act or other applicable securities laws. 
 (b) I
have been advised that offerings of the shares of Common Stock have not been registered under the Securities Act or other applicable securities laws, on the ground that no public offering of the shares of Common Stock is to be effected (it being
understood, however, that the shares of Common Stock are being offered in reliance on the exemption provided under Rule 701 under the Securities Act), and that the shares of Common Stock must be held indefinitely, unless they are subsequently
registered under the applicable securities laws or I obtain an opinion of counsel (in the form and substance satisfactory to the Company and its counsel) that registration is not required. I further acknowledge and understand that the Company is
under no obligation hereunder to register offerings of the shares of Common Stock. 
 (c) I am aware of the adoption of Rule 144 by the
Securities and Exchange Commission under the Securities Act, which permits limited public resales of securities acquired in a non-public offering, subject to the satisfaction of certain conditions. I
acknowledge that I am familiar with the conditions for resale set forth in Rule 144, and I acknowledge and understand that the conditions for resale set forth in Rule 144 have not been satisfied and that the Company has no plans to satisfy these
conditions in the foreseeable future. 
 (d) I will not sell, transfer or otherwise dispose of the shares of Common Stock in violation of the
Vir Biotechnology, Inc. 2016 Equity Incentive Plan, my option award agreement, the Agreements, the Securities Act (or the rules and regulations promulgated thereunder) or under any other applicable securities laws. I agree that I will not dispose of
the Common Stock unless and until I have complied with all requirements applicable to the disposition of the shares of Common Stock. 
 (e) I
have been furnished with, and have had access to, such information as I consider necessary or appropriate for deciding whether to invest in the shares of Common Stock, and I have had an opportunity to ask questions and receive answers from the
Company regarding the terms and conditions of the offering of the Common Stock. 
 (f) I am aware that my investment in the Company is a
speculative investment that has limited liquidity and is subject to the risk of complete loss. I am able, without impairing my financial condition, to hold the Common Stock for an indefinite period and to suffer a complete loss of my investment in
the Common Stock. 
  

			
	  
 [Name of
Participant]

		
	Address:	 	
	  

	  

	  

	Telephone:	 	  

	Attention:	 	  

  

  
 Page 2 of 2 

 THE SECURITIES REPRESENTED BY THIS NOTICE AND AGREEMENT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF
1933, AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT OF 1933 AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. 
 INCENTIVE STOCK OPTION GRANT NOTICE AND
AGREEMENT 
 Vir Biotechnology, Inc. (the “Company”), pursuant to its 2016 Equity Incentive Plan (the
“Plan”), hereby grants to Participant an Option to purchase the number of shares of the Company’s Common Stock (referred to herein as “Shares”) set forth below. This Option is subject to all of
the terms and conditions as set forth herein and in the Incentive Stock Option Agreement attached hereto as Exhibit A (the “Agreement”) and the Plan, each of which is incorporated herein by reference. Unless otherwise
defined herein, the terms defined in the Plan shall have the same defined meanings in this Incentive Stock Option Grant Notice (“Grant Notice”) and the Agreement. 

 

			
	Participant:	  	«Participant_Name»
		
	Grant Date:	  	«Grant_Date»
		
	Vesting Commencement Date:	  	«Vesting_Commencement_Date»
		
	Exercise Price per Share:	  	$«Exercise_Price»
		
	Total Number of Shares Subject to Option:	  	«No_of_Shares»
		
	Expiration Date:	  	«Expiration_Date»
		
	Type of Option:	  	Incentive Stock Option
		
	Vesting Schedule:	  	Subject to Section 3(b), [the Option shall vest and become exercisable over a four-year period commencing on the Vesting Commencement Date, with 25% of the Option vesting on the one-year
anniversary of the Vesting Commencement Date, and the remainder of the Option vesting in 36 equal installments beginning on the date that is the one-month anniversary of such
one-year anniversary date, and each one-month anniversary date thereafter; provided, however, that the Participant has not experienced a Termination prior to each
applicable vesting date.]

 By his or her signature and the Company’s signature below, Participant agrees to be bound by the terms
and conditions of the Plan, the Agreement and this Grant Notice. Participant has reviewed the Agreement, the Plan and this Grant Notice in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Grant Notice
and fully understands all provisions of this Grant Notice, the Agreement and the Plan. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Committee upon any questions arising under the Plan
or the Agreement. 
  

									
	VIR BIOTECHNOLOGY, INC.	 	    	  	PARTICIPANT:
					
	By:	 	              
	 		  	By:	 	  

	Print Name:	 	              
	 		  	Print Name:	 	  

	Title:	 	              
	 		  	State of Residence:	 	  

 EXHIBIT A 

TO STOCK OPTION GRANT NOTICE 

INCENTIVE STOCK OPTION AGREEMENT 

PURSUANT TO THE 
 VIR
BIOTECHNOLOGY, INC. 
 2016 EQUITY INCENTIVE PLAN 

Pursuant to the Grant Notice to which this Agreement is attached, the Company has granted to Participant an Option under the Plan to purchase
the number of Shares indicated in the Grant Notice. 
 Preliminary Statement 

The Committee hereby grants this stock option (the “Option”) as of the Grant Date pursuant to the Vir Biotechnology,
Inc. 2016 Equity Incentive Plan, as it may be amended from time to time (the “Plan”), to purchase the number of shares of the common stock of the Company, $0.0001 par value per share (the “Common
Stock”), set forth in the Grant Notice, to the Participant, as an Eligible Employee of the Company or one of its Affiliates (collectively, the Company and all of its Affiliates shall be referred to as the
“Employer”). Except as otherwise indicated, any capitalized term used but not defined herein shall have the meaning ascribed to such term in the Grant Notice or the Plan, as applicable. A copy of the Plan has been delivered
to the Participant. By signing and returning this Agreement, the Participant acknowledges having received and read a copy of the Plan and agrees to comply with it, this Agreement and all applicable laws and regulations. 

Accordingly, the parties hereto agree as follows: 

1. Tax Matters. The Option is intended to qualify as an “incentive stock option” under Section 422 of the
Internal Revenue Code of 1986, as amended. Notwithstanding the foregoing, the Option will not qualify as an “incentive stock option,” among other events, (i) if the Participant disposes of any shares of Common Stock acquired pursuant
to the Option at any time during the two (2) year period following the date of this Agreement or the one (1) year period following the date on which the Option is exercised; (ii) except in the event of the Participant’s death or
disability, as defined in Section 22(e)(3) of the Code, if the Participant is not employed by the Company, any “parent corporation” of the Company within the meaning of Section 424(e) of the Code
(“Parent”), or any “subsidiary corporation” within the meaning of Section 424(f) of the Code (“Subsidiary”), at all times during the period beginning on the Grant Date (as defined
herein) and ending on the day three (3) months before the date of exercise of the Option; or (iii) to the extent the aggregate Fair Market Value (determined as of the time the Option is granted) of the shares of Common Stock subject to
“incentive stock options” which become exercisable for the first time by the Participant in any calendar year exceeds $100,000. To the extent that the Option does not qualify as an “incentive stock option,” it shall not affect
the validity of the Option and shall constitute a separate non-qualified stock option. 
 2.
Common Stock Subject to Option; Exercise Price. Subject in all respects to the Plan and the terms and conditions set forth herein and therein, the Option entitles the Participant to purchase from the Company, upon exercise, the
Total Number of Shares Subject to Option (as set forth in the Grant Notice ) at the Exercise Price per Share (as set forth in the Grant Notice). 

 3. Vesting; Exercise. 

(a) [Subject to Section 3(b), the Option shall vest and become exercisable over a four-year period commencing on the Vesting Commencement
Date, with 25% of the Option vesting on the one-year anniversary of the Vesting Commencement Date, and the remainder of the Option vesting in 36 equal installments beginning on the date that is the one-month anniversary of such one-year anniversary date, and each one-month anniversary date thereafter; provided, however, that the
Participant has not experienced a Termination prior to each applicable vesting date.] 
 (b) To the extent that the Option has become vested
and exercisable with respect to a number of shares of Common Stock, the Option may thereafter be exercised by the Participant, in whole or in part, at any time or from time to time prior to the expiration of the Option in accordance with the Plan.
Notwithstanding the foregoing, the Participant may not exercise the Option unless the offering of shares of Common Stock issuable upon such exercise (i) is then registered under the Securities Act, or, if such offering is not then so
registered, the Company has determined that such offering is exempt from the registration requirements of the Securities Act and (ii) complies with all other applicable laws and regulations governing the Option, and the Participant may not
exercise the Option if the Committee determines that such exercise would not be so registered or exempt and otherwise in compliance with such laws and regulations. 

(c) To exercise the Option, unless otherwise directed or permitted by the Committee, the Participant must: 

(i) execute and deliver to the Company a properly completed Notice of Exercise in the form attached hereto as Exhibit I.

 (ii) execute and deliver such other documentation as required by the Committee (including, without limitation, the
Stockholder Agreements) which may set forth certain restrictions on transferability of the shares of Common Stock acquired upon exercise, a right of first refusal or a right of first offer of the Company and other Persons with respect to shares, and
such other terms or restrictions as the Board or Committee may from time to time establish, including any drag along rights, tag along rights, transfer restrictions and registration rights, and 

(iii) remit the aggregate Exercise Price to the Company in full, payable (A) in cash or by check, bank draft or money
order payable to the order of the Company; or (B) on such other terms and conditions as may be acceptable to the Committee (including, without limitation, making arrangements with the Company to have such Exercise Price withheld from other
compensation). 
 (d) In addition, unless otherwise directed or permitted by the Committee, the Participant must pay or provide for all
applicable withholding taxes in respect of the exercise of the Option, by (i) remitting the aggregate amount of such taxes to the Company in full, in cash or by check, bank draft or money order payable to the order of the Company, or
(ii) making arrangements with the Company to have such taxes withheld from other compensation, to the extent permitted by the Committee. 

4. Termination. The term of the Option shall be until the tenth anniversary of the Grant Date, after which time it shall
expire (the “Expiration Date”), subject to earlier termination in the event of the Participant’s Termination as specified in the Plan and this Agreement. Notwithstanding anything herein to the contrary, upon the
Expiration Date, the Option (whether vested or not) shall be immediately forfeited, canceled and terminated for no consideration and no longer shall be exercisable. The provisions in the Plan regarding Termination shall apply to the Option,
provided that, to the extent applicable, if the Participant’s employment agreement expressly provides more favorable rights with respect to the Option in the event of Termination, such rights shall apply. 

  
 Page 2 of 5 

 5. Market Stand-Off. If
requested by the Company or the lead underwriter of any public offering of the Common Stock (the “Lead Underwriter”), the Participant shall irrevocably agree not to sell, contract to sell, grant any option to purchase,
transfer the economic risk of ownership in, make any short sale of, pledge or otherwise Transfer or dispose of, any interest in any Common Stock or any securities convertible into, derivative of, or exchangeable or exercisable for Common Stock, or
any other rights to purchase or acquire Common Stock (except Common Stock included in such public offering or acquired on the public market after such offering) during such period of time following the effective date of a registration statement of
the Company filed under the Securities Act that the Lead Underwriter shall specify (the “Lock-up Period”). The Participant shall further agree to sign such documents as may be requested
by the Lead Underwriter or the Company to effect the foregoing and agree that the Company may impose stop transfer instructions with respect to Common Stock acquired pursuant to an Award until the end of such
Lock-up Period. 
 6. Restriction on Transfer of Option. Unless otherwise
determined by the Committee in accordance with the Plan, (a) no part of the Option shall be Transferable other than by will or by the laws of descent and distribution and (b) during the lifetime of the Participant, the Option may be
exercised only by the Participant. Any attempt to Transfer the Option other than in accordance with the Plan shall be void. 
 7. No
Rights as Stockholder. The Participant shall have no rights as a stockholder with respect to any shares of Common Stock covered by the Option unless and until the Participant has become the holder of record of such shares, and no
adjustments shall be made for dividends (whether in cash, in kind or other property), distributions or other rights in respect of any such shares, except as otherwise specifically provided for in the Plan. 

8. Provisions of Plan Control. This Agreement is subject to all the terms, conditions and provisions of the Plan,
including the amendment provisions thereof, and to such rules, regulations and interpretations relating to the Plan as may be adopted by the Committee and as may be in effect from time to time. The Plan is incorporated herein by reference. If and to
the extent that this Agreement conflicts or is inconsistent with the Plan, the Plan shall control, and this Agreement shall be deemed to be modified accordingly. 

9. Withholding of Taxes. The Company shall have the right to deduct from any payment to be made to the Participant
pursuant to this Agreement, or to otherwise require, prior to the issuance or delivery of any shares of Common Stock or the payment of any cash hereunder, payment by the Participant of, any Federal, state or local taxes required by law to be
withheld. 
 10. No Right to Employment. This Agreement is not an agreement of employment. None of this Agreement, the
Plan or the grant of the Option hereunder shall (a) guarantee that the Employer will employ the Participant for any specific time period or (b) modify or limit in any respect the Employer’s right to terminate or modify the
Participant’s employment or compensation. Moreover, this Agreement is not intended to and does not amend any existing employment contract between the Participant and the Company or any of its Affiliates; to the extent there is a conflict
between this Agreement and such an employment contract, the employment contract shall govern and take priority. 

  
 Page 3 of 5 

 11. Notices. All notices, demands or requests made pursuant to, under
or by virtue of this Agreement must be in writing or by electronic means as set forth in Section 11 below and sent to the party to which the notice, demand or request is being made: 

(a) unless otherwise specified by the Company in a notice delivered by the Company in accordance with this Section 11, any notice required
to be delivered to the Company shall be properly delivered if delivered to: 
 Vir Biotechnology, Inc. 

499 Illinois Street, Floor 5 
 San
Francisco, CA 94158 
 (b) if to the Participant, to the address on file with the Company. 

Any notice, demand or request, if made in accordance with this Section 11 shall be deemed to have been duly given: (i) when delivered in person or by
electronic means; (ii) three days after being sent by United States mail; or (iii) on the first business day following the date of deposit if delivered by a nationally recognized overnight delivery service. 

12. Mode of Communications. The Participant agrees, to the fullest extent permitted by applicable law, in lieu of
receiving documents in paper format, to accept electronic delivery of any documents that the Company or any of its Affiliates may deliver in connection with this Option grant and any other grants offered by the Company, including, without
limitation, prospectuses, grant notifications, account statements, annual or quarterly reports, and other communications. The Participant further agrees that electronic delivery of a document may be made via the Company’s email system or by
reference to a location on the Company’s intranet or website or the online brokerage account system. 
 13. Governing
Law. All matters arising out of or relating to this Agreement and the transactions contemplated hereby, including its validity, interpretation, construction, performance and enforcement, shall be governed by and construed in
accordance with the internal laws of the State of Delaware, without giving effect to principles of conflict of laws which would result in the application of the laws of any other jurisdiction. 

14. Dispute Resolution. All controversies and claims arising out of or relating to this Agreement, or the breach hereof,
shall be settled by the Employer’s mandatory dispute resolution procedures as may be in effect from time to time with respect to matters arising out of or relating to Participant’s employment with the Employer. 

15. WAIVER OF JURY TRIAL. EACH PARTY TO THIS AGREEMENT, FOR ITSELF AND ITS AFFILIATES, HEREBY IRREVOCABLY AND UNCONDITIONALLY
WAIVES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW ANY RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THE ACTIONS OF THE PARTIES HERETO OR THEIR
RESPECTIVE AFFILIATES PURSUANT TO THIS AGREEMENT OR IN THE NEGOTIATION, ADMINISTRATION, PERFORMANCE OR ENFORCEMENT OF THIS AGREEMENT. 

16. Construction. All section titles and captions in this Agreement are for convenience only, shall not be deemed part of
this Agreement, and in no way shall define, limit, extend or describe the scope or intent of any provisions of this Agreement. Wherever any words are used in this Agreement in the masculine gender they shall be construed as though they were also
used in the feminine gender in all cases where they would so apply. As used herein, (i) “or” shall mean “and/or” and (ii) “including” or “include” shall mean “including, without limitation.” Any
reference herein to an agreement in writing shall be deemed to include an electronic writing to the extent permitted by applicable law. 

  
 Page 4 of 5 

 17. Severability of Provisions. If at any time any of the provisions of
this Agreement shall be held invalid or unenforceable, or are prohibited by the laws of the jurisdiction where they are to be performed or enforced, by reason of being vague or unreasonable as to duration or geographic scope or scope of the
activities restricted, or for any other reason, such provisions shall be considered divisible and shall become and be immediately amended to include only such restrictions and to such extent as shall be deemed to be reasonable and enforceable by the
court or other body having jurisdiction over this Agreement and the Company and the Participant agree that the provisions of this Agreement, as so amended, shall be valid and binding as though any invalid or unenforceable provisions had not been
included; provided that if the Company’s call rights and rights of first refusal or rights of first offer set forth in the Stockholder Agreements or any other agreement shall be held invalid or unenforceable, the Option shall be cancelled and
terminated. 
 18. No Waiver. No failure by any party to insist upon the strict performance of any covenant, duty,
agreement or condition of this Agreement or to exercise any right or remedy consequent upon a breach thereof shall constitute waiver of any such breach or any other covenant, duty, agreement or condition. 

19. Entire Agreement. This Agreement contains the entire understanding of the parties with respect to the subject matter
hereof and supersedes any prior agreements between the Company and the Participant with respect to the subject matter hereof. 
 20.
Counterparts. This Agreement may be executed in counterparts, all of which together shall constitute one agreement binding on all the parties hereto, notwithstanding that all such parties are not signatories to the original or
the same counterpart. 
 [Remainder of Page Left Intentionally Blank] 

  
 Page 5 of 5 

 Exhibit I 

VIR BIOTECHNOLOGY, INC. 

2016 EQUITY INCENTIVE PLAN 

NOTICE OF EXERCISE 
 Date: [●],
20     
 Vir Biotechnology, Inc. 

499 Illinois Street, Floor 5 
 San Francisco, CA 94158 

Attention: [●] 
 Ladies and Gentlemen: 

This document constitutes notice under my stock option agreement that I elect to purchase the number of shares for the aggregate payment set forth below. 

 

					
	 Type of option (check one):
	  	Incentive ☒   Nonqualified  ☐	  	                        
			
	 Option number and grant date:
	  	 [●] options – [●], 20    

 
	  	
			
	 Number of shares as to which option is exercised:
	  		  	
			
	 Per share exercise price:
	  	  
 $[●]

 
	  	
			
	 Aggregate exercise price (number of shares as to which option is exercised multiplied by per share exercise
price):
	  	 $
	  	

 I (i) agree that the shares purchased pursuant to this Notice of Exercise will be bound by and subject to the terms of
(a) that certain Right of First Refusal and Co-Sale Agreement dated as of August 25, 2017 (the “ROFR Agreement”), by and among Vir Biotechnology, Inc. and certain of its
stockholders, as such ROFR Agreement may be amended or restated and (b) that certain Voting Agreement dated as of August 25, 2017 (the “Voting Agreement” and together with the ROFR Agreement, the
“Agreements”), by and among Vir Biotechnology, Inc. and certain of its stockholders, as such Voting Agreement may be amended or restated; (ii) hereby adopt the Agreements with the same force and effect as if I were
originally a party thereto; (iii) acknowledge that I will be considered a “Key Holder” for all purposes of the Agreements; and (iv) agree to sign any such documents as may be required in connection with my becoming a party
to the Agreements. 
 Any notice required or permitted by the Agreements will be given to me at the address listed below my signature hereto. 

☐ Attached is [cash, or] a check, bank draft or money order payable to Vir Biotechnology, Inc. in the amount of
$             (aggregate exercise price). 
  

					
	Estimated withholding taxes:	  	$	  	

 ☐ Attached is [cash, or] a check, bank draft or money order payable to Vir Biotechnology, Inc. in the
amount of $             (estimated withholding taxes). 
 ☐ I have
made arrangements with Vir Biotechnology, Inc. to have the aggregate exercise price and/or the applicable withholding taxes withheld from other compensation. 

 By signing below, I (i) acknowledge that I remain subject to the applicable provisions of my option
award agreement, (ii) acknowledge and make the representations and warranties set forth below, and (iii) acknowledge that the Company is relying in part upon such representations and warranties: 

(a) I am acquiring and will hold the shares of Common Stock for investment for my account only and not with a view to, or for resale in
connection with, any “distribution” thereof within the meaning of the Securities Act or other applicable securities laws. 
 (b) I
have been advised that offerings of the shares of Common Stock have not been registered under the Securities Act or other applicable securities laws, on the ground that no public offering of the shares of Common Stock is to be effected (it being
understood, however, that the shares of Common Stock are being offered in reliance on the exemption provided under Rule 4(a)(2) under the Securities Act), and that the shares of Common Stock must be held indefinitely, unless they are subsequently
registered under the applicable securities laws or I obtain an opinion of counsel (in the form and substance satisfactory to the Company and its counsel) that registration is not required. I further acknowledge and understand that the Company is
under no obligation hereunder to register offerings of the shares of Common Stock. 
 (c) I am aware of the adoption of Rule 144 by the
Securities and Exchange Commission under the Securities Act, which permits limited public resales of securities acquired in a non-public offering, subject to the satisfaction of certain conditions. I
acknowledge that I am familiar with the conditions for resale set forth in Rule 144, and I acknowledge and understand that the conditions for resale set forth in Rule 144 have not been satisfied and that the Company has no plans to satisfy these
conditions in the foreseeable future. 
 (d) I will not sell, transfer or otherwise dispose of the shares of Common Stock in violation of the
Vir Biotechnology, Inc. 2016 Equity Incentive Plan, my option award agreement, the Agreements, the Securities Act (or the rules and regulations promulgated thereunder) or under any other applicable securities laws. I agree that I will not dispose of
the Common Stock unless and until I have complied with all requirements applicable to the disposition of the shares of Common Stock. 
 (e) I
have been furnished with, and have had access to, such information as I consider necessary or appropriate for deciding whether to invest in the shares of Common Stock, and I have had an opportunity to ask questions and receive answers from the
Company regarding the terms and conditions of the offering of the Common Stock. 
 (f) I am aware that my investment in the Company is a
speculative investment that has limited liquidity and is subject to the risk of complete loss. I am able, without impairing my financial condition, to hold the Common Stock for an indefinite period and to suffer a complete loss of my investment in
the Common Stock. 
 (g) I represent and warrant that I am an “accredited investor” within the meaning of Regulation D under the
Securities Act. In addition, I either (a) have a preexisting personal or business relationship with the Company or its principals or (b) have substantial knowledge and experience in financial business smatters, have specific experience in
making investment decisions of a similar nature, and am capable, without the use of a financial advisor, of utilizing and analyzing the information made available in connection with the acquisition of the shares of Common Stock and of evaluating the
merits and risks of an investment in the shares of Common Stock and protecting my own interests in connection with this transaction. 

  
 Page 2 of 3 

 
			
	  
 [Name of
Participant]

		
	Address:	 	
	
	  

	  

	  

	Telephone:	 	  

	Attention:	 	  

  

  
 Page 3 of 3 

 VIR BIOTECHNOLOGY, INC. 

2016 EQUITY INCENTIVE PLAN 

NONQUALIFIED STOCK OPTION GRANT NOTICE AND AGREEMENT 

Vir Biotechnology, Inc. (the “Company”), pursuant to its 2016 Equity Incentive Plan (the
“Plan”), hereby grants to Participant an Option to purchase the number of shares of the Company’s Common Stock (referred to herein as “Shares”) set forth below. This Option is subject to all of
the terms and conditions as set forth herein and in the Nonqualified Stock Option Agreement attached hereto as Exhibit A (the “Agreement”) and the Plan, each of which is incorporated herein by reference. Unless
otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in this Nonqualified Stock Option Grant Notice (“Grant Notice”) and the Agreement. 

 

			
	Participant:	  	«Participant_Name»
		
	Grant Date:	  	«Grant_Date»
		
	Vesting Commencement Date:	  	«Vesting_Commencement_Date»
		
	Exercise Price per Share:	  	$«Exercise_Price»
		
	Total Number of Shares Subject to Option:	  	«No_of_Shares»
		
	Expiration Date:	  	«Expiration_Date»
		
	Type of Option:	  	Nonqualified Stock Option
		
	Vesting Schedule:	  	Subject to Section 3(b), [the Option shall vest and become exercisable over a four-year period commencing on the Vesting Commencement Date, with 25% of the Option vesting on the one-year
anniversary of the Vesting Commencement Date, and the remainder of the Option vesting in 36 equal installments beginning on the date that is the one-month anniversary of such
one-year anniversary date, and each one-month anniversary date thereafter; provided, however, that the Participant has not experienced a Termination prior to each
applicable vesting date.]

 By his or her signature and the Company’s signature below, Participant agrees to be bound by the terms
and conditions of the Plan, the Agreement and this Grant Notice. Participant has reviewed the Agreement, the Plan and this Grant Notice in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Grant Notice
and fully understands all provisions of this Grant Notice, the Agreement and the Plan. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Committee upon any questions arising under the Plan
or the Agreement. 
  

									
	VIR BIOTECHNOLOGY, INC.	 	    	  	PARTICIPANT:
					
	By:	 	              
	 		  	By:	 	  

	Print Name:	 	              
	 		  	Print Name:	 	  

	Title:	 	              
	 		  	State of Residence:	 	  

 EXHIBIT A 

TO STOCK OPTION GRANT NOTICE 

NONQUALIFIED STOCK OPTION AGREEMENT 

PURSUANT TO THE 
 VIR
BIOTECHNOLOGY, INC. 
 2016 EQUITY INCENTIVE PLAN 

Pursuant to the Grant Notice to which this Agreement is attached, the Company has granted to Participant an Option under the Plan to purchase
the number of Shares indicated in the Grant Notice. 
 Preliminary Statement 

The Committee hereby grants this stock option (the “Option”) as of the Grant Date pursuant to the Vir Biotechnology,
Inc. 2016 Equity Incentive Plan, as it may be amended from time to time (the “Plan”), to purchase the number of shares of the common stock of the Company, $0.0001 par value per share (the “Common
Stock”), set forth in the Grant Notice, to the Participant, as [an Eligible Employee][a Consultant] of the Company. Except as otherwise indicated, any capitalized term used but not defined herein shall have the meaning ascribed to such
term in the Grant Notice or the Plan, as applicable. A copy of the Plan has been delivered to the Participant. By signing and returning this Agreement, the Participant acknowledges having received and read a copy of the Plan and agrees to comply
with it, this Agreement and all applicable laws and regulations. 
 Accordingly, the parties hereto agree as follows: 

1. Tax Matters. No part of the Option granted hereby is intended to qualify as an “incentive stock option” under
section 422 of the Code. 
 2. Common Stock Subject to Option; Exercise Price. Subject in all respects to the Plan and
the terms and conditions set forth herein and therein, the Option entitles the Participant to purchase from the Company, upon exercise, the Total Number of Shares Subject to Option (as set forth in the Grant Notice ) at the Exercise Price per Share
(as set forth in the Grant Notice). 
 3. Vesting; Exercise. 

(a) Subject to Section 3(b), [the Option shall vest and become exercisable over a four-year period commencing on the Vesting Commencement
Date, with 25% of the Option vesting on the one-year anniversary of the Vesting Commencement Date, and the remainder of the Option vesting in 36 equal installments beginning on the date that is the one-month anniversary of such one-year anniversary date, and each one-month anniversary date thereafter; provided, however, that the
Participant has not experienced a Termination prior to each applicable vesting date.] 
 (b) To the extent that the Option has become vested
and exercisable with respect to a number of shares of Common Stock, the Option may thereafter be exercised by the Participant, in whole or in part, at any time or from time to time prior to the expiration of the Option in accordance with
Section 4 and the Plan. Notwithstanding the foregoing, the Participant may not exercise the Option unless the offering of shares of Common Stock issuable upon such exercise (i) is then registered under the Securities Act, or, if such
offering is not then so registered, the Company has determined that such offering is exempt from the registration requirements of the Securities Act and (ii) complies with all other applicable laws and regulations governing the Option, and the
Participant may not exercise the Option if the Committee determines that such exercise would not be so registered or exempt and otherwise in compliance with such laws and regulations. 

 (c) To exercise the Option, unless otherwise directed or permitted by the Committee, the
Participant must: 
 (i) execute and deliver to the Company a properly completed Notice of Exercise in the form attached
hereto as Exhibit I. 
 (ii) execute and deliver such other documentation as required by the Committee (including,
without limitation, the Stockholder Agreements) which may set forth certain restrictions on transferability of the shares of Common Stock acquired upon exercise, a right of first refusal or a right of first offer of the Company and other Persons
with respect to shares, and such other terms or restrictions as the Board or Committee may from time to time establish, including any drag along rights, tag along rights, transfer restrictions and registration rights, and 

(iii) remit the aggregate Exercise Price to the Company in full, payable (A) in cash or by check, bank draft or money
order payable to the order of the Company; or (B) on such other terms and conditions as may be acceptable to the Committee (including, without limitation, making arrangements with the Company to have such Exercise Price withheld from other
compensation). 
 (d) In addition, unless otherwise directed or permitted by the Committee, the Participant must pay or provide for all
applicable withholding taxes in respect of the exercise of the Option, by (i) remitting the aggregate amount of such taxes to the Company in full, in cash or by check, bank draft or money order payable to the order of the Company, or
(ii) making arrangements with the Company to have such taxes withheld from other compensation, to the extent permitted by the Committee. 

4. Termination. The term of the Option shall be until the tenth anniversary of the Grant Date, after which time it shall
expire (the “Expiration Date”), subject to earlier termination in the event of the Participant’s Termination as specified in the Plan and this Agreement. Notwithstanding anything herein to the contrary, upon the
Expiration Date, the Option (whether vested or not) shall be immediately forfeited, canceled and terminated for no consideration and no longer shall be exercisable. Except as otherwise provided in Section 3(a), the provisions in the Plan
regarding Termination shall apply to the Option; provided, that, to the extent applicable, if the Participant’s employment agreement or consulting agreement expressly provides more favorable rights with respect to the Option in the event
of Termination, such rights shall apply. 
 5. Market Stand-Off. If requested by
the Company or the lead underwriter of any public offering of the Common Stock (the “Lead Underwriter”), the Participant shall irrevocably agree not to sell, contract to sell, grant any option to purchase, transfer the
economic risk of ownership in, make any short sale of, pledge or otherwise Transfer or dispose of, any interest in any Common Stock or any securities convertible into, derivative of, or exchangeable or exercisable for Common Stock, or any other
rights to purchase or acquire Common Stock (except Common Stock included in such public offering or acquired on the public market after such offering) during such period of time following the effective date of a registration statement of the Company
filed under the Securities Act that the Lead Underwriter shall specify (the “Lock-up Period”). The Participant shall further agree to sign such documents as may be requested by the Lead
Underwriter or the Company to effect the foregoing and agree that the Company may impose stop transfer instructions with respect to Common Stock acquired pursuant to an Award until the end of such Lock-up
Period. 

 6. Restriction on Transfer of Option. Unless otherwise determined by
the Committee in accordance with the Plan, (a) no part of the Option shall be Transferable other than by will or by the laws of descent and distribution and (b) during the lifetime of the Participant, the Option may be exercised only by
the Participant. Any attempt to Transfer the Option other than in accordance with the Plan shall be void. 
 7. No Rights as
Stockholder. The Participant shall have no rights as a stockholder with respect to any shares of Common Stock covered by the Option unless and until the Participant has become the holder of record of such shares, and no adjustments
shall be made for dividends (whether in cash, in kind or other property), distributions or other rights in respect of any such shares, except as otherwise specifically provided for in the Plan. 

8. Provisions of Plan Control. This Agreement is subject to all the terms, conditions and provisions of the Plan,
including the amendment provisions thereof, and to such rules, regulations and interpretations relating to the Plan as may be adopted by the Committee and as may be in effect from time to time. The Plan is incorporated herein by reference. If and to
the extent that this Agreement conflicts or is inconsistent with the Plan, the Plan shall control, and this Agreement shall be deemed to be modified accordingly. 

9. Withholding of Taxes. The Company shall have the right to deduct from any payment to be made to the Participant
pursuant to this Agreement, or to otherwise require, prior to the issuance or delivery of any shares of Common Stock or the payment of any cash hereunder, payment by the Participant of, any Federal, state or local taxes required by law to be
withheld. 
 10. No Right to Employment or Consultancy Service. This Agreement is not an agreement of employment or to
provide consultancy services. None of this Agreement, the Plan or the grant of the Option hereunder shall (a) guarantee that the Company will employ or retain the Participant as an employee or consultant for any specific time period or
(b) modify or limit in any respect the Company’s right to terminate or modify the Participant’s employment, consultancy arrangement or compensation. Moreover, this Agreement is not intended to and does not amend any existing
employment or consulting contract between the Participant and the Company or any of its Affiliates; to the extent there is a conflict between this Agreement and such an employment or consulting contract, the employment or consulting contract shall
govern and take priority. 
 11. Notices. All notices, demands or requests made pursuant to, under or by virtue of this
Agreement must be in writing or by electronic means as set forth in Section 11 below and sent to the party to which the notice, demand or request is being made: 

(a) unless otherwise specified by the Company in a notice delivered by the Company in accordance with this Section 11, any notice required
to be delivered to the Company shall be properly delivered if delivered to: 
 Vir Biotechnology, Inc. 

499 Illinois Street, Floor 5 
 San
Francisco, CA 94158 
 (b) if to the Participant, to the address on file with the Company. 

 Any notice, demand or request, if made in accordance with this Section 11 shall be deemed to have been
duly given: (i) when delivered in person or by electronic means; (ii) three days after being sent by United States mail; or (iii) on the first business day following the date of deposit if delivered by a nationally recognized
overnight delivery service. 
 12. Mode of Communications. The Participant agrees, to the fullest extent permitted by
applicable law, in lieu of receiving documents in paper format, to accept electronic delivery of any documents that the Company or any of its Affiliates may deliver in connection with this Option grant and any other grants offered by the Company,
including, without limitation, prospectuses, grant notifications, account statements, annual or quarterly reports, and other communications. The Participant further agrees that electronic delivery of a document may be made via the Company’s
email system or by reference to a location on the Company’s intranet or website or the online brokerage account system. 
 13.
Governing Law. All matters arising out of or relating to this Agreement and the transactions contemplated hereby, including its validity, interpretation, construction, performance and enforcement, shall be governed by and
construed in accordance with the internal laws of the State of Delaware, without giving effect to principles of conflict of laws which would result in the application of the laws of any other jurisdiction. 

14. Dispute Resolution. All controversies and claims arising out of or relating to this Agreement, or the breach hereof,
shall be settled by the Company’s mandatory dispute resolution procedures as may be in effect from time to time with respect to matters arising out of or relating to Participant’s employment or consultancy arrangement with the Company.

 15. WAIVER OF JURY TRIAL. EACH PARTY TO THIS AGREEMENT, FOR ITSELF AND ITS AFFILIATES, HEREBY IRREVOCABLY AND
UNCONDITIONALLY WAIVES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW ANY RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THE ACTIONS OF THE PARTIES
HERETO OR THEIR RESPECTIVE AFFILIATES PURSUANT TO THIS AGREEMENT OR IN THE NEGOTIATION, ADMINISTRATION, PERFORMANCE OR ENFORCEMENT OF THIS AGREEMENT. 

16. Construction. All section titles and captions in this Agreement are for convenience only, shall not be deemed part of
this Agreement, and in no way shall define, limit, extend or describe the scope or intent of any provisions of this Agreement. Wherever any words are used in this Agreement in the masculine gender they shall be construed as though they were also
used in the feminine gender in all cases where they would so apply. As used herein, (i) “or” shall mean “and/or” and (ii) “including” or “include” shall mean “including, without limitation.” Any
reference herein to an agreement in writing shall be deemed to include an electronic writing to the extent permitted by applicable law. 

17. Severability of Provisions. If at any time any of the provisions of this Agreement shall be held invalid or
unenforceable, or are prohibited by the laws of the jurisdiction where they are to be performed or enforced, by reason of being vague or unreasonable as to duration or geographic scope or scope of the activities restricted, or for any other reason,
such provisions shall be considered divisible and shall become and be immediately amended to include only such restrictions and to such extent as shall be deemed to be reasonable and enforceable by the court or other body having jurisdiction over
this Agreement and the Company and the Participant agree that the provisions of this Agreement, as so amended, shall be valid and binding as though any invalid or unenforceable provisions had not been included; provided that if the Company’s
call rights and rights of first refusal or rights of first offer set forth in the Stockholder Agreements or any other agreement shall be held invalid or unenforceable, the Option shall be cancelled and terminated. 

 18. No Waiver. No failure by any party to insist upon the strict
performance of any covenant, duty, agreement or condition of this Agreement or to exercise any right or remedy consequent upon a breach thereof shall constitute waiver of any such breach or any other covenant, duty, agreement or condition. 

19. Entire Agreement. This Agreement contains the entire understanding of the parties with respect to the subject matter
hereof and supersedes any prior agreements between the Company and the Participant with respect to the subject matter hereof. 
 20.
Counterparts. This Agreement may be executed in counterparts, all of which together shall constitute one agreement binding on all the parties hereto, notwithstanding that all such parties are not signatories to the original or
the same counterpart. 
 [Remainder of Page Left Intentionally Blank] 

 Exhibit I 

VIR BIOTECHNOLOGY, INC. 

2016 EQUITY INCENTIVE PLAN 

NOTICE OF EXERCISE 
 Date: [●], 20__

 Vir Biotechnology, Inc. 
 499 Illinois Street, Floor 5 

San Francisco, CA 94158 
 Attention: [●] 

Ladies and Gentlemen: 
 This document constitutes notice under my
stock option agreement that I elect to purchase the number of shares for the aggregate payment set forth below. 
  

					
	 Type of option (check one):
	  	Incentive  ☐     Nonqualified  ☒	  	                        
			
	 Option number and grant date:
	  	 [●] options – [●], 20__
  
	  	
			
	 Number of shares as to which option is exercised:
	  	  
	  	
			
	 Per share exercise price:
	  	 $[●]
	  	
			
	 Aggregate exercise price (number of shares as to which option is exercised multiplied by per share exercise
price):
	  	 $
	  	

 I (i) agree that the shares purchased pursuant to this Notice of Exercise will be bound by and subject to the terms of
(a) that certain Right of First Refusal and Co-Sale Agreement dated as of August 25, 2017 (the “ROFR Agreement”), by and among Vir Biotechnology, Inc. and certain of its
stockholders, as such ROFR Agreement may be amended or restated and (b) that certain Voting Agreement dated as of August 25, 2017 (the “Voting Agreement” and together with the ROFR Agreement, the
“Agreements”), by and among Vir Biotechnology, Inc. and certain of its stockholders, as such Voting Agreement may be amended or restated; (ii) hereby adopt the Agreements with the same force and effect as if I were
originally a party thereto; (iii) acknowledge that I will be considered a “Key Holder” for all purposes of the Agreements; and (iv) agree to sign any such documents as may be required in connection with my becoming a party
to the Agreements. 
 Any notice required or permitted by the Agreements will be given to me at the address listed below my signature hereto. 

☐ Attached is [cash, or] a check, bank draft or money order payable to Vir Biotechnology, Inc. in the amount of
$             (aggregate exercise price). 
 Estimated withholding taxes:
                                    $ 

☐ Attached is [cash, or] a check, bank draft or money order payable to Vir Biotechnology, Inc. in the amount of
$             (estimated withholding taxes). 
 ☐ I have made
arrangements with Vir Biotechnology, Inc. to have the aggregate exercise price and/or the applicable withholding taxes withheld from other compensation. 

 By signing below, I (i) acknowledge that I remain subject to the applicable provisions of my option
award agreement, (ii) acknowledge and make the representations and warranties set forth below, and (iii) acknowledge that the Company is relying in part upon such representations and warranties: 

(a) I am acquiring and will hold the shares of Common Stock for investment for my account only and not with a view to, or for resale in
connection with, any “distribution” thereof within the meaning of the Securities Act or other applicable securities laws. 
 (b) I
have been advised that offerings of the shares of Common Stock have not been registered under the Securities Act or other applicable securities laws, on the ground that no public offering of the shares of Common Stock is to be effected (it being
understood, however, that the shares of Common Stock are being offered in reliance on the exemption provided under Rule 701 under the Securities Act), and that the shares of Common Stock must be held indefinitely, unless they are subsequently
registered under the applicable securities laws or I obtain an opinion of counsel (in the form and substance satisfactory to the Company and its counsel) that registration is not required. I further acknowledge and understand that the Company is
under no obligation hereunder to register offerings of the shares of Common Stock. 
 (c) I am aware of the adoption of Rule 144 by the
Securities and Exchange Commission under the Securities Act, which permits limited public resales of securities acquired in a non-public offering, subject to the satisfaction of certain conditions. I
acknowledge that I am familiar with the conditions for resale set forth in Rule 144, and I acknowledge and understand that the conditions for resale set forth in Rule 144 have not been satisfied and that the Company has no plans to satisfy these
conditions in the foreseeable future. 
 (d) I will not sell, transfer or otherwise dispose of the shares of Common Stock in violation of the
Vir Biotechnology, Inc. 2016 Equity Incentive Plan, my option award agreement, the Agreements, the Securities Act (or the rules and regulations promulgated thereunder) or under any other applicable securities laws. I agree that I will not dispose of
the Common Stock unless and until I have complied with all requirements applicable to the disposition of the shares of Common Stock. 
 (e) I
have been furnished with, and have had access to, such information as I consider necessary or appropriate for deciding whether to invest in the shares of Common Stock, and I have had an opportunity to ask questions and receive answers from the
Company regarding the terms and conditions of the offering of the Common Stock. 
 (f) I am aware that my investment in the Company is a
speculative investment that has limited liquidity and is subject to the risk of complete loss. I am able, without impairing my financial condition, to hold the Common Stock for an indefinite period and to suffer a complete loss of my investment in
the Common Stock. 
  

			
	  
 [Name of
Participant]

		
	Address:	 	
	
	  

	  

	  

			
	Telephone:	 	  

	Attention:	 	  

 VIR BIOTECHNOLOGY, INC. 

2016 EQUITY INCENTIVE PLAN 
 THE SECURITIES
REPRESENTED BY THIS NOTICE AND AGREEMENT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 OR PURSUANT TO
AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT OF 1933 AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. 

NONQUALIFIED STOCK OPTION GRANT NOTICE AND AGREEMENT 

Vir Biotechnology, Inc. (the “Company”), pursuant to its 2016 Equity Incentive Plan (the “Plan”), hereby
grants to Participant an Option to purchase the number of shares of the Company’s Common Stock (referred to herein as “Shares”) set forth below. This Option is subject to all of the terms and conditions as set forth
herein and in the Nonqualified Stock Option Agreement attached hereto as Exhibit A (the “Agreement”) and the Plan, each of which is incorporated herein by reference. Unless otherwise defined herein, the terms defined
in the Plan shall have the same defined meanings in this Nonqualified Stock Option Grant Notice (“Grant Notice”) and the Agreement. 
  

			
	Participant:	  	«Participant_Name»
		
	Grant Date:	  	«Grant_Date»
		
	Vesting Commencement Date:	  	«Vesting_Commencement_Date»
		
	Exercise Price per Share:	  	$«Exercise_Price»
		
	Total Number of Shares Subject to Option:	  	«No_of_Shares»
		
	Expiration Date:	  	«Expiration_Date»
		
	Type of Option:	  	Nonqualified Stock Option
		
	Vesting Schedule:	  	Subject to Section 3(b), [the Option shall vest and become exercisable over a four-year period commencing on the Vesting Commencement Date, with 25% of the Option vesting on the one-year
anniversary of the Vesting Commencement Date, and the remainder of the Option vesting in 36 equal installments beginning on the date that is the one-month anniversary of such
one-year anniversary date, and each one-month anniversary date thereafter; provided, however, that the Participant has not experienced a Termination prior to each
applicable vesting date.]

 By his or her signature and the Company’s signature below, Participant agrees to be bound by the terms
and conditions of the Plan, the Agreement and this Grant Notice. Participant has reviewed the Agreement, the Plan and this Grant Notice in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Grant Notice
and fully understands all provisions of this Grant Notice, the Agreement and the Plan. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Committee upon any questions arising under the Plan
or the Agreement. 
  

									
	VIR BIOTECHNOLOGY, INC.	 		 	PARTICIPANT:
					
	By:	 	              
	 		 	By:	 	  

	Print Name:	 	              
	 		 	Print Name:	 	  

	Title:	 	              
	 		 	State of Residence:	 	  

 EXHIBIT A 

TO STOCK OPTION GRANT NOTICE 

NONQUALIFIED STOCK OPTION AGREEMENT 

PURSUANT TO THE 
 VIR
BIOTECHNOLOGY, INC. 
 2016 EQUITY INCENTIVE PLAN 

Pursuant to the Grant Notice to which this Agreement is attached, the Company has granted to Participant an Option under the Plan to purchase
the number of Shares indicated in the Grant Notice. 
 Preliminary Statement 

The Committee hereby grants this stock option (the “Option”) as of the Grant Date pursuant to the Vir Biotechnology,
Inc. 2016 Equity Incentive Plan, as it may be amended from time to time (the “Plan”), to purchase the number of shares of the common stock of the Company, $0.0001 par value per share (the “Common
Stock”), set forth in the Grant Notice, to the Participant, as [an Eligible Employee][a Consultant] of the Company. Except as otherwise indicated, any capitalized term used but not defined herein shall have the meaning ascribed to such
term in the Grant Notice or the Plan, as applicable. A copy of the Plan has been delivered to the Participant. By signing and returning this Agreement, the Participant acknowledges having received and read a copy of the Plan and agrees to comply
with it, this Agreement and all applicable laws and regulations. 
 Accordingly, the parties hereto agree as follows: 

1. Tax Matters. No part of the Option granted hereby is intended to qualify as an “incentive stock option” under
section 422 of the Code. 
 2. Common Stock Subject to Option; Exercise Price. Subject in all respects to the Plan and
the terms and conditions set forth herein and therein, the Option entitles the Participant to purchase from the Company, upon exercise, the Total Number of Shares Subject to Option (as set forth in the Grant Notice ) at the Exercise Price per Share
(as set forth in the Grant Notice). 
 3. Vesting; Exercise. 

(a) [Subject to Section 3(b), the Option shall vest and become exercisable over a four-year period commencing on the Vesting Commencement
Date, with 25% of the Option vesting on the one-year anniversary of the Vesting Commencement Date, and the remainder of the Option vesting in 36 equal installments beginning on the date that is the one-month anniversary of such one-year anniversary date, and each one-month anniversary date thereafter; provided, however, that the
Participant has not experienced a Termination prior to each applicable vesting date.] 
 (b) To the extent that the Option has become vested
and exercisable with respect to a number of shares of Common Stock, the Option may thereafter be exercised by the Participant, in whole or in part, at any time or from time to time prior to the expiration of the Option in accordance with
Section 4 and the Plan. Notwithstanding the foregoing, the Participant may not exercise the Option unless the offering of shares of Common Stock issuable upon such exercise (i) is then registered under the Securities Act, or, if such
offering is not then so registered, the Company has determined that such offering is exempt from the registration requirements of the Securities Act and (ii) complies with all other applicable laws and regulations governing the Option, and the
Participant may not exercise the Option if the Committee determines that such exercise would not be so registered or exempt and otherwise in compliance with such laws and regulations. 

 (c) To exercise the Option, unless otherwise directed or permitted by the Committee, the
Participant must: 
 (i) execute and deliver to the Company a properly completed Notice of Exercise in the form attached
hereto as Exhibit I. 
 (ii) execute and deliver such other documentation as required by the Committee (including,
without limitation, the Stockholder Agreements) which may set forth certain restrictions on transferability of the shares of Common Stock acquired upon exercise, a right of first refusal or a right of first offer of the Company and other Persons
with respect to shares, and such other terms or restrictions as the Board or Committee may from time to time establish, including any drag along rights, tag along rights, transfer restrictions and registration rights, and 

(iii) remit the aggregate Exercise Price to the Company in full, payable (A) in cash or by check, bank draft or money
order payable to the order of the Company; or (B) on such other terms and conditions as may be acceptable to the Committee (including, without limitation, making arrangements with the Company to have such Exercise Price withheld from other
compensation). 
 (d) In addition, unless otherwise directed or permitted by the Committee, the Participant must pay or provide for all
applicable withholding taxes in respect of the exercise of the Option, by (i) remitting the aggregate amount of such taxes to the Company in full, in cash or by check, bank draft or money order payable to the order of the Company, or
(ii) making arrangements with the Company to have such taxes withheld from other compensation, to the extent permitted by the Committee. 

4. Termination. The term of the Option shall be until the tenth anniversary of the Grant Date, after which time it shall
expire (the “Expiration Date”), subject to earlier termination in the event of the Participant’s Termination as specified in the Plan and this Agreement. Notwithstanding anything herein to the contrary, upon the
Expiration Date, the Option (whether vested or not) shall be immediately forfeited, canceled and terminated for no consideration and no longer shall be exercisable. Except as otherwise provided in Section 3(a), the provisions in the Plan
regarding Termination shall apply to the Option; provided, that, to the extent applicable, if the Participant’s employment agreement or consulting agreement expressly provides more favorable rights with respect to the Option in the event
of Termination, such rights shall apply. 
 5. Market Stand-Off. If requested by
the Company or the lead underwriter of any public offering of the Common Stock (the “Lead Underwriter”), the Participant shall irrevocably agree not to sell, contract to sell, grant any option to purchase, transfer the
economic risk of ownership in, make any short sale of, pledge or otherwise Transfer or dispose of, any interest in any Common Stock or any securities convertible into, derivative of, or exchangeable or exercisable for Common Stock, or any other
rights to purchase or acquire Common Stock (except Common Stock included in such public offering or acquired on the public market after such offering) during such period of time following the effective date of a registration statement of the Company
filed under the Securities Act that the Lead Underwriter shall specify (the “Lock-up Period”). The Participant shall further agree to sign such documents as may be requested by the Lead
Underwriter or the Company to effect the foregoing and agree that the Company may impose stop transfer instructions with respect to Common Stock acquired pursuant to an Award until the end of such Lock-up
Period. 

 6. Restriction on Transfer of Option. Unless otherwise determined by
the Committee in accordance with the Plan, (a) no part of the Option shall be Transferable other than by will or by the laws of descent and distribution and (b) during the lifetime of the Participant, the Option may be exercised only by
the Participant. Any attempt to Transfer the Option other than in accordance with the Plan shall be void. 
 7. No Rights as
Stockholder. The Participant shall have no rights as a stockholder with respect to any shares of Common Stock covered by the Option unless and until the Participant has become the holder of record of such shares, and no adjustments
shall be made for dividends (whether in cash, in kind or other property), distributions or other rights in respect of any such shares, except as otherwise specifically provided for in the Plan. 

8. Provisions of Plan Control. This Agreement is subject to all the terms, conditions and provisions of the Plan,
including the amendment provisions thereof, and to such rules, regulations and interpretations relating to the Plan as may be adopted by the Committee and as may be in effect from time to time. The Plan is incorporated herein by reference. If and to
the extent that this Agreement conflicts or is inconsistent with the Plan, the Plan shall control, and this Agreement shall be deemed to be modified accordingly. 

9. Withholding of Taxes. The Company shall have the right to deduct from any payment to be made to the Participant
pursuant to this Agreement, or to otherwise require, prior to the issuance or delivery of any shares of Common Stock or the payment of any cash hereunder, payment by the Participant of, any Federal, state or local taxes required by law to be
withheld. 
 10. No Right to Employment or Consultancy Service. This Agreement is not an agreement of employment or to
provide consultancy services. None of this Agreement, the Plan or the grant of the Option hereunder shall (a) guarantee that the Company will employ or retain the Participant as an employee or consultant for any specific time period or
(b) modify or limit in any respect the Company’s right to terminate or modify the Participant’s employment, consultancy arrangement or compensation. Moreover, this Agreement is not intended to and does not amend any existing
employment or consulting contract between the Participant and the Company or any of its Affiliates; to the extent there is a conflict between this Agreement and such an employment or consulting contract, the employment or consulting contract shall
govern and take priority. 
 11. Notices. All notices, demands or requests made pursuant to, under or by virtue of this
Agreement must be in writing or by electronic means as set forth in Section 11 below and sent to the party to which the notice, demand or request is being made: 

(a) unless otherwise specified by the Company in a notice delivered by the Company in accordance with this Section 11, any notice required
to be delivered to the Company shall be properly delivered if delivered to: 
 Vir Biotechnology, Inc. 

499 Illinois Street, Floor 5 
 San
Francisco, CA 94158 
 (b) if to the Participant, to the address on file with the Company. 

 Any notice, demand or request, if made in accordance with this Section 11 shall be deemed to have been
duly given: (i) when delivered in person or by electronic means; (ii) three days after being sent by United States mail; or (iii) on the first business day following the date of deposit if delivered by a nationally recognized
overnight delivery service. 
 12. Mode of Communications. The Participant agrees, to the fullest extent permitted by
applicable law, in lieu of receiving documents in paper format, to accept electronic delivery of any documents that the Company or any of its Affiliates may deliver in connection with this Option grant and any other grants offered by the Company,
including, without limitation, prospectuses, grant notifications, account statements, annual or quarterly reports, and other communications. The Participant further agrees that electronic delivery of a document may be made via the Company’s
email system or by reference to a location on the Company’s intranet or website or the online brokerage account system. 
 13.
Governing Law. All matters arising out of or relating to this Agreement and the transactions contemplated hereby, including its validity, interpretation, construction, performance and enforcement, shall be governed by and
construed in accordance with the internal laws of the State of Delaware, without giving effect to principles of conflict of laws which would result in the application of the laws of any other jurisdiction. 

14. Dispute Resolution. All controversies and claims arising out of or relating to this Agreement, or the breach hereof,
shall be settled by the Company’s mandatory dispute resolution procedures as may be in effect from time to time with respect to matters arising out of or relating to Participant’s employment or consultancy arrangement with the Company.

 15. WAIVER OF JURY TRIAL. EACH PARTY TO THIS AGREEMENT, FOR ITSELF AND ITS AFFILIATES, HEREBY IRREVOCABLY AND
UNCONDITIONALLY WAIVES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW ANY RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THE ACTIONS OF THE PARTIES
HERETO OR THEIR RESPECTIVE AFFILIATES PURSUANT TO THIS AGREEMENT OR IN THE NEGOTIATION, ADMINISTRATION, PERFORMANCE OR ENFORCEMENT OF THIS AGREEMENT. 

16. Construction. All section titles and captions in this Agreement are for convenience only, shall not be deemed part of
this Agreement, and in no way shall define, limit, extend or describe the scope or intent of any provisions of this Agreement. Wherever any words are used in this Agreement in the masculine gender they shall be construed as though they were also
used in the feminine gender in all cases where they would so apply. As used herein, (i) “or” shall mean “and/or” and (ii) “including” or “include” shall mean “including, without limitation.” Any
reference herein to an agreement in writing shall be deemed to include an electronic writing to the extent permitted by applicable law. 

17. Severability of Provisions. If at any time any of the provisions of this Agreement shall be held invalid or
unenforceable, or are prohibited by the laws of the jurisdiction where they are to be performed or enforced, by reason of being vague or unreasonable as to duration or geographic scope or scope of the activities restricted, or for any other reason,
such provisions shall be considered divisible and shall become and be immediately amended to include only such restrictions and to such extent as shall be deemed to be reasonable and enforceable by the court or other body having jurisdiction over
this Agreement and the Company and the Participant agree that the provisions of this Agreement, as so amended, shall be valid and binding as though any invalid or unenforceable provisions had not been included; provided that if the Company’s
call rights and rights of first refusal or rights of first offer set forth in the Stockholder Agreements or any other agreement shall be held invalid or unenforceable, the Option shall be cancelled and terminated. 

 18. No Waiver. No failure by any party to insist upon the strict
performance of any covenant, duty, agreement or condition of this Agreement or to exercise any right or remedy consequent upon a breach thereof shall constitute waiver of any such breach or any other covenant, duty, agreement or condition. 

19. Entire Agreement. This Agreement contains the entire understanding of the parties with respect to the subject matter
hereof and supersedes any prior agreements between the Company and the Participant with respect to the subject matter hereof. 
 20.
Counterparts. This Agreement may be executed in counterparts, all of which together shall constitute one agreement binding on all the parties hereto, notwithstanding that all such parties are not signatories to the original or
the same counterpart. 
 [Remainder of Page Left Intentionally Blank] 

 Exhibit I 

VIR BIOTECHNOLOGY, INC. 

2016 EQUITY INCENTIVE PLAN 

NOTICE OF EXERCISE 
 Date: [●], 20__

 Vir Biotechnology, Inc. 
 499 Illinois Street, Floor 5 

San Francisco, CA 94158 
 Attention: [●] 

Ladies and Gentlemen: 
 This document constitutes notice under my
stock option agreement that I elect to purchase the number of shares for the aggregate payment set forth below. 
  

					
	 Type of option (check one):
	  	Incentive  ☐  Nonqualified  ☒	  	                        
			
	 Option number and grant date:
	  	 [●] options – [●], 20__
  
	  	
			
	 Number of shares as to which option is exercised:
	  	  
	  	
			
	 Per share exercise price:
	  	 $[●]
  
	  	
			
	 Aggregate exercise price (number of shares as to which option is exercised multiplied by per share exercise
price):
	  	 $
  
	  	

 I (i) agree that the shares purchased pursuant to this Notice of Exercise will be bound by and subject to the terms of
(a) that certain Right of First Refusal and Co-Sale Agreement dated as of August 25, 2017 (the “ROFR Agreement”), by and among Vir Biotechnology, Inc. and certain of its
stockholders, as such ROFR Agreement may be amended or restated and (b) that certain Voting Agreement dated as of August 25, 2017 (the “Voting Agreement” and together with the ROFR Agreement, the
“Agreements”), by and among Vir Biotechnology, Inc. and certain of its stockholders, as such Voting Agreement may be amended or restated; (ii) hereby adopt the Agreements with the same force and effect as if I were
originally a party thereto; (iii) acknowledge that I will be considered a “Key Holder” for all purposes of the Agreements; and (iv) agree to sign any such documents as may be required in connection with my becoming a party
to the Agreements. 
 Any notice required or permitted by the Agreements will be given to me at the address listed below my signature hereto. 

☐ Attached is [cash, or] a check, bank draft or money order payable to Vir Biotechnology, Inc. in the amount of
$             (aggregate exercise price). 
 Estimated
withholding taxes:                                     $ 

☐ Attached is [cash, or] a check, bank draft or money order payable to Vir Biotechnology, Inc. in the amount of
$             (estimated withholding taxes). 
 ☐ I have made
arrangements with Vir Biotechnology, Inc. to have the aggregate exercise price and/or the applicable withholding taxes withheld from other compensation. 

 By signing below, I (i) acknowledge that I remain subject to the applicable provisions of my option
award agreement, (ii) acknowledge and make the representations and warranties set forth below, and (iii) acknowledge that the Company is relying in part upon such representations and warranties: 

(a) I am acquiring and will hold the shares of Common Stock for investment for my account only and not with a view to, or for resale in
connection with, any “distribution” thereof within the meaning of the Securities Act or other applicable securities laws. 
 (b) I
have been advised that offerings of the shares of Common Stock have not been registered under the Securities Act or other applicable securities laws, on the ground that no public offering of the shares of Common Stock is to be effected (it being
understood, however, that the shares of Common Stock are being offered in reliance on the exemption provided under Rule 4(a)(2) under the Securities Act), and that the shares of Common Stock must be held indefinitely, unless they are subsequently
registered under the applicable securities laws or I obtain an opinion of counsel (in the form and substance satisfactory to the Company and its counsel) that registration is not required. I further acknowledge and understand that the Company is
under no obligation hereunder to register offerings of the shares of Common Stock. 
 (c) I am aware of the adoption of Rule 144 by the
Securities and Exchange Commission under the Securities Act, which permits limited public resales of securities acquired in a non-public offering, subject to the satisfaction of certain conditions. I
acknowledge that I am familiar with the conditions for resale set forth in Rule 144, and I acknowledge and understand that the conditions for resale set forth in Rule 144 have not been satisfied and that the Company has no plans to satisfy these
conditions in the foreseeable future. 
 (d) I will not sell, transfer or otherwise dispose of the shares of Common Stock in violation of the
Vir Biotechnology, Inc. 2016 Equity Incentive Plan, my option award agreement, the Agreements, the Securities Act (or the rules and regulations promulgated thereunder) or under any other applicable securities laws. I agree that I will not dispose of
the Common Stock unless and until I have complied with all requirements applicable to the disposition of the shares of Common Stock. 
 (e) I
have been furnished with, and have had access to, such information as I consider necessary or appropriate for deciding whether to invest in the shares of Common Stock, and I have had an opportunity to ask questions and receive answers from the
Company regarding the terms and conditions of the offering of the Common Stock. 
 (f) I am aware that my investment in the Company is a
speculative investment that has limited liquidity and is subject to the risk of complete loss. I am able, without impairing my financial condition, to hold the Common Stock for an indefinite period and to suffer a complete loss of my investment in
the Common Stock. 
 (g) I represent and warrant that I am an “accredited investor” within the meaning of Regulation D under the
Securities Act. In addition, I either (a) have a preexisting personal or business relationship with the Company or its principals or (b) have substantial knowledge and experience in financial business smatters, have specific experience in
making investment decisions of a similar nature, and am capable, without the use of a financial advisor, of utilizing and analyzing the information made available in connection with the acquisition of the shares of Common Stock and of evaluating the
merits and risks of an investment in the shares of Common Stock and protecting my own interests in connection with this transaction. 

 
			
	  
 [Name of
Participant]

		
	Address:	 	
	  

	  

	  

	Telephone:	 	  

	Attention:	 	  

 VIR BIOTECHNOLOGY, INC. 

RESTRICTED STOCK AGREEMENT 

PURSUANT TO THE 
 VIR
BIOTECHNOLOGY, INC. 
 2016 EQUITY INCENTIVE PLAN 

This RESTRICTED STOCK AGREEMENT (“Agreement”) is effective as of [●], 20__ (the “Grant
Date”), between Vir Biotechnology, Inc., a Delaware corporation (the “Company”), and [●] (the “Participant”). 

Terms and Conditions 

The Committee hereby grants to the Participant as [an Eligible Employee][a Consultant] of the Company or any of its Affiliates, as of
[●], 20__ (the “Grant Date”), pursuant to the Vir Biotechnology, Inc. 2016 Equity Incentive Plan, as it may be amended from time to time (the “Plan”), the
number of shares of the Company’s Common Stock set forth in Section 1 below. Except as otherwise indicated, any capitalized term used but not defined herein shall have the meaning ascribed to such term in the
Plan. A copy of the Plan has been delivered to the Participant. By signing and returning this Agreement, the Participant acknowledges having received and read a copy of the Plan and agrees to comply with the Plan, this Agreement and all applicable
laws and regulations. 
 Accordingly, the parties hereto agree as follows: 

21. Grant of Shares. Subject in all respects to the Plan and the terms and conditions set forth herein and therein,
effective as of the Grant Date, the Company hereby awards to the Participant [●] shares of its Common Stock. Such shares are subject to certain restrictions set forth in Section 2
hereof, which restrictions shall lapse at the times provided under Section 2(b) hereof. For the period during which such restrictions are in effect, the shares of Common Stock subject to such restrictions are referred to
herein as the “Restricted Stock.” The Restricted Stock, in the sole discretion of the Committee, shall be evidenced by a certificate or be credited to a book entry account maintained by the Company (or its designee) on behalf
of the Participant and such certificate or book entry (as applicable) shall be noted appropriately to record the restrictions on the Restricted Stock imposed hereby. 

22. Restricted Stock. 

(a) Rights as a Stockholder. Prior to the time the Restricted Stock is fully vested hereunder, (i) the Participant
shall have no right to tender shares of Restricted Stock, (ii) dividends or other distributions (collectively, “dividends”) on shares of Restricted Stock shall be withheld, in each case, while the Restricted Stock is subject to
restrictions, and (iii) in no event shall dividends or other distributions payable thereunder be paid unless and until the shares of Restricted Stock to which they relate no longer are subject to a risk of forfeiture. Dividends that are not
paid currently shall be credited to bookkeeping accounts on the Company’s records for purposes of the Plan and shall not accrue interest. Such dividends shall be paid to the Participant in the same form as paid on the Common Stock upon the
lapse of the restrictions. 
 (b) Vesting. The Restricted Stock shall vest and cease to be Restricted Stock (but will
remain subject to the terms of this Agreement and the Plan) over a four-year period commencing on the Grant Date, with 25% of the Restricted Stock vesting on the one-year anniversary of the Grant Date, and the
remainder of the Restricted Stock vesting in 36 equal installments beginning on the date that is the one-month anniversary of such one-year anniversary date, and each one-month anniversary date thereafter; provided, however, that the Participant has not experienced a Termination prior to each applicable vesting date. There shall be no proportionate or partial vesting in the
periods prior to the applicable vesting date(s) and all vesting shall occur only on the applicable vesting date(s). 

 (c) Forfeiture. The Participant shall forfeit to the Company, without
compensation, any and all unvested Restricted Stock immediately upon the Participant’s Termination for any reason.
 (d)
Section 83(b). If the Participant properly elects (as permitted by section 83(b) of the Code) within thirty (30) days after the issuance of the Restricted Stock to include in gross income
for federal income tax purposes in the year of issuance the fair market value of such Restricted Stock, the Participant shall deliver to the Company a signed copy of such election promptly after the making of such election, and shall pay to the
Company or make arrangements satisfactory to the Company to pay to the Company upon such election, any federal, state, local or other taxes of any kind that the Company is required to withhold with respect to the Restricted Stock. The Participant
acknowledges that it is his or her sole responsibility, and not the Company’s, to file timely and properly the election under section 83(b) of the Code and any corresponding provisions of state tax laws if he or she elects to utilize such
election.  
 (e) Certificates. If, after the Grant Date, certificates are issued with respect to the shares of
Restricted Stock, such issuance and delivery of certificates shall be made in accordance with the applicable terms of the Plan. 
 23.
Certain Legal Restrictions. The Plan, this Agreement, the granting and vesting of the Restricted Stock, and any obligations of the Company under the Plan and this Agreement, shall be subject to all applicable federal, state and
local laws, rules and regulations, and to such approvals by any regulatory or governmental agency as may be required, and to any rules or regulations of any exchange on which the Common Stock is listed. 

24. Change in Control. The provisions in the Plan regarding Change in Control shall apply to the Restricted Stock. 

25. Withholding of Taxes. The Company shall have the right to deduct from any payment to be made pursuant to this
Agreement and the Plan, or to otherwise require, prior to the issuance or delivery of any shares of Common Stock, payment by the Participant of, any federal, state or local taxes required by law to be withheld. 

26. Provisions of Plan Control. This Agreement is subject to all the terms, conditions and provisions of the Plan,
including, without limitation, the amendment provisions thereof, and to such rules, regulations and interpretations relating to the Plan as may be adopted by the Committee and as may be in effect from time to time. The Plan is incorporated herein by
reference. If and to the extent that any provision of this Agreement conflicts or is inconsistent with the terms set forth in the Plan, the Plan shall control, and this Agreement shall be deemed to be modified accordingly. 

27. Recoupment Policy. The Participant acknowledges and agrees that the Restricted Stock shall be subject to the terms and
provisions of any “clawback” or recoupment policy that may be adopted by the Company from time to time or as may be required by any applicable law (including, without limitation, the Dodd-Frank Wall Street Reform and Consumer Protection
Act and rules and regulations thereunder). 
 28. No Right to Employment or Consultancy Service. This Agreement is not
an agreement of employment or to provide consultancy services. None of this Agreement, the Plan or the grant of the Restricted Stock hereunder shall (a) guarantee that the Company will employ or retain the Participant as an employee or
consultant for any specific time period or (b) modify or limit in any respect the Company’s right to terminate or modify the Participant’s employment, consultancy arrangement or compensation. Moreover, this Agreement is not intended
to and does not amend any existing employment or consulting contract between the Participant and the Company or any of its Affiliates; to the extent there is a conflict between this Agreement and such an employment or consulting contract, the
employment or consulting contract shall govern and take priority. 

 29. Notices. Any notice or communication given hereunder shall be in
writing or by electronic means as set forth in Section 10 below and, if in writing, shall be deemed to have been duly given: (i) when delivered in person or by electronic means; (ii) three days after being sent by United States mail;
or (iii) on the first business day following the date of deposit if delivered by a nationally recognized overnight delivery service, to the appropriate party at the following address (or such other address as the party shall from time to time
specify): (i) if to the Company, to its principal executive offices; and (ii) if to the Participant, to the address on file with the Company. 

30. Mode of Communications. The Participant agrees, to the fullest extent permitted by applicable law, in lieu of
receiving documents in paper format, to accept electronic delivery of any documents that the Company or any of its Affiliates may deliver in connection with this grant of Restricted Stock and any other grants offered by the Company, including,
without limitation, prospectuses, grant notifications, account statements, annual or quarterly reports, and other communications. The Participant further agrees that electronic delivery of a document may be made via the Company’s email system
or by reference to a location on the Company’s intranet or website or the online brokerage account system. 
 31. Governing
Law. All matters arising out of or relating to this Agreement and the transactions contemplated hereby, including its validity, interpretation, construction, performance and enforcement, shall be governed by and construed in
accordance with the internal laws of the State of Delaware, without giving effect to principles of conflict of laws which would result in the application of the laws of any other jurisdiction. 

32. Dispute Resolution. All controversies and claims arising out of or relating to this Agreement, or the breach hereof,
shall be settled by the Company’s mandatory dispute resolution procedures as may be in effect from time to time with respect to matters arising out of or relating to Participant’s employment or consultancy arrangement with the Company.

 33. WAIVER OF JURY TRIAL. EACH PARTY TO THIS AGREEMENT, FOR ITSELF AND ITS AFFILIATES, HEREBY IRREVOCABLY AND
UNCONDITIONALLY WAIVES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW ANY RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THE ACTIONS OF THE PARTIES
HERETO OR THEIR RESPECTIVE AFFILIATES PURSUANT TO THIS AGREEMENT OR IN THE NEGOTIATION, ADMINISTRATION, PERFORMANCE OR ENFORCEMENT OF THIS AGREEMENT. 

34. Construction. All section titles and captions in this Agreement are for convenience only, shall not be deemed part of
this Agreement, and in no way shall define, limit, extend or describe the scope or intent of any provisions of this Agreement. Wherever any words are used in this Agreement in the masculine gender they shall be construed as though they were also
used in the feminine gender in all cases where they would so apply. As used herein, (i) “or” shall mean “and/or” and (ii) “including” or “include” shall mean “including, without limitation.” Any
reference herein to an agreement in writing shall be deemed to include an electronic writing to the extent permitted by applicable law. 

35. Severability of Provisions. If at any time any of the provisions of this Agreement shall be held invalid or
unenforceable, or are prohibited by the laws of the jurisdiction where they are to be performed or enforced, by reason of being vague or unreasonable as to duration or geographic scope or scope of the activities restricted, or for any other reason,
such provisions shall be considered divisible and shall become and be immediately amended to include only such restrictions and to such extent as shall be 

 
deemed to be reasonable and enforceable by the court or other body having jurisdiction over this Agreement and the Company and the Participant agree that the provisions of this Agreement, as so
amended, shall be valid and binding as though any invalid or unenforceable provisions had not been included; provided that if the Company’s call rights and rights of first refusal or rights of first offer set forth in the Stockholder Agreements
or any other agreement shall be held invalid or unenforceable, the Restricted Stock shall be cancelled and terminated. 
 36. No
Waiver. No failure by any party to insist upon the strict performance of any covenant, duty, agreement or condition of this Agreement or to exercise any right or remedy consequent upon a breach thereof shall constitute waiver of any
such breach or any other covenant, duty, agreement or condition. 
 37. Entire Agreement. This Agreement contains the
entire understanding of the parties with respect to the subject matter hereof and supersedes any prior agreements between the Company and the Participant with respect to the subject matter hereof. 

38. Counterparts. This Agreement may be executed in any number of counterparts, all of which taken together shall
constitute one instrument. Execution and delivery of this Agreement by facsimile or other electronic signature is legal, valid and binding for all purposes. 

[Remainder of Page Left Intentionally Blank] 

 IN WITNESS WHEREOF, the parties have executed this Agreement on the date and year first
above written. 
  

			
	VIR BIOTECHNOLOGY, INC.
		
	By:	 	                                
                
	Name:	 	
	Title:	 	

  

			
	PARTICIPANT
		
	By:	 	                                
                    
	Name:	 	

 Form of Restricted Stock Purchase Agreement 

Last Updated February 2, 2017 

VIR BIOTECHNOLOGY, INC. 

RESTRICTED STOCK PURCHASE AGREEMENT 

PURSUANT TO THE 
 VIR
BIOTECHNOLOGY, INC. 
 2016 EQUITY INCENTIVE PLAN 

This Restricted Stock Purchase Agreement (the “Agreement”) is made as of [●] by and between Vir
Biotechnology, Inc., a Delaware corporation (the “Company”), and [●] (the “Purchaser”). 

Terms and Conditions 
 The
Committee hereby sells to the Purchaser as an Eligible Employee of the Company or any of its Affiliates, and the Purchaser agrees to purchase from the Company, as of the Closing (as defined in Section 2 below),
pursuant to the Vir Biotechnology, Inc. 2016 Equity Incentive Plan, as amended from time to time (the “Plan”), the number of shares of the Company’s Common Stock set forth in Section 1
below. Except as otherwise indicated, any capitalized term used but not defined herein shall have the meaning ascribed to such term in the Plan. A copy of the Plan has been delivered to the Purchaser. By signing and returning this Agreement, the
Purchaser acknowledges having received and read a copy of the Plan and agrees to comply with the Plan, this Agreement and all applicable laws and regulations. 

In consideration of the mutual covenants and representations set forth below, the Company and the Purchaser agree as follows: 

1. Purchase and Sale of the Shares. Subject to the terms and conditions of this Agreement, the Company agrees to sell to the
Purchaser and the Purchaser agrees to purchase from the Company on the Closing (as defined below) [●] shares of the Company’s Common Stock, par value $0.0001 per Share (the “Shares”), at a price of $0.19 per share
(the “Purchase Price”), for an aggregate purchase price of $[●]. 
 2. Closing. The purchase and
sale of the Shares shall occur at a closing (the “Closing”) to be held on the date first set forth above, or at any other time mutually agreed upon by the Company and the Purchaser. The Closing will take place at the
principal office of the Company or at such other place as shall be designated by the Company. Simultaneous with the Closing, Purchaser and the Company shall enter into that certain Loan and Security Agreement and Promissory Note, dated as of the
Closing, pursuant to which the Company will loan to Purchaser the aggregate Purchase Price for the Shares, and the Company will issue, as promptly thereafter as practicable, a stock certificate, registered in the name of the Purchaser, reflecting
the Shares. 
 3. Repurchase Option. 

(a) Option. In the event the Purchaser’s Termination for any or no reason, including, without limitation, by reason
of the Purchaser’s death or Disability, resignation or involuntary termination, the Company shall, from such time (as determined by the Company in its discretion), have the right, but not the obligation (the “Repurchase
Option”), for a period of 90 days from the date of the Purchaser’s Termination, to repurchase any Shares which have not yet been released from the Repurchase Option (the “Unreleased Shares”) at a price per
share equal to the lesser of (x) the fair market value of the shares at the time the Repurchase Option is exercised, as determined by the Company’s board of directors (the “Board”) in its sole discretion and
(y) the Purchase Price (such lesser amount, the “Repurchase Price”). The Repurchase Option shall be exercised by the Company by delivering written notice to the Purchaser or, in the event of the Purchaser’s death,
the Purchaser’s executor and, at the Company’s option, (i) by delivering to the Purchaser or the Purchaser’s executor a check in the amount of the aggregate Repurchase Price, or (ii) by canceling an amount of
the Purchaser’s indebtedness to the Company equal to the aggregate 

 
Repurchase Price, or (iii) by a combination of (i) and (ii) such that the combined payment and cancellation of indebtedness equals the aggregate Repurchase Price. Upon delivery of such
notice and the payment of the aggregate Repurchase Price, the Company shall become the legal and beneficial owner of the Unreleased Shares being repurchased and all rights and interests therein or relating thereto, and the Company shall have the
right to retain and transfer to its own name the number of Unreleased Shares being repurchased by the Company. 
 (b)
Assignability. The Company in its sole discretion may assign all or part of the Repurchase Option to one or more employees, officers, directors or stockholders of the Company or other persons or organizations. 

4. Release of Shares from Repurchase Option; Vesting. 

(a) Vesting. Subject to the Purchaser not experiencing a Termination prior to each such date, the Shares shall be released
from the Repurchase Option over a four-year period commencing on the date hereof, with 25% of the Shares vesting on the one-year anniversary of the date hereof, and the remainder of the Shares vesting in 36
equal installments beginning on the date that is the one-month anniversary of such one-year anniversary date, and each one-month
anniversary date thereafter. In the event of the Purchaser’s Termination by the Company without “Cause” or by the Purchaser for “Good Reason” (each as defined in the Offer Letter), a number of Shares shall be released from
the Repurchase Option equal to the number of Shares, if any, that would have been released from the Repurchase Option within [•] months of such Termination. 

(b) Delivery of Released Shares. Subject to the provisions of Section 6, the Shares that have
been released from the Company’s Repurchase Option shall be delivered to the Purchaser at the Purchaser’s request. 
 5.
Restrictions on Transfer. 
 (a) Investment Representations and Legend Requirements. The Purchaser hereby
makes the investment representations listed on Exhibit A to the Company as of the date of this Agreement and as of the date of the Closing, and agrees that such representations are incorporated into this Agreement by this reference, such that
the Company may rely on them in issuing the Shares and for any other lawful purpose. The Purchaser understands and agrees that the Company shall cause the legends set forth below, or substantially equivalent legends, to be placed upon any
certificate(s) evidencing ownership of the Shares, together with any other legends that may be required by the Company or by applicable state or federal securities laws: 

THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE “ACT”) AND MAY NOT BE
OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT OR, IN THE OPINION OF COUNSEL SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION OTHERWISE
COMPLIES WITH THE ACT. 
 THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN RESTRICTIONS ON TRANSFER, A RIGHT OF FIRST
REFUSAL, A LOCK-UP PERIOD IN THE EVENT OF A PUBLIC OFFERING AND A REPURCHASE OPTION HELD BY THE ISSUER OR ITS ASSIGNEE(S) AS SET FORTH IN THE RESTRICTED STOCK PURCHASE AGREEMENT BETWEEN THE

 
ISSUER AND THE ORIGINAL HOLDER OF THESE SHARES, A COPY OF WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF THE ISSUER. SUCH TRANSFER RESTRICTIONS, RIGHT OF FIRST REFUSAL, LOCK-UP PERIOD AND REPURCHASE OPTION ARE BINDING ON TRANSFEREES OF THESE SHARES. 
 (b) Stop-Transfer
Notices. The Purchaser agrees that to ensure compliance with the restrictions referred to herein, the Company may issue appropriate “stop transfer” instructions to its transfer agent, if any, and that, if the Company
transfers its own securities, it may make appropriate notations to the same effect in its own records. 
 (c) Refusal to
Transfer. The Company shall not be required (i) to transfer on its books any Shares that have been sold or otherwise transferred in violation of any of the provisions of this Agreement or (ii) to treat as owner of such
Shares or to accord the right to vote or pay dividends to any purchaser or other transferee to whom such Shares shall have been so transferred. 

(d) Lock-Up Period. The Purchaser hereby agrees that the Purchaser shall not sell,
offer, pledge, contract to sell, grant any option or contract to purchase, purchase any option or contract to sell, grant any right or warrant to purchase, lend or otherwise transfer or encumber, directly or indirectly, any Shares or other
securities of the Company, nor shall the Purchaser enter into any swap, hedging or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any Shares or other securities of the Company,
during the period from the filing of the first registration statement of the Company filed under the Securities Act, that includes securities to be sold on behalf of the Company to the public in an underwritten public offering under the Securities
Act through the end of the 180-day period following the effective date of such registration statement (or such other period as may be requested by the Company or the underwriters to accommodate regulatory
restrictions on (i) the publication or other distribution of research reports and (ii) analyst recommendations and opinions, including, but not limited to, the restrictions contained in NASD Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any
successor provisions or amendments thereto). The obligations described in this section shall not apply to a registration relating solely to employee benefit plans on Form S-l or Form S-8 or similar forms that may be promulgated in the future, or a registration relating solely to a transaction on Form S-4 or similar forms that may be promulgated in the
future. The Purchaser further agrees, if so requested by the Company or any representative of its underwriters, to enter into such underwriter’s standard form of “lockup” or “market standoff” agreement in a form satisfactory
to the Company and such underwriter. In the event that the Purchaser refuses to execute any such agreement, the Purchaser hereby agrees to comply with all of the transfer restrictions set forth above in this section for an additional 30 days beyond
each 180-day (or other) period otherwise called for above. The Purchaser agrees that the Company may assign any or all of its rights under this section to the managing underwriter for any registered offering
described in this section, and that such managing underwriter shall be able to further assign such rights in its sole discretion, in each case without any notice to or consent from the Purchaser being required. The Purchaser further agrees that any
assignee of the Company’s rights under this section shall not be subject to any obligation of the Company set forth in this Agreement. The Company may impose stop-transfer instructions with respect to securities subject to the foregoing
restrictions until the end of any such restriction period. 
 (e) Unreleased Shares. No Unreleased Shares subject to the
Repurchase Option contained in Section 3 of this Agreement, nor any beneficial interest in such Shares, shall be sold, transferred, encumbered or otherwise disposed of in any way (whether by operation of law or otherwise)
by the Purchaser, other than as expressly permitted or required by Section 3. 

 (f) Released Shares. No Shares purchased pursuant to this Agreement,
nor any beneficial interest in such Shares, shall be sold, transferred, encumbered or otherwise disposed of in any way (whether by operation of law or otherwise) by the Purchaser or any subsequent transferee, other than in compliance with the
Company’s right of first refusal provisions contained in the Company’s Bylaws. 
 (g) No Transfers to Bad
Actors. The Purchaser agrees not to sell, assign, transfer, pledge, encumber or otherwise dispose of any securities of the Company, or any beneficial interest therein, to any person (other than the Company) unless and until the
proposed transferee confirms to the reasonable satisfaction of the Company that neither the proposed transferee nor any of its directors, executive officers, other officers that may serve as a director or officer of any company in which it invests,
general partners or managing members nor any person that would be deemed a beneficial owner of those securities (in accordance with Rule 506(d) of the Securities Act) is subject to any of the “bad actor” disqualifications described in Rule
506(d)(1)(i) through (viii) under the Securities Act (“Bad Actor Disqualifications”), except as set forth in Rule 506(d)(2)(ii) or (iii) or (d)(3) under the Securities Act and disclosed, reasonably in advance of the
transfer, in writing in reasonable detail to the Company. The Purchaser will promptly notify the Company in writing if the Purchaser or, to the Purchaser’s knowledge, any person specified in Rule 506(d)(1) under the Securities Act becomes
subject to any Bad Actor Disqualification. 
 (h) Restrictions Binding on Transferees. All transferees of Shares or any
interest therein shall receive and hold such Shares or interest subject to all of the provisions of this Agreement, and there shall be no further transfer of such Shares except in accordance with the terms of this Agreement. 

6. Escrow. 
 (a)
Deposit. As security for the faithful performance of this Agreement, the Purchaser agrees, immediately upon receipt of the certificate(s) evidencing the Shares, to deliver such certificate(s), together with a stock power in the
form of Exhibit B attached to this Agreement, executed by the Purchaser and by the Purchaser’s spouse, if any (with the date and number of Shares left blank), to the Secretary of the Company or to another designee of the Company (the
“Escrow Agent”). These documents shall be held by the Escrow Agent pursuant to the Joint Escrow Instructions of the Company and the Purchaser set forth in Exhibit C attached to this Agreement, which instructions are
incorporated into this Agreement by this reference, and which instructions shall also be delivered to the Escrow Agent after the Closing. 

(b) Rights in Escrow Shares. Subject to the terms hereof, the Purchaser shall have all the rights of a stockholder with
respect to such Shares while they are held in escrow, including without limitation, the right to vote the Shares. If, from time to time during the term of the Company’s Repurchase Option, there is any stock dividend, stock split or other change
in the Shares, any and all new, substituted or additional securities to which the Purchaser is entitled by reason of the Purchaser’s ownership of the Shares shall immediately become subject to this escrow, deposited with the Escrow Agent and
included thereafter as “Shares” for purposes of this Agreement and the Company’s Repurchase Option. 
 7. Tax
Consequences. The Purchaser has reviewed with the Purchaser’s own tax advisors the federal, state, local and foreign tax consequences of this investment and the transactions contemplated by this Agreement. The Purchaser is relying
solely on such advisors and not on any statements or representations of the Company or any of its agents. The Purchaser understands that the Purchaser (and not the Company) shall be responsible for any tax liability that may arise as a result of the
transactions contemplated by this Agreement. The Purchaser understands that Section 83 of the Code, taxes as ordinary income the difference between the purchase price for the Shares and the fair market value of the Shares as of the date any
restrictions on the Shares lapse. In this context, “restriction” includes the right of the Company to buy back the Shares pursuant to the Repurchase Option. The Purchaser understands that the Purchaser may elect to be taxed
at the time the Shares are purchased rather than when and as the Repurchase Option expires by filing an election under Section 83(b) of the Code with the IRS within 30 days from the date of purchase. THE FORM FOR MAKING THIS SECTION 83(B)
ELECTION IS ATTACHED TO THIS AGREEMENT AS EXHIBIT D AND THE PURCHASER (AND NOT THE COMPANY OR ANY OF ITS AGENTS) SHALL BE SOLELY RESPONSIBLE FOR APPROPRIATELY FILING SUCH FORM, EVEN IF THE PURCHASER REQUESTS THE COMPANY OR ITS
AGENTS TO MAKE THIS FILING ON THE PURCHASER’S BEHALF. 

 8. General Provisions. 

(a) Governing Law. All matters arising out of or relating to this Agreement and the transactions contemplated hereby,
including its validity, interpretation, construction, performance and enforcement, shall be governed by and construed in accordance with the internal laws of the State of Delaware, without giving effect to principles of conflict of laws which would
result in the application of the laws of any other jurisdiction. 
 (b) Successors. The Company will require any
successors or assigns to expressly assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession or assignment had taken place. The terms of this Agreement
and all of the rights of the parties hereunder will be binding upon, inure to the benefit of, and be enforceable by, the Purchaser’s personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and
legatees. 
 (c) Integration. This Agreement, including all exhibits hereto, represents the entire agreement between the
parties with respect to the purchase of the Shares by the Purchaser and supersedes and replaces any and all prior written or oral agreements regarding the subject matter of this Agreement including, but not limited to, any representations made
during any interviews, relocation discussions or negotiations whether written or oral. 
 (d) Notices. Any notice or
communication given hereunder shall be in writing or by electronic means as set forth in Section 8(e) below and, if in writing, shall be deemed to have been duly given: (i) when delivered in person or by electronic
means; (ii) three days after being sent by United States mail; or (iii) on the first business day following the date of deposit if delivered by a nationally recognized overnight delivery service, to the appropriate party at the following
address (or such other address as the party shall from time to time specify): (i) if to the Company, to Vir Biotechnology, Inc. at its then current headquarters, which shall initially be 4640 SW Macadam Avenue, Suite 130A, Portland, OR 97239 and,
upon the establishment of an office in the State of California, at such address therein; and (ii) if to the Purchaser, to the address on file with the Company. 

(e) Mode of Communications. The Purchaser agrees, to the fullest extent permitted by applicable law, in lieu of receiving
documents in paper format, to accept electronic delivery of any documents that the Company or any of its Affiliates may deliver in connection with this grant of Restricted Stock and any other grants offered by the Company, including, without
limitation, prospectuses, grant notifications, account statements, annual or quarterly reports, and other communications. The Purchaser further agrees that electronic delivery of a document may be made via the Company’s email system or by
reference to a location on the Company’s intranet or website or the online brokerage account system. 
 (f) WAIVER OF JURY
TRIAL. EACH PARTY TO THIS AGREEMENT, FOR ITSELF AND ITS AFFILIATES, HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW ANY RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM
(WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THE ACTIONS OF THE PARTIES HERETO OR THEIR RESPECTIVE AFFILIATES PURSUANT TO THIS AGREEMENT OR IN THE NEGOTIATION, ADMINISTRATION, PERFORMANCE OR ENFORCEMENT OF THIS
AGREEMENT. 

 (g) Assignment; Transfers. Except as set forth in this Agreement, this
Agreement, and any and all rights, duties and obligations hereunder, shall not be assigned, transferred, delegated or sublicensed by the Purchaser without the prior written consent of the Company. Any attempt by the Purchaser without such consent to
assign, transfer, delegate or sublicense any rights, duties or obligations that arise under this Agreement shall be void. Except as set forth in this Agreement, any transfers in violation of any restriction upon transfer contained in any section of
this Agreement shall be void, unless such restriction is waived in accordance with the terms of this Agreement. 
 (h) Purchaser
Investment Representations and Further Documents. The Purchaser agrees upon request to execute any further documents or instruments necessary or reasonably desirable in the view of the Company to carry out the purposes or intent of
this Agreement, including (but not limited to) the applicable exhibits and attachments to this Agreement. 
 (i) Withholding of
Taxes. The Company shall have the right to deduct from any payment to be made to the Purchaser pursuant to this Agreement or the Plan, or to otherwise require, prior to the issuance or delivery of any shares of Common Stock or the
payment of any cash hereunder, payment by the Purchaser of, any Federal, state or local taxes required by law to be withheld. 
 (j) No
Right to Employment or Consultancy Service. This Agreement is not an agreement of employment or to provide consultancy services. None of this Agreement, the Plan or the grant of the Shares hereunder shall (a) guarantee that the
Company will employ or retain the Purchaser as an employee or consultant for any specific time period or (b) modify or limit in any respect the Company’s right to terminate or modify the Purchaser’s employment, consultancy arrangement
or compensation. Moreover, this Agreement is not intended to and does not amend the Offer Letter, and to the extent there is a conflict between this Agreement and the Offer Letter, the Offer Letter shall govern and take priority. 

(k) Certain Legal Restrictions. The Plan, this Agreement, the purchase and vesting of the Shares, and any obligations of
the Company under the Plan and this Agreement, shall be subject to all applicable federal, state and local laws, rules and regulations, and to such approvals by any regulatory or governmental agency as may be required, and to any rules or
regulations of any exchange on which the Common Stock is listed. 
 (l) Severability of Provisions. If at any time any
of the provisions of this Agreement shall be held invalid or unenforceable, or are prohibited by the laws of the jurisdiction where they are to be performed or enforced, by reason of being vague or unreasonable as to duration or geographic scope or
scope of the activities restricted, or for any other reason, such provisions shall be considered divisible and shall become and be immediately amended to include only such restrictions and to such extent as shall be deemed to be reasonable and
enforceable by the court or other body having jurisdiction over this Agreement and the Company and the Purchaser agree that the provisions of this Agreement, as so amended, shall be valid and binding as though any invalid or unenforceable provisions
had not been included; provided that if the Company’s call rights and rights of first refusal or rights of first offer set forth in the Stockholder Agreements or any other agreement shall be held invalid or unenforceable, the Restricted Stock
shall be cancelled and terminated. 
 (m) No Waiver. No failure by any party to insist upon the strict performance of
any covenant, duty, agreement or condition of this Agreement or to exercise any right or remedy consequent upon a breach thereof shall constitute waiver of any such breach or any other covenant, duty, agreement or condition. 

(n) Entire Agreement. This Agreement contains the entire understanding of the parties with respect to the subject matter
hereof and supersedes any prior agreements between the Company and the Purchaser with respect to the subject matter hereof. 

 (o) Rights as Stockholder. Subject to the terms and conditions of this
Agreement, the Purchaser shall have all of the rights of a stockholder of the Company with respect to the Shares from and after the date that the Purchaser delivers a fully executed copy of this Agreement (including the applicable exhibits and
attachments to this Agreement) and full payment for the Shares to the Company, and until such time as the Purchaser disposes of the Shares in accordance with this Agreement. Upon such transfer, the Purchaser shall have no further rights as a holder
of the Shares so purchased except (in the case of a transfer to the Company) the right to receive payment for the Shares so purchased in accordance with the provisions of this Agreement, and the Purchaser shall forthwith cause the certificate(s)
evidencing the Shares so purchased to be surrendered to the Company for transfer or cancellation. 
 (p) Adjustment for Stock
Split. All references to the number of Shares and the purchase price of the Shares in this Agreement shall be adjusted to reflect any stock split, stock dividend or other change in the Shares which may be made after the date of this
Agreement. 
 (q) Employment at Will. THE PURCHASER ACKNOWLEDGES AND AGREES THAT THE VESTING OF SHARES PURSUANT TO THIS
AGREEMENT IS EARNED ONLY BY CONTINUING TO PROVIDE SERVICES TO THE COMPANY AT WILL (AND NOT THROUGH THE ACT OF BEING HIRED OR PURCHASING SHARES HEREUNDER). THE PURCHASER FURTHER ACKNOWLEDGES AND AGREES THAT THIS AGREEMENT, THE TRANSACTIONS
CONTEMPLATED HEREUNDER AND THE VESTING SCHEDULE SET FORTH HEREIN DO NOT CONSTITUTE AN EXPRESS OR IMPLIED PROMISE OF CONTINUED EMPLOYMENT OR ENGAGEMENT BY THE COMPANY FOR THE VESTING PERIOD, OR FOR ANY PERIOD AT ALL, AND SHALL NOT INTERFERE WITH THE
PURCHASER’S RIGHT OR THE COMPANY’S RIGHT TO TERMINATE THE PURCHASER’S RELATIONSHIP WITH THE COMPANY AT ANY TIME, WITH OR WITHOUT CAUSE OR NOTICE. 

(r) Reliance on Counsel and Advisors. The Purchaser acknowledges that Proskauer Rose LLP is representing only the Company
in this transaction. The Purchaser acknowledges that he or she has had the opportunity to review this Agreement, including all attachments hereto, and the transactions contemplated by this Agreement with his or her own legal counsel, tax advisors
and other advisors. The Purchaser is relying solely on his or her own counsel and advisors and not on any statements or representations of the Company or its agents for legal or other advice with respect to this investment or the transactions
contemplated by this Agreement. 
 (s) Construction. All section titles and captions in this Agreement are for
convenience only, shall not be deemed part of this Agreement, and in no way shall define, limit, extend or describe the scope or intent of any provisions of this Agreement. Wherever any words are used in this Agreement in the masculine gender they
shall be construed as though they were also used in the feminine gender in all cases where they would so apply. As used herein, (i) “or” shall mean “and/or” and (ii) “including” or “include” shall mean
“including, without limitation.” Any reference herein to an agreement in writing shall be deemed to include an electronic writing to the extent permitted by applicable law. 

(t) Spousal Consent. If the Purchaser is a resident of Arizona, California, Idaho, Louisiana, Nevada, New Mexico, Texas,
Washington, or Wisconsin, or the Commonwealth of Puerto Rico and is married on the date of this Agreement, the Purchaser’s spouse shall execute and deliver to the Company a consent of spouse in the form of Exhibit E hereto
(“Consent of Spouse”), effective on the date hereof. Notwithstanding the execution and delivery thereof, such consent shall not be deemed to confer or convey to the spouse any rights in the Purchaser’s Shares that do not
otherwise exist by operation of law or the agreement of the parties. If the Purchaser should marry or remarry subsequent to the date of this Agreement, the Purchaser shall within ninety (90) days thereafter obtain his/her new spouse’s
acknowledgement of and consent to the existence and binding effect of all restrictions contained in this Agreement by causing such spouse to execute and deliver a Consent of Spouse acknowledging the restrictions and obligations contained in this
Agreement and agreeing and consenting to the same. 

 (u) Recoupment Policy. The Purchaser acknowledges and agrees that the
Restricted Stock shall be subject to the terms and provisions of any “clawback” or recoupment policy that may be adopted by the Company from time to time or as may be required by any applicable law (including, without limitation, the
Dodd-Frank Wall Street Reform and Consumer Protection Act and rules and regulations thereunder). 
 (v) Provisions of Plan
Control. This Agreement is subject to all the terms, conditions and provisions of the Plan, including, without limitation, the amendment provisions thereof, and to such rules, regulations and interpretations relating to the Plan as
may be adopted by the Committee and as may be in effect from time to time. The Plan is incorporated herein by reference. If and to the extent that any provision of this Agreement conflicts or is inconsistent with the terms set forth in the Plan, the
Plan shall control, and this Agreement shall be deemed to be modified accordingly. 
 (w) Counterparts. This Agreement
may be executed in one or more counterparts, each of which will be deemed an original, but all of which together will constitute one and the same agreement. Facsimile copies of signed signature pages shall be binding originals. 

(signature page follows) 

 Form of Restricted Stock Purchase Agreement 

Last Updated February 2, 2017 

The parties represent that they have read this Agreement in its entirety, have had an opportunity to obtain the advice of counsel prior to
executing this Agreement and fully understand this Agreement. The Purchaser agrees to notify the Company of any change in his or her contact information below. 
  

	
	PURCHASER:
	
	  

	Signature
	
	  

	Print Name
	
	Address:
	
	  

	  

	
	  

	Email
	
	VIR BIOTECHNOLOGY, INC.
	
	  

	Signature
	
	  

	Print Name
	
	  

	Print Title
	
	Address:
	
	  

	  

 Exhibit A 

INVESTMENT REPRESENTATION STATEMENT 
  

							
	PURCHASER    	  	:	    	[●]	  	
				
	COMPANY	  	:	    	Vir Biotechnology, Inc.	  	
				
	SECURITY	  	:	    	Common Stock	  	
				
	AMOUNT	  	:	    	[●] shares	  	
				
	DATE	  	:	    	[●]	  	

  
  

In connection with the purchase of the above-listed shares, I, the undersigned purchaser, represent to the Company as follows: 

1. The Company may rely on these representations. I understand that the Company’s sale of the shares to me has not been
registered under the Securities Act of 1933, as amended (the “Securities Act”), because the Company believes, relying in part on my representations in this document, that an exemption from such registration requirement is available for
such sale. I understand that the availability of this exemption depends upon the representations I am making to the Company in this document being true and correct. 

2. I am purchasing for investment. I am purchasing the shares solely for investment purposes, and not for further
distribution. My entire legal and beneficial ownership interest in the shares is being purchased and shall be held solely for my account, except to the extent I intend to hold the shares jointly with my spouse. I am not a party to, and do not
presently intend to enter into, any contract or other arrangement with any other person or entity involving the resale, transfer, grant of participation with respect to or other distribution of any of the shares. My investment intent is not limited
to my present intention to hold the shares for the minimum capital gains period specified under any applicable tax law, for a deferred sale, for a specified increase or decrease in the market price of the shares, or for any other fixed period in the
future. 
 3. I can protect my own interests. I can properly evaluate the merits and risks of an investment in the
shares and can protect my own interests in this regard, whether by reason of my own business and financial expertise, the business and financial expertise of certain professional advisors unaffiliated with the Company with whom I have consulted, or
my preexisting business or personal relationship with the Company or any of its officers, directors or controlling persons. 
 4. I am
informed about the Company. I am sufficiently aware of the Company’s business affairs and financial condition to reach an informed and knowledgeable decision to acquire the shares. I have had an opportunity to discuss the plans,
operations and financial condition of the Company with its officers, directors or controlling persons, and have received all information I deem appropriate for assessing the risk of an investment in the shares. 

5. I recognize my economic risk. I realize that the purchase of the shares involves a high degree of risk, and that the
Company’s future prospects are uncertain. I am able to hold the shares indefinitely if required, and am able to bear the loss of my entire investment in the shares. 

 6. I know that the shares are restricted securities. I understand that
the shares are “restricted securities” in that the Company’s sale of the shares to me has not been registered under the Securities Act in reliance upon an exemption for non-public offerings. In
this regard, I also understand and agree that: 
 1. I must hold the shares indefinitely, unless any subsequent proposed
resale by me is registered under the Securities Act, or unless an exemption from registration is otherwise available (such as Rule 144); 

2. the Company is under no obligation to register any subsequent proposed resale of the shares by me; and 

3. the certificate evidencing the shares will be imprinted with a legend which prohibits the transfer of the shares unless such
transfer is registered or such registration is not required in the opinion of counsel for the Company. 
 7. I am familiar with Rule
144. I am familiar with Rule 144 adopted under the Securities Act, which in some circumstances permits limited public resales of “restricted securities” like the shares acquired from an issuer in a non-public offering. I understand that my ability to sell the shares under Rule 144 in the future is uncertain, and may depend upon, among other things: (i) the availability of certain current public
information about the Company; (ii) the resale occurring more than a specified period after my purchase and full payment (within the meaning of Rule 144) for the shares; and (iii) if I am an affiliate of the Company (A) the sale being
made in an unsolicited “broker’s transaction”, transactions directly with a market maker or riskless principal transactions, as those terms are defined under the Securities Exchange Act of 1934, as amended, (B) the amount of
shares being sold during any three-month period not exceeding the specified limitations stated in Rule 144, and (C) timely filing of a notice of proposed sale on Form 144, if applicable. 

8. I know that Rule 144 may never be available. I understand that the requirements of Rule 144 may never be met, and that
the shares may never be saleable under the rule. I further understand that at the time I wish to sell the shares, there may be no public market for the Company’s stock upon which to make such a sale, or the current public information
requirements of Rule 144 may not be satisfied, either of which may preclude me from selling the shares under Rule 144 even if the relevant holding period had been satisfied. 

9. I know that I am subject to further restrictions on resale. I understand that in the event Rule 144 is not available to
me, any future proposed sale of any of the shares by me will not be possible without prior registration under the Securities Act, compliance with some other registration exemption (which may or may not be available), or each of the following:
(i) my written notice to the Company containing detailed information regarding the proposed sale, (ii) providing an opinion of my counsel to the effect that such sale will not require registration, and (iii) the Company notifying me
in writing that its counsel concurs in such opinion. I understand that neither the Company nor its counsel is obligated to provide me with any such opinion. I understand that although Rule 144 is not exclusive, the Staff of the SEC has stated that
persons proposing to sell private placement securities other than in a registered offering or pursuant to Rule 144 will have a substantial burden of proof in establishing that an exemption from registration is available for such offers or sales, and
that such persons and their respective brokers who participate in such transactions do so at their own risk. 
 10. I know that I may
have tax liability due to the uncertain value of the shares. I understand that the board of directors believes its valuation of the shares represents a fair appraisal of their worth, but that it remains possible that, with the
benefit of hindsight, the Internal Revenue Service may successfully assert that the value of the shares on the date of my purchase is substantially greater than the board of directors’ appraisal. I understand that any additional value ascribed
to the shares by such an IRS determination will constitute ordinary income to me as of the purchase date, and that any additional taxes and interest due as a result will be my sole responsibility payable only by me, and that the Company need not and
will not reimburse me for that tax liability. 

 11. Residence. The address of my principal residence is set forth on
the signature page below. 
 12. No “bad actor” disqualification events. Neither I nor any person that would
be deemed a beneficial owner of the shares (in accordance with Rule 506(d) of the Securities Act) is subject to any of the “bad actor” disqualifications described in Rule 506(d)(l)(i) through (viii) under the Securities Act, except as
set forth in Rule 506(d)(2)(h) or (iii) or (d)(3) under the Securities Act and disclosed, reasonably in advance of the purchase or acquisition of the shares, in writing in reasonable detail to the Company. 

By signing below, I acknowledge my agreement with each of the statements contained in this Investment Representation Statement as of the date
first set forth above, and my intent for the Company to rely on such statements in issuing the shares to me. 
  

	
	  
 Purchaser’s
Signature

	
	  

	Print Name

 Address of the Purchaser’s principal residence: 

 Exhibit B 

STOCK POWER AND ASSIGNMENT 

SEPARATE FROM CERTIFICATE 

FOR VALUE RECEIVED and pursuant to that certain Restricted Stock Purchase Agreement dated as of [●], the undersigned hereby sells,
assigns and transfers unto                     ,
                     (            ) shares of Common Stock of Vir Biotechnology, Inc., a
Delaware corporation, standing in the undersigned’s name on the books of said corporation represented by certificate number              delivered herewith, and does hereby irrevocably
constitute and appoint                      as attorney-in-fact, with
full power of substitution, to transfer said stock on the books of said corporation. 
 Dated: 

 

	
	  
 (Signature)

	
	  

	(Print Name)
	
	  

	(Spouse’s Signature, if any)
	
	  

	(Print Name)

 This Assignment Separate From Certificate was executed in conjunction with the terms of a Restricted
Stock Purchase Agreement between the above assignor and the above corporation, dated as of [●]. 
 Instruction: Please do not fill
in any blanks other than the signature and name lines. 

 Exhibit C 

JOINT ESCROW INSTRUCTIONS 

[●] 
 Vir Biotechnology, Inc. 

Attn: Secretary 
 4640 SW Macadam 

Avenue, Suite 130A, Portland, OR 97239 
 Dear Secretary: 

As Escrow Agent for both Vir Biotechnology, Inc., a Delaware corporation (the “Company”), and [●] (the
“Purchaser”), you are hereby authorized and directed to hold the documents delivered to you pursuant to the terms of that certain Restricted Stock Purchase Agreement (the “Agreement”), dated as of
[●], to which a copy of these Joint Escrow Instructions is attached, in accordance with the following instructions: 
 1. In the event
that the Company and/or any assignee of the Company (referred to collectively for convenience herein as the “Company”) exercises the Repurchase Option set forth in the Agreement, the Company shall give to the Purchaser and
you a written notice specifying the number of shares of stock to be purchased, the purchase price, and the time for a closing hereunder at the principal office of the Company. The Purchaser and the Company hereby irrevocably authorize and direct you
to close the transaction contemplated by such notice in accordance with the terms of said notice. 
 2. At the closing, you are directed
(a) to date the stock assignments necessary for the transfer in question, (b) to fill in the number of shares being transferred, and (c) to deliver same, together with the certificate evidencing the shares of stock to be transferred,
to the Company against the simultaneous delivery to you of the purchase price (by check or such other form of consideration mutually agreed to by the parties) for the number of shares of stock being purchased pursuant to the exercise of the
Repurchase Option. 
 3. The Purchaser irrevocably authorizes the Company to deposit with you any certificates evidencing shares of stock to
be held by you hereunder and any additions and substitutions to said shares as defined in the Agreement. The Purchaser does hereby irrevocably constitute and appoint you as his or her
attorney-in-fact and agent for the term of this escrow to execute with respect to such securities all documents necessary or appropriate to make such securities
negotiable and to complete any transaction herein contemplated. Subject to the provisions of this paragraph 3, the Purchaser shall exercise all rights and privileges of a stockholder of the Company while the stock is held by you. 

4. Upon written request of the Purchaser after each successive one-year period from the date of the
Agreement, unless the Repurchase Option has been exercised, you will deliver to the Purchaser a certificate or certificates representing so many shares of stock remaining in escrow as are not then subject to the Repurchase Option. On or prior to the
date that is 95 days after the date the Purchaser’s status as a service provider (as defined in the Agreement) to the Company terminates, you will deliver to the Purchaser a certificate or certificates representing the aggregate number of
shares sold and issued pursuant to the Agreement and not purchased by the Company or its assignees pursuant to the exercise of the Repurchase Option. 

 5. If at the time of termination of this escrow you should have in your possession any
documents, securities, or other property belonging to the Purchaser, you shall deliver all of same to the Purchaser and shall be discharged of all further obligations hereunder. 

6. Your duties hereunder may be altered, amended, modified or revoked only by a writing signed by all of the parties hereto. 

7. You shall be obligated only for the performance of such duties as are specifically set forth herein and may rely and shall be protected in
relying or refraining from acting on any instrument reasonably believed by you to be genuine and to have been signed or presented by the proper party or parties. You shall not be personally liable for any act you may do or omit to do hereunder as
Escrow Agent or as attorney-in-fact for the Purchaser while acting in good faith and in the exercise of your own good judgment, and any act done or omitted by you
pursuant to the advice of your own attorneys shall be conclusive evidence of such good faith. 
 8. The Company and the Purchaser hereby
jointly and severally expressly agree to indemnify and hold harmless you and your designees against any and all claims, losses, liabilities, damages, deficiencies, costs and expenses, including reasonable attorneys’ fees and expenses of
investigation and defense incurred or suffered by you and your designees, directly or indirectly, as a result of any of your actions or omissions or those of your designees while acting in good faith and in the exercise of your judgment under the
Agreement, these Joint Escrow Instructions, exhibits hereto or written instructions from the Company or the Purchaser hereunder. 
 9. You
are hereby expressly authorized to disregard any and all warnings given by any of the parties hereto or by any other person or corporation, excepting only orders or process of courts of law, and are hereby expressly authorized to comply with and
obey orders, judgments or decrees of any court. In case you obey or comply with any such order, judgment or decree, you shall not be liable to any of the parties hereto or to any other person, firm or corporation by reason of such compliance,
notwithstanding any such order, judgment or decree being subsequently reversed, modified, annulled, set aside, vacated or found to have been entered without jurisdiction. 

10. You shall not be liable in any respect on account of the identity, authorities or rights of the parties executing or delivering or
purporting to execute or deliver the Agreement or any documents or papers deposited or called for hereunder. 
 11. You shall be entitled to
employ such legal counsel and other experts as you may deem necessary properly to advise you in connection with your obligations hereunder, may rely upon the advice of such counsel, and may pay such counsel reasonable compensation therefor. The
Company shall reimburse you for any such disbursements. 
 12. Your responsibilities as Escrow Agent hereunder shall terminate if you shall
resign by written notice to each party. In the event of any such termination, the Company shall appoint a successor Escrow Agent. 
 13. You
are expressly authorized to delegate your duties as Escrow Agent hereunder to the law firm of Proskauer Rose LLP or any other law firm, which delegation, if any, may change from time to time and shall survive your resignation as Escrow Agent. 

14. If you reasonably require other or further instruments in connection with these Joint Escrow Instructions or obligations in respect hereto,
the necessary parties hereto shall join in furnishing such instruments. 

 15. It is understood and agreed that should any dispute arise with respect to the delivery
and/or ownership or right of possession of the securities held by you hereunder, you are authorized and directed to retain in your possession without liability to anyone all or any part of said securities until such disputes shall have been settled
either by mutual written agreement of the parties concerned or by a final order, decree or judgment of a court of competent jurisdiction after the time for appeal has expired and no appeal has been perfected, but you shall be under no duty
whatsoever to institute or defend any such proceedings. 
 16. Any notice required or permitted hereunder shall be given in writing and shall
be deemed effectively given upon personal delivery or four days following deposit in the United States Post Office, by registered or certified mail with postage and fees prepaid and return receipt requested, addressed to each of the other parties
thereunto entitled at the following addresses, or at such other addresses as a party may designate by written notice to each of the other parties hereto. 
  

					
	COMPANY:	  	Vir Biotechnology, Inc.	  	
		  	4640 SW Macadam Avenue, Suite 130A,	  	
		  	Portland, OR 97239	  	
		  	Attn: Secretary	  	
			
	PURCHASER:	  	  
	  	
		  	  
	  	
		  	  
	  	
			
	ESCROW AGENT:	  	Secretary	  	
			
		  	  
	  	
		  	  
	  	

 17. By signing these Joint Escrow Instructions, you become a party hereto only for the purpose of said Joint
Escrow Instructions; you do not become a party to the Agreement. 
 18. This instrument shall be binding upon and inure to the benefit of the
parties hereto, and their respective successors and permitted assigns. 
 19. These Joint Escrow Instructions shall be governed by, and
construed and enforced in accordance with, the laws of the State of Delaware. 
 [Signature page follows] 

 
			
	Very truly yours,
	
	VIR BIOTECHNOLOGY, INC.
		
	By:	 	            

 
			
		
	Print Name:	 	 

 
			
		
	Title:	 	            
	
	PURCHASER:
		
	[●]	 	
	
	  

	(signature)

 ESCROW AGENT: 
  

	
	  
 Name:

	Title: Secretary

 IF YOU WISH TO MAKE A SECTION 83(B) 

ELECTION, THE FILING OF SUCH 

ELECTION IS YOUR RESPONSIBILITY. 

THE FORM FOR MAKING THIS 

SECTION 83(B) ELECTION IS ATTACHED 

TO THIS AGREEMENT AS EXHIBIT D. 

YOU MUST FILE THIS FORM WITHIN 30 

DAYS OF PURCHASING THE SHARES. 

YOU (AND NOT THE COMPANY OR ANY OF 

ITS AGENTS) SHALL BE SOLELY 

RESPONSIBLE FOR FILING SUCH FORM 

WITH THE IRS, EVEN IF YOU REQUEST 

THE COMPANY OR ITS AGENTS TO MAKE 

THIS FILING ON YOUR BEHALF AND EVEN 

IF THE COMPANY OR ITS AGENTS HAVE 

PREVIOUSLY MADE THIS FILING ON YOUR 

BEHALF. 
 The election
should be filed by mailing a signed election form by certified mail, return receipt requested to the IRS Service Center where you file your tax returns. See www.irs.gov 

 Exhibit D 

ELECTION UNDER SECTION 83(b) OF THE 

INTERNAL REVENUE CODE OF 1986, AS AMENDED 

The undersigned taxpayer hereby elects, pursuant to Section 83(b) of the Internal Revenue Code of 1986, as amended, to include in his or
her gross income for the current taxable year, the amount of any compensation taxable to him or her in connection with his or her receipt of the property described below: 

1. The name, address, taxpayer identification number and taxable year of the undersigned are as follows: 

 

							
	        	 	NAME OF TAXPAYER: ______________	  	    SPOUSE: ______________	  	            
			
		 	TAXPAYER’S ADDRESS: ______________________________________	  	
				
		 	TAXPAYER ID #: _________________	  	SPOUSE’S ID #: ____________	  	

 2. The property with respect to which the election is made is described as follows:
                     shares (the “Shares”) of the Common Stock of Vir Biotechnology, Inc. (the “Company”). 

3. The date on which the property was transferred is:             
        , ______. 
 4. The property is subject to the following restrictions: The Shares may
be repurchased by the Company, or its assignee, upon the occurrence of certain events. This right lapses with regard to a portion of the Shares over time. 

5. The fair market value at the time of transfer, determined without regard to any restriction other than a restriction which by its terms will
never lapse, of such property is: $            . 
 6. The amount, if any,
paid for such property: $            . 
 The undersigned has submitted a
copy of this statement to the person for whom the services were performed in connection with the undersigned’s receipt of the above-described property. The transferee of such property is the person performing the services in connection with the
transfer of said property. 
 The undersigned understand(s) that the foregoing election may not be revoked except with the consent of the
Commissioner. 
  

					
	Dated:                    	  	_____________________________	  	
		  	                    , Taxpayer	  	

 The undersigned spouse of taxpayer joins in this election. 

 

					
	Dated:                    	  		  	
		  	_____________________________	  	
		  	                    , Spouse of Taxpayer	  	

 Exhibit E 

CONSENT OF SPOUSE 
 I,
[NAME], spouse of [●], have read and approve of the foregoing Restricted Stock Purchase Agreement, dated as of [●], together with all exhibits and attachments thereto (collectively, the “Agreement”), by and
between my spouse and Vir Biotechnology, Inc., a Delaware corporation (the “Company”). In consideration of the Company’s granting of the right to [●] to purchase [●] shares of Common Stock of the Company as
set forth in the Agreement, I hereby appoint [●] as my attorney-in-fact in respect to the exercise or waiver of any rights under the Agreement, and agree to be
bound by the provisions of the Agreement insofar as I may have any rights in said Agreement or any shares issued pursuant thereto under the community property laws of the State of California, or under similar laws relating to marital property in
effect in the state of our residence as of the date of the signing of the foregoing Agreement. 
 Dated: [●] 

 

	
	  
 (Signature)

	
	  

	(Print Name)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}]]